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ABSTRACT 
Stabilized reverse transcriptase fusion proteins including a 
thermostable reverse transcriptase connected to a stabilizer 
protein are described . Attaching the stabilizer protein to the 
thermostable reverse transcriptase stabilizes the fusion pro 
tein and can aid in its purification , provide increased solu 
bility , allow for longer storage , or allow the fusion protein to 
be used under more rigorous conditions such as higher 
temperature . The stabilized reverse transcriptase fusion pro 
tein can also include a linker between the stabilizer protein 
and the thermostable reverse temperature . The stabilized 
reverse transcriptase fusion proteins are suitable for use in 
nucleic acid amplification methods such as the reverse 
transcription polymerase chain reaction and other applica 
tions involving cDNA synthesis . 
FOREIGN PATENT DOCUMENTS 
WO 2005084409 9 / 2005 
OTHER PUBLICATIONS 
Search Report from European Patent Application No . 10749312 . 4 
2403 dated Aug . 8 , 2012 . 
12 Claims , 24 Drawing Sheets 
Specification includes a Sequence Listing . 
US 10 , 150 , 955 B2 
Page 2 
( 56 ) References Cited 
OTHER PUBLICATIONS 
Blocker , Forrest J . H . et al . “ Domain Structure and Three 
Dimensional Model of a Group II intron - encoded Reverse 
Transcriptase , ” RNA , vol . 11 , pp . 14 - 28 , ( 2005 ) . 
Vellore , Jaisheer et al . “ A group II Intron - Type open reading frame 
from the thermophile bacilius ( Geobacillus ) stearothermophukys 
encodes a heat - stable reverse transcriptase , ” Appl . Environ . Microbiol . 
vol . 70 , pp . 7140 - 7147 ( 2004 ) . 
NG , Bernie et al . , “ Reverse Transcriptase : Intron - encoded proteins 
found in thermophillic bacteria , " Gene vol . 393 , pp . 137 - 144 
( 2007 ) 
Janin , Joel et al . , " Structural Domains in Proteins and Their Role in 
the Dynmanics of Protein Function , ” Progress in Biophysics and 
Molecular Biology , vol . 42 , pp . 21 - 78 ( 1983 ) . 
Idicula , Susan et al . , “ Understanding the relationship between the 
primary structure of proteins and its propensity to be soluble on 
overexpression in Escherichia coli , ” Protein Science , vol . 14 , pp . 
582 - 592 ( 2005 ) . 
Harrison , R . G . , “ Expression of soluble heterologous proteins via 
fusion with NuSA protein , ” InNovations , vol . 11 , pp . 4 - 7 ( 2000 ) . 
Collins - Racie et al . , Biotechnology , 13 , p . 982 - 987 ( 1995 ) . 
Wriggers , Willey et al . , “ Control of Protein Functional Dynamics of 
Peptide Linkers , ” Biopolymers , vol . 80 , pp . 736 - 746 ( 2005 ) . 
George , Richard A . et al . , “ An analysis of protein domain linkers : 
their classification and role in protein folding , ” Protein Engineering , 
vol . 15 , pp . 871 - 879 ( 2003 ) . 
Saldanha , Roland et al . , “ RNA and protein catalysis in Group II 
intron splicing and mobility reactions using purified components , " 
Biochemistry , vol . 38 , pp . 9069 - 9083 , ( 1999 ) . 
Nallamsetty , Sreedevi et al . , Solubility - enhancing proteins MBP and 
NusA play a passive role in the folding of their fusion partners : 
Protein Expression and Purification , vol . 45 , pp . 175 - 182 , ( 2005 ) . 
Smyth , Douglas et al . , “ Crystal Structure of fusion proteins with 
large affinity flags , ” Protein Science , pp . 1313 - 1322 , ( 2003 ) . 
Guo Huatato et al . , " Group II Introns Designed to Insert into 
Therapeutically Relevant DNA Targetr Sites in Human Cells , " 
Science 289 , pp . 452 - 457 , ( 2000 ) . 
Karberg , Michael et al . , “ Group II introns as controllable gene 
targeting vectors for genetic manipulation of bacteria , ” Nature 
Biotechnology , vol . 19 , pp . 1162 - 1167 , ( 2001 ) . 
San Filippo , Joseph et al . , “ Characterization of the C - Terminal 
DNA - binding / DNA endonuclear region of a Group II intron 
encoded protein , ” Journal of Molecular Biology , vol . 324 , pp . 
933 - 9851 , ( 2002 ) . 
Potter , “ SuperScript III First - Strand Synthesis Supermis for qRT 
PCR , ” Focus ( Invitrogen Newsletter ) 25 . 1 , pp . 19 - 24 ( 2003 ) . 
Chee , Gab - Joo et al . , “ Housekeeping RecA give interrupted by 
Group II intron in a thermophilic Geobacillus Kaustrophilus , ” Gene , 
vol . 363 , pp . 211 - 220 , ( 2005 ) . 
Kristelly , Romana et al . , “ Preliminary structure analysis of the 
DH / PH domains of leukemia - associated RhoGEF , ” Acta Crystal 
lographica , Section D , Biological Crystallography , D59 , pp . 859 
1862 , ( 2003 ) . 
Makarova , Olga et al . , “ Generation of Deletion and Point Mutations 
with One Primer in a Single Cloning Step , ” Inventrogen Bio Techniques 
vol . 29 , pp . 970 - 972 , ( 2000 ) . 
Database UnitProt [ online ] , " Subname : full = reverse transcriptase , ” 
Mar . 1 , 2003 , retreived from EBI accession No . UNIPORT : Q8CMOO . 
Kapust and Waugh , Protein Science , vol . 8 , pp . 1688 - 1674 , 1999 . 
Nomine , Yves , et al . “ Formation of soluble inclusion bodies by hpv 
e6 oncoprotein fused to maltose - binding protein . ” Protein expres 
sion and purification 23 . 1 ( 2001 ) : 22 - 32 . 
Ke , Ailong , and Cynthia Wolberger . “ Insights into binding coop 
erativity of MATal / MATa2 from the crystal structure of a MATal 
homeodomain - maltose binding protein chimera . ” Protein science 
12 . 2 ( 2003 ) : 306 - 312 . 
Terpe , K . " Overview of tag protein fusions : from molecular and 
biochemical fundamentals to commercial systems . " Applied micro 
biology and biotechnology 60 . 5 ( 2003 ) : 523 - 533 . 
Esposito , Dominic , and Deb K . Chatterjee . “ Enhancement of soluble 
protein expression through the use of fusion tags . ” Current opinion 
in biotechnology 17 . 4 ( 2006 ) : 353 - 358 . 
Chan , Pedro , Robin A . Curtis , and Jim Warwicker . “ Soluble expres 
sion of proteins correlates with a lack of positively - charged sur 
face . ” Scientific reports 3 ( 2013 ) : 1 - 6 . 
Wang , Xueyin , Jacob C . Schwartz , and Thomas R . Cech . “ Nucleic 
acid - binding specificity of human FUS protein . ” Nucleic Acids 
Research 43 . 15 ( 2015 ) : 7535 - 7543 . 
Mohr , Sabine , et al . “ Thermostable group II intron reverse transcriptase 
fusion proteins and their use in cDNA synthesis and next - generation 
RNA sequencing . " Rna 19 . 7 ( 2013 ) : 958 - 970 . 
England , New . " MALTM Protein Fusion and Purification System . ” 
( 1991 ) . 
Examination Report from European Patent Application No . 10749312 . 
4 - 1410 dated Jun . 10 , 2016 . 
Canadian Examination Report for corresponding PCTUS2010 / 
026165 dated Mar . 29 , 2016 . 
Database UniProt [ online ] Mar . 1 , 2003 ( Mar . 1 , 2003 ) , “ SubName : 
Full = Reverse transcriptase ; " , XP002680473 , retrieved from EBI 
accession No . UNIPROT : Q8CMOO Database accession No . Q8CM00 . 
Examination Report from European Patent Application No . 10749312 . 
4 - 1406 dated Jan . 23 , 2015 . 
Modi Safra , “ The MIA Landscape on Cytosolic and Mitochondrial 
mRNA at Single - Base Resolution ” , Nature . Nov . 9 . 2017 ; 551 ( 7679 ) : 251 
255 . 
Xiaoyu Li , “ Base - Resolution Mapping Reveals Distinct mlA Methylome 
in Nuclear - and Mitochondrial - Encoded Transcripts ” , Molecular 
Cell 68 , Dec . 7 , 2017 , pp . 993 - 1005 . 
Sofia Costa , “ Fusion Tags for Protein Solubility , Purification , and 
Immunogenicity in Escherichia coil : the novel Fh8 System ” . Fron 
tiers in Microbiology , Feb . 2014 , vol . 5 , Article 63 , 20 pages . 
Maffitt et al . , “ Rapid Screening for Protein Solubility and Expres 
sion ” , Nature Methods 12 , Jun . 2015 . 
Kathleen Collins , “ Enzyme Engineering Through Evolution : 
Thermostable Recombinant Group II Intron Reverse Transcriptases 
Provide New Tools for RNA Research and Biotechnology ” , Aug . 
2013 , RNA 19 ( 8 ) : 1017 - 1018 . 
Xuebing Wu , “ Widespread Influence of 3 ' - End Structures on Mam 
malian mRNA Processing and Stability ” , Cell 169 , pp . 905 - 917 , 
May 18 , 2017 
Samuel Carrell , “ Detection of Expanded RNA Repeats Using 
Thermostable Group II Intron Reverse Transcriptase ” . Nucleic 
Acids Research , Jan . 9 , 2018 , vol . 46 , 12 pages . 
Han Li , “ Design and Specificity of Long ssDNA donors for CRISPR 
based Knock - In ” Aug . 21 , 2017 , available at https : / / doi . org / 10 . 1101 / 
178905 . 
George E . Katibah , “ Broad and Adaptable RNA Structure Recog 
nition by the Human Interferon - Induced Tetratricopeptide Repeat 
Protein IFIT5 ” , PNAS , Aug . 19 , 2014 , vol . 111 , No . 33 , pp . 
12025 - 12030 . 
Matthew J . Shurtleff , “ Broad Role for YBX1 in Defining the Small 
Noncoding RNA Composition of Exosomes ” , PNAS , Oct . 10 , 2017 , 
EB987 - EB995 . 
Yidan Qin , “ High - Throughput Sequencing of Human Plasma RNA 
by Using Thermostable Group II Intron Reverse Transcriptases ” , 
RNA 22 ( 1 ) , pp . 111 - 128 , Jan . 2016 . 
Brian J . Zarnegar , “ irCLIP Platform for Efficient Characterization of 
Protein — RNA Interactions ” , Nat Methods , Jun . 2016 , 13 ( 6 ) 489 
492 . 
Meghan Zubradt , “ DMS - MaPseq for Genome - Wide or Targeted 
RNA Structure Probing in vivo ” , Nat Methods , Jan . 2017 , 14 ( 1 ) 
75 - 82 . 
U . S . Patent Dec . 11 , 2018 Sheet 1 of 24 US 10 , 150 , 955 B2 
1 MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI 
61 IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK 
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK 
181 DVGVDNAGAK AGLIFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDA 
361 ALAAAQTAAA AAMETROMTV DOTTGAVTNQ TETSWHSINW TKANREVKRL QVRIAKAVKE 
421 GRWGKVKALQ WLLTHSFYGK ALAVKRVTDN SGSRTPGVDG ITWSTQEQKT QAIKSLRRRG 
481 YKPQPLRRVY IPKANGKQRP LGIPTMKDRA MQALYALALE PVAETTADRN SYGFRRGRCT 
541 ADAAGQCFLA LAKAKSAEHV LDADISGCFD NISHEWLLAN TPLDKGILRK WLKSGFVWKO 
601 QLFPTHAGTP QGGVISPVLA NITLDGMEEL LAKHLRGQKV NLIRYADDFV VTGEDEETLE 
661 KARNLIQEFL KERGLTLSPE KTKIVHIEEG FDFLGWNIRK YNGVLLIKPA KKNVKAFLKK 
721 IRDTLRELRT ATQEIVIDTL NPIIRGWANY HKGQVSKETF NRVDFATWHK LWRWARRRHP 
781 NKPAQWVKDK YFIKNGSRDW VFGMVMKDKN GELRTKRLIK TSDTRIQRHV KIKADANPFL 
841 PEWAEYFEKR KKIKKAPAQY RRIRRELWKK OGGICPVCGG EIEQDMLTDI HHILPKHKGG 
901 SDDLDNLVLI HANCHKQVHS RDGQHSRSLL KEGL * 
FIG . 1 
1 MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI .
61 IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK 
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK 
181 DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNI PQMSAF WYAVRTAVIN AASGRQTVDA 
361 ALAAAQTAAA AAMETROMAV EQTTGAVTNQ TETSWHSIDW AKANREVKRL QVRIAKAVKE 
421 GRWGKVKALQ WLLTHSFYGK ALAVKRVTDN SGSKTPGVDG ITWSTQEQKA QAIKSLRRRG 
481 YKPOPLRRVY IPKANGKORP LGIPTMKDRA MQALYALALE PVAETTADRN SYGFRRGRCI 
541 ADAATQCHIT LAKTDRAQYV LDADIAGCFD NISHEWLLAN IPLDKRILRK WLKSGFVWKQ 
601 QLFPIHAGTP QGGVISPMLA NMTLDGMEEL LNKFPRAHKV KLIRYADDFV VTGETKEVLY 
661 IAGAVIQAFL KERGLTLSKE KTKIVHIEEG FDFLGWNIRK YDGKLLIKPA KKNVKAFLKK 
721 IRDTLRELRT APOEIVIDTL NPIIRGWTNY HKNOASKETF VGVDHLIWOK LWRWARRRHP 
781 SKSVRWVKSK YFIQIGNRKW MFGIWTKDKN GDPWAKHLIK ASEIRIQRRG KIKADANPFL 
841 PEWAEYFEQR KKLKEAPAQY RRTRRELWKK QGGICPVCGG EIEQDMLTEI HHILPKHKGG 
901 TDDLDNLVLI HTNCHKQVHN RDGQHSRFLL KEGL * 
FIG . 2 
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SEQ ID NO : 8 
1 MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI 
61 IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK 
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK 
181 DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPOMSAF WYAVRTAVIN AASGROTVDA 
361 ALAAAQTAAA AAMETRQMAV EQTTGAVTNQ TETSWHSIDW AKANREVKRL OVRIAKAVKE 
421 GRWGKVKALQ WLLTHSFYGK ALAVKRVTDN SGSKTPGVDG ITWSTQEQKA QAIKSLRRRG 
481 YKPQPLRRVY IPKASGKQRP LGIPTTKDRA MQALYALALE PVAETTADRN SYGFRQGRCT 
541 ADAAGQCFTV LGRSDCAKYI LDADITGCFD NISHEWLLDN IPLDKEVLRK WLKSGFVWKQ 
601 QLFPTHAGTP QGGVISPMLA NMTLDGMEEL LKKHLRKQKV NLIRYADDFV VTGESKETLE 
661 KVTTVIQEFL KERGLTLSEE KTKVVHIEEG FDFLGWNIRK YGEKLLIKPA KKNIKAFHKK 
721 IRDALKELRT ATQEAVIDTL NPIIKGWANY HRNOVSKRIF NRADDNIWHK LWRWAKRRHP 
781 NKPARWTKNK YFIKIGNRHW VFGTWKKDKE GRLRSRYLIK AGDTRIQRHV KIKADANPFL 
841 PEWAEYFEER KKLKEAPAQY RRIRRELWKK OGGICPVCGG EIEQDMLTEI HHILPKHKGG 
901 SDDLDNLVLI HANCHKQVHS RDGQHSRFLL KEGL * 
FIG . 3 
SEQ ID NO : 9 
8 
1 MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI 
61 IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK 
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK 
181 DVGVDNAGAK AGLTFLVDLI KINKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPOMSAF WYAVRTAVIN AASGROTVDA 
361 ALAAAQTAAA AAMKVNKLWV KSEQDLRNCL DLLYQEAKKG KHFYGMLELL QNDWILEAI 
421 RNIKSNKGSK TAGIDQKIVD DYLLMPTEKV FGMIKAKLND YKPIPVRRCN KPKGNAKSSK 
481 RKGNSPNEEG ETRPLGISAV TDRIIOEMLR IVLEPIFEAQ FYPHSYGFRP YRSTEHALAW 
541 MLKIINGSKL YWVVKGDIES YFDHINHKKL LNIMWNMGVR DKRVLCIVKK MLKAGQVIQG 
601 KFYPTAKGIP QGGIISPLLA NVYLNSFDWM VGQEYEYHPN NANYREKKNA LAALRNKGHH 
661 PVFYIRYADD WVILTDTKEY AEKIREQCKQ YLACELHLTL SDEKTFIADI REQRVKFLGF 
721 CIEAGKRRFH KKGFAARMIP DMEKVNAKVK EIKRDIRLLR TRKSELEKAL DIENINTKII 
781 GLANHLKIGI SKYIMGKVDR VIEETAYRTW VKMYGKEKAA QYKRPVSEFH NRIDRHKGYQ 
841 MKHFSVVTED GIRVGITHAK ITPIQYATVF KQEMTPYTAD GRKMYEEKHR KIRLPDKMSL 
901 FDHDSIFIYI LSEHNDGKYN LEYFLNRVNV FHRDKGKCKI CAVYLSPGNF HCHHIDPSKP 
961 LSEINKTVNL ISLCNQCHRL VHSNQEPPFT ERKMFDKLTK YRNKLKI * 
FIG . 4 
SEQ ID NO : 10 
1 MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI 
61 IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK 
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK 
1 DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK 
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL 
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPOMSAF WYAVRTAVIN AASGRQTVDA 
361 ALAAAQTAAA AAMALLERIL ARDNLITALK RVEANQGAPG IDGVSTDCLR DYIRAHWSTI 
421 HAQLLAGTYR PAPVRRVEIP KPGGGTRQLG IPTVVDRLIQ QAILQELTPI FDPDFSSSSF 
481 GFRPGRNAHD AVRQAQGYIQ EGYRYVVDMD LEKFFDRVNH DILMSRVARK VKDKRVLKLI 
541 RAYLQAGVMI EGVKVOTEEG TPQGGPLSPL LANILLDDLD KELEKRGLKF CRYADDCNIY 
601 VKSLRAGQRV KQSIQRFLEK TLKLKVNEEK SAVDRPWKRA FLGFSFTPER KARIRLAPRS 
661 IQRLKQRIRQ LTNPNWSISM PERIHRVNQY VMGWIGYFRL VETPSVLQTI EGWIRRRLRL 
721 COWLOWKRVR TRIRELRALG LKETAVMEIA NTRKGAWRTT KTPQLHQALG KTYWTAQGLK 
781 SLTQRYFELR QG * 
FIG . 5 
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h 
) 
1 CCGACACCAT CGAATGGTGC AAAACCTTTC GCGGTATGGC ATGATAGCGC CCGGAAGAGA 
61 GTCAATTCAG GGTGGTGAAT GTGAAACCAG TAACGTTATA CGATGTCGCA GAGTATGCCG 
121 GTGTCTCTTA TCAGACCGTT TCCCGCGTGG TGAACCAGGC CAGCCACGTT TCTGCGAAAA 
181 CGCGGGAAAA AGTGGAAGCG GCGATGGCGG AGCTGAATTA CATTCCCAAC CGCGTGGCAC 
241 AACAACTGGC GGGCAAACAG TCGTTGCTGA TTGGCGTTGC CACCTCCAGT CTGGCCCTGC 
301 ACGCGCCGTC GCAAATTGTC GCGGCGATTA AATCTCGCGC CGATCAACTG GGTGCCAGCG 
361 TGGTGGTGTC GATGGTAGAA CGAAGCGGCG TCGAAGCCTG TAAAGCGGCG GTGCACAATC
421 TTCTCGCGCA ACGCGTCAGT GGGCTGATCA TTAACTATCC GCTGGATGAC CAGGATGCCA 
481 TTGCTGTGGA AGCTGCCTGC ACTAATGTTC CGGCGTTATT TCTTGATGTC TCTGACCAGA 
541 CACCCATCAA CAGTATTATT TTCTCCCATG AAGACGGTAC GCGACTGGGC GTGGAGCATC 
601 TGGTCGCATT GGGTCACCAG CAAATCGCGC TGTTAGCGGG CCCATTAAGT TCTGTCTCGG 
661 CGCGTCTGCG TCTGGCTGGC TGGCATAAAT ATCTCACTCG CAATCAAATT CAGCCGATAG 
721 CGGAACGGGA AGGCGACTGG AGTGCCATGT CCGGTTTTCA ACAAACCATG CAAATGCTGA 
781 ATGAGGGCAT CGTTCCCACT GCGATGCTGG TTGCCAACGA TCAGATGGCG CTGGGCGCAA 
841 TGCGCGCCAT TACCGAGTCC GGGCTGCGCG TTGGTGCGGA TATCTCGGTA GTGGGATACG 
901 ACGATACCGA AGACAGCTCA TGTTATATCC CGCCGTTAAC CACCATCAAA CAGGATTTTC 
961 GCCTGCTGGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC CAGGCGGTGA 
1021 AGGGCAATCA GCTGTTGCCC GTCTCACTGG TGAAAAGAAA AACCACCCTG GCGCCCAATA 
1081 CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT 
1141 CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TAAGTTAGCT CACTCATTAG 
1201 GCACAATTCT CATGTTTGAC AGCTTATCAT CGACTGCACG GTGCACCAAT GCTTCTGGCG 
1261 TCAGGCAGCC ATCGGAAGCT GTGGTATGGC TGTGCAGGTC GTAAATCACT GCATAATTCG 
1321 TGTCGCTCAA GGCGCACTCC CGTTCTGGAT AATGTTTTTT GCGCCGACAT CATAACGGTT 
1381 CTGGCAAATA TTCTGAAATG AGCTGTTGAC AATTAATCAT CGGCTCGTAT AATGTGTGGA 
1441 ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCCAGT CCGTTTAGGT GTTTTCACGA 
1501 GCACTTCACC AACAAGGACC ATAGCATATG AAAATCGAAG AAGGTAAACT GGTAATCTGG 
1561 ATTAACGGCG ATAAAGGCTA TAACGGTCTC GCTGAAGTCG GTAAGAAATT CGAGAAAGAT 
1621 ACCGGAATTA AAGTCACCGT TGAGCATCCG GATAAACTGG AAGAGAAATT CCCACAGGTT 
1681 GCGGCAACTG GCGATGGCCC TGACATTATC TTCTGGGCAC ACGACCGCTT TGGTGGCTAC 
1741 GCTCAATCTG GCCTGTTGGC TGAAATCACC CCGGACAAAG CGTTCCAGGA CAAGCTGTAT 
1801 CCGTTTACCT GGGATGCCGT ACGTTACAAC GGCAAGCTGA TTGCTTACCC GATCGCTGIT 
1861 GAAGCGTTAT CGCTGATTTA TAACAAAGAT CTGCTGCCGA ACCCGCCAAA AACCTGGGAA 
1921 GAGATCCCGG CGCTGGATAA AGAACTGAAA GCGAAAGGTA AGAGCGCGCT GATGTTCAAC 
1981 CTGCAAGAAC CGTACTTCAC CTGGCCGCTG ATTGCTGCTG ACGGGGGTTA TGCGTTCAAG 
2041 TATGAAAACG GCAAGTACGA CATTAAAGAC GTGGGCGTGG ATAACGCTGG CGCGAAAGCG 
2101 GGTCTGACCT TCCTGGTTGA CCTGATTAAA AACAAACACA TGAATGCAGA CACCGATTAC 
2161 TCCATCGCAG AAGCTGCCTT TAATAAAGGC GAAACAGCGA TGACCATCAA CGGCCCGTGG 
2221 GCATGGTCCA ACATCGACAC CAGCAAAGTG AATTATGGTG TAACGGTACT GCCGACCTTC 
2281 AAGGGTCAAC CATCCAAACC GTTCGTTGGC GTGCTGAGCG CAGGTATTAA CGCCGCCAGT 
2341 CCGAACAAAG AGCTGGCAAA AGAGTTCCTC GAAAACTATC TGCTGACTGA TGAAGGTCTG 
2401 GAAGCGGTTA ATAAAGACAA ACCGCTGGGT GCCGTAGCGC TGAAGTCTTA CGAGGAAGAG 
2461 TTGGCGAAAG ATCCACGTAT TGCCGCCACT ATGGAAAACG CCCAGAAAGG TGAAATCATG 
2521 CCGAACATCC CGCAGATGTC CGCTTTCTGG TATGCCGTGC GTACTGCGGT GATCAACGCC 
2581 GCCAGCGGTC GTCAGACTGT CGATGCCGCC CTGGCCGCCG CGCAGACTGC CGCCGCCGCC 
2641 GCCATGGAGA CAAGGCAAAT GACGGTGGAC CAAACCACTG GTGCGGTCAC CAACCAAACG 
2701 GAAACAAGCT GGCACAGCAT AAACTGGACC AAAGCCAACC GTGAGGTAAA GAGGCTGCAA 
2761 GTGCGTATCG CAAAGGCTGT GAAGGAAGGA CGCTGGGGCA AAGTGAAAGC TTTGCAATGG 
2821 CTCCTGACCC ACTCGTTCTA CGGCAAAGCC CTCGCCGTGA AACGGGTAAC TGACAACTCA 
2881 GGCAGTAGAA CACCTGGTGT GGACGGGATA ACCTGGTCCA CACAAGAGCA GAAAACCCAA 
2941 GCCATAAAGT CCCTCAGGAG AAGAGGCTAT AAACCCCAAC CCCTGAGGCG GGTATACATC 
3001 CCGAAAGCAA ACGGCAAACA GCGCCCGCTA GGAATCCCGA CAATGAAGGA CAGGGCAATG 
3061 CAGGCACTAT ATGCCCTAGC CCTAGAACCA GTCGCGGAAA CCACAGCGGA CCGGAACTCC 
3121 TATGGGTTCC GCCGAGGGCG ATGTACGGCA GATGCGGCAG GACAATGCTT CCTTGCTCTG 
3181 GCAAAAGCCA AGTCGGCTGA ACACGTCCTT GACGCTGACA TATCCGGATG CTTTGATAAC 
3241 ATCAGCCATG AGTGGCTACT AGCCAACACT CCACTGGACA AAGGGATCTT ACGGAAATGG 
3301 CTTAAATCTG GGTTCGTCTG GAAACAGCAA CTCTTCCCCA CCCATGCTGG GACACCTCAG 
3361 GGAGGGGTAA TCTCCCCAGT TCTTGCCAAT ATAACCCTAG ATGGGATGGA AGAACTGTTG 
3421 GCCAAACACC TCAGAGGTCA AAAAGTCAAC CTCATCCGAT ATGCTGACGA TTTTGTCGTG 
3481 ACGGGAAAAG ATGAGGAAAC CCTGGAGAAA GCCAGAAACC TAATCCAGGA GTTCCTAAAA 
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3541 GAACGGGGCT TGACCCTGTC CCCCGAGAAG ACAAAAATCG TCCATATTGA GGAAGGCTTC 
3601 GACTTTCTCG GATGGAACAT TCGCAAGTAC AACGGGGTTC TTCTCATCAA ACCCGCGAAG 
3661 AAGAACGTGA AAGCGTTCCT CAAGAAAATC CGAGACACTC TAAGGGAACT TAGGACAGCA 
3721 ACCCAGGAAA TCGTGATAGA CACACTCAAC CCAATCATTA GAGGTTGGGC CAACTATCAC 
3781 AAAGGACAAG TCTCTAAGGA AACCTTCAAC CGAGTGGACT TCGCCACCTG GCACAAATTG 
3841 TGGCGATGGG CAAGGCGCCG GCACCCAAAC AAACCTGCCC AATGGGTGAA GGACAAATAC 
3901 TTCATCAAAA ACGGAAGCAG AGACTGGGTG TTCGGTATGG TGATGAAAGA CAAGAACGGG 
3961 GAACTGAGGA CCAAACGCCT AATCAAAACC TCTGACACCC GAATCCAACG CCACGTCAAA 
4021 ATCAAGGCAG ACGCCAATCC GTTTCTCCCA GAGTGGGCAG AATACTTTGA GAAACGCAAG 
4081 AAACTCAAAA AAGCCCCTGC TCAATATCGG CGCATCCGCC GAGAACTATG GAAGAAACAG 
4141 GGTGGTATCT GTCCAGTATG CGGGGGTGAA ATTGAGCAAG ACATGCTCAC TGACATCCAC 
4201 CACATATTGC CCAAACACAA GGGTGGTTCT GACGACCTGG ATAATCTTGT CTTAATCCAC 
4261 GCCAACTGCC ACAAACAGGT GCACAGCCGA GATGGTCAGC ACAGCCGGTC CCTCTTGAAA 
4321 GAGGGGCTTT GACTGCAGGC AAGCTTGGCA CTGGCCGTCG TTTTACAACG TCGTGACTGG 
4381 GAAAACCCTG GCGTTACCCA ACTTAATCGC CTTGCAGCAC ATCCCCCTTT CGCCAGCTGG 
4441 CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC 
4501 GAATGGCAGC TTGGCTGTTT TGGCGGATGA GATAAGATTT TCAGCCTGAT ACAGATTAAA 
4561 TCAGAACGCA GAAGCGGTCT GATAAAACAG AATTTGCCTG GCGGCAGTAG CGCGGTGGTC 
4621 CCACCTGACC CCATGCCGAA CTCAGAAGTG AAACGCCGTA GCGCCGATGG TAGTGTGGGG 
4681 TCTCCCCATG CGAGAGTAGG GAACTGCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA 
4741 AGACTGGGCC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCCTGA GTAGGACAAA 
4801 TCCGCCGGGA GCGGATTTGA ACGTTGCGAA GCAACGGCCC GGAGGGTGGC GGGCAGGACG 
4861 CCCGCCATAA ACTGCCAGGC ATCAAATTAA GCAGAAGGCC ATCCTGACGG ATGGCCTTTT 
4921 TGCGTTTCTA CAAACTCTTT TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC 
4981 ATGAGACAAT AACCCTGATA AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT 
5041 CAACATTTCC GTGTCGCCCT TATTCCCTIT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT 
5101 CACCCAGAAA CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT 
5161 TACATCGAAC TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT 
5221 TCTCCAATGA TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTGTTGAC 
GCO GGGCAAG AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC 
5341 TCACCAGTCA CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT 
5401 GCCATAACCA TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG 
5461 AAGGAGCTAA CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG 
5521 GAACCGGAGC TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGCA 
5581 ATGGCAACAA CGTTGCGCAA ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA 
5641 CAATTAATAG ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT 
5701 CCGGCTGGCT GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC 
5761 ATTGCAGCAC TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG 
5821 AGTCAGGCAA CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT 
5881 AAGCATTGGT AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA TTTACCCCGG 
5941 TTGATAATCA GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA 
6001 . ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC 
6061 AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGACCGAG ATAGGGTTGA 
6121 GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG 
6181 GGCGAAAAAC CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT 
6241 TITTGGGGTC GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA 
6301 GAGCTTGACG GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA GCGAAAGGAG 
6361 CGGGCGCTAG GGCGCTGGCA AGTGTAGCGG TCACGCTGCG CGTAACCACC ACACCCGCCG 
6421 CGCTTAATGC GCCGCTACAG GGCGCGTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT 
6481 CTCATGACCA AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA 
6541 AAGATCAAAG GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA 
6601 AAAAAACCAC CGCTACCAGC GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT 
6661 CCGAAGGTAA CTGGCTTCAG CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG 
6721 TAGTTAGGCC ACCACTTCAA GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC 
6781 CTGTTACCAG TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA 
6841 CGATAGTTAC CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC 
6901 AGCTTGGAGC GAACGACCTA CACCGAACTG AGATACCTAC AGCGTGAGCT ATGAGAAAGC 
6961 GCCACGCTTC CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA 
7021 GGAGAGCGCA CGAGGGAGCT TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG 
7081 TTTCGCCACC TCTGACTTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA 
7141 TGGAAAAACG CCAGCAACGC GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT 
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7201 CACATGTTCT TTCCTGCGTT ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCTTTGAG 
7261 TGAGCTGATA CCGCTCGCCG CAGCCGAACG ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA 
7321 GCGGAAGAGC GCCTGATGCG GTATTTTCTC CTTACGCATC TGTGCGGTAT TTCACACCGC 
7381 ATATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC CAGTATACAC 
7441 TCCGCTATCG CTACGTGACT GGGTCATGGC TGCGCCCCGA CACCCGCCAA CACCCGCTGA 
7501 CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC 
7561 CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GGCAGCTGCG 
7621 GTAAAGCTCA TCAGCGTGGT CGTGCAGCGA TTCACAGATG TCTGCCTGTT CATCCGCGTC 
7681 CAGCTCGTTG AGTTTCTCCA GAAGCGTTAA TGTCTGGCTT CTGATAAAGC GGGCCATGTT 
7741 AAGGGCGGTT TTTTCCTGTT TGGTCACTGA TGCCTCCGTG TAAGGGGGAT TTCTGTTCAT 
7801 GGGGGTAATG ATACCGATGA AACGAGAGAG GATGCTCACG ATACGGGTTA CTGATGATGA 
7861 ACATGCCCGG TTACTGGAAC GTTGTGAGGG TAAACAACTG GCGGTATGGA TGCGGCGGGA 
7921 CCAGAGAAAA ATCACTCAGG GTCAATGCCA GCGCTTCGTT AATACAGATG TAGGTGTTCC 
7981 ACAGGGTAGC CAGCAGCATC CTGCGATGCA GATCCGGAAC ATAATGGTGC AGGGCGCTGA 
8041 CTTCCGCGTT TCCAGACTTT ACGAAACACG GAAACCGAAG ACCATTCATG TTGTTGCTCA 
8101 GGTCGCAGAC GTTTTGCAGC AGCAGTCGCT TCACGTTCGC TCGCGTATCG GTGATTCATT 
8161 CTGCTAACCA GTAAGGCAAC CCCGCCAGCC TAGCCGGGTC CTCAACGACA GGAGCACGAT 
8221 CATGCGCACC CGTGGCCAGG ACCCAACGCT GCCCGAAATT 
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1 CCGACACCAT CGAATGGTGC AAAACCTTTC GCGGTATGGC ATGATAGCGC CCGGAAGAGA 
61 GTCAATTCAG GGTGGTGAAT GTGAAACCAG TAACGTTATA CGATGTCGCA GAGTATGCCG 
121 GTGTCTCTTA TCAGACCGTT TCCCGCGTGG TGAACCAGGC CAGCCACGTT TCTGCGAAAA 
181 CGCGGGAAAA AGTGGAAGCG GCGATGGCGG AGCTGAATTA CATTCCCAAC CGCGTGGCAC 
241 AACAACTGGC GGGCAAACAG TCGTTGCTGA TTGGCGTTGC CACCTCCAGT CTGGCCCTGC 
301 ACGCGCCGTC GCAAATTGTC GCGGCGATTA AATCTCGCGC CGATCAACTG GGTGCCAGCG 
361 TGGTGGTGTC GATGGTAGAA CGAAGCGGCG TCGAAGCCTG TAAAGCGGCG GTGCACAATC 
421 TTCTCGCGCA ACGCGTCAGT GGGCTGATCA TTAACTATCC GCTGGATGAC CAGGATGCCA 
481 TTGCTGTGGA AGCTGCCTGC ACTAATGTTC CGGCGTTATT TCTTGATGTC TCTGACCAGA 
541 CACCCATCAA CAGTATTATT TTCTCCCATG AAGACGGTAC GCGACTGGGC GTGGAGCATC 
601 TGGTCGCATT GGGTCACCAG CAAATCGCGC TGTTAGCGGG CCCATTAAGT TCTGTCTCGG 
661 CGCGTCTGCG TCTGGCTGGC TGGCATAAAT ATCTCACTCG CAATCAAATT CAGCCGATAG 
721 CGGAACGGGA AGGCGACTGG AGTGCCATGT CCGGTTTTCA ACAAACCATG CAAATGCTGA 
781 ATGAGGGCAT CGTTCCCACT GCGATGCTGG TTGCCAACGA TCAGATGGCG CTGGGCGCAA 
841 TGCGCGCCAT TACCGAGTCC GGGCTGCGCG TTGGTGCGGA TATCTCGGTA GTGGGATACG 
901 ACGATACCGA AGACAGCTCA TGTTATATCC CGCCGTTAAC CACCATCAAA CAGGATTTTC 
961 GCCTGCTGGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC CAGGCGGTGA 
1021 AGGGCAATCA GCTGTTGCCC GTCTCACTGG TGAAAAGAAA AACCACCCTG GCGCCCAATA 
1081 CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT 
1141 CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TAAGTTAGCT CACTCATTAG 
1201 GCACAATTCT CATGTTTGAC AGCTTATCAT CGACTGCACG GTGCACCAAT GCTTCTGGCG 
1261 TCAGGCAGCC ATCGGAAGCT GTGGTATGGC TGTGCAGGTC GTAAATCACT GCATAATTCG 
1321 TGTCGCTCAA GGCGCACTCC CGTTCTGGAT AATGTTTTTT GCGCCGACAT CATAACGGTT 
1381 CTGGCAAATA TTCTGAAATG AGCTGTTGAC AATTAATCAT CGGCTCGTAT AATGTGTGGA 
1441 . ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCCAGT CCGTTTAGGT GTTTTCACGA 
1501 GCACTTCACC AACAAGGACC ATAGCATATG AAAATCGAAG AAGGTAAACT GGTAATCTGG 
1561 ATTAACGGCG ATAAAGGCTA TAACGGTCTC GCTGAAGTCG GTAAGAAATT CGAGAAAGAT 
1621 ACCGGAATTA AAGTCACCGT TGAGCATCCG GATAAACTGG AAGAGAAATT CCCACAGGTT 
1681 GCGGCAACTG GCGATGGCCC TGACATTATC TTCTGGGCAC ACGACCGCTT TGGTGGCTAC 
1741 GCTCAATCTG GCCTGTTGGC TGAAATCACC CCGGACAAAG CGTTCCAGGA CAAGCTGTAT 
1801 CCGTTTACCT GGGATGCCGT ACGTTACAAC GGCAAGCTGA TTGCTTACCC GATCGCTGTT 
1861 GAAGCGTTAT CGCTGATTTA TAACAAAGAT CTGCTGCCGA ACCCGCCAAA AACCTGGGAA 
1921 GAGATCCCGG CGCTGGATAA AGAACTGAAA GCGAAAGGTA AGAGCGCGCT GATGTTCAAC 
1981 CTGCAAGAAC CGTACTTCAC CTGGCCGCTG ATTGCTGCTG ACGGGGGTTA TGCGTTCAAG 
2041 TATGAAAACG GCAAGTACGA CATTAAAGAC GTGGGCGTGG ATAACGCTGG CGCGAAAGCG 
2101 GGTCTGACCT TCCTGGTTGA CCTGATTAAA AACAAACACA TGAATGCAGA CACCGATTAC 
2161 TCCATCGCAG AAGCTGCCTT TAATAAAGGC GAAACAGCGA TGACCATCAA CGGCCCG ' IGG 
2221 GCATGGTCCA ACATCGACAC CAGCAAAGTG AATTATGGTG TAACGGTACT GCCGACCTTC 
2281 AAGGGTCAAC CATCCAAACC GTTCGTTGGC GTGCTGAGCG CAGGTATTAA CGCCGCCAGT 
2341 CCGAACAAAG AGCTGGCAAA AGAGTTCCTC GAAAACTATC TGCTGACTGA TGAAGGTCTG 
2401 GAAGCGGTTA ATAAAGACAA ACCGCTGGGT GCCGTAGCGC TGAAGTCTTA CGAGGAAGAG 
2461 TTGGCGAAAG ATCCACGTAT TGCCGCCACT ATGGAAAACG CCCAGAAAGG TGAAATCATG 
2521 CCGAACATCC CGCAGATGTC CGCITTCTGG TATGCCGTGC GTACTGCGGT GATCAACGCC 
2581 GCCAGCGGTC GTCAGACTGT CGATGCCGCC CTGGCCGCCG CGCAGACTGC CGCCGCCGCC 
2641 GCCATGGAGA CAAGGCAAAT GGCAGTGGAA CAAACCACTG GTGCGGTCAC CAACCAAACG 
2701 GAAACAAGCT GGCACAGCAT AGACTGGGCC AAAGCCAACC GTGAGGTAAA GAGGCTGCAA 
2761 GTGCGTATCG CAAAGGCTGT GAAGGAAGGA CGCTGGGGCA AAGTGAAAGC TTTGCAATGG 
2821 CTCCTGACCC ACTCGTTCTA CGGCAAAGCC CTCGCCGTGA AACGGGTAAC TGACAACTCG 
2881 GGCAGCAAAA CACCTGGTGT GGACGGGATA ACCTGGTCCA CACAAGAGCA GAAAGCCCAA 
2941 GCCATAAAGT CCCTCAGGAG AAGAGGCTAT AAACCCCAAC CCCTGAGGCG GGTATACATC 
3001 CCGAAAGCAA ACGGCAAACA GCGCCCGCTA GGAATCCCGA CAATGAAGGA CAGGGCAATG 
3061 CAGGCACTAT ATGCCCTAGC CCTAGAACCA GTCGCGGAAA CCACAGCAGA CCGGAACTCC 
3121 TATGGGTTCC GGCGAGGACG ATGCATAGCC GATGCAGCGA CGCAGTGTCA CATCACGCTA 
3181 GCCAAAACAG ACCGTGCACA ATACGTTCTC GACGCCGATA TTGCTGGGTG CTTTGACAAC 
3241 ATCAGCCATG AGTGGCTACT AGCTAACATT CCACTAGACA AAAGAATTCT ACGGAAATGG 
3301 CTTAAATCTG GGTTTGTCTG GAAGCAGCAA CTCTTCCCCA TCCATGCTGG AACACCTCAG 
3361 GGAGGGGTAA TCTCCCCGAT GCTTGCCAAC ATGACACTGG ATGGGATGGA AGAATTGTTA 
3421 AACAAGTTTC CCAGGGCGCA CAAGGTCAAA CTCATCCGAT ATGCCGACGA CTTCGTCGTA 
3481 ACCGGTGAAA CGAAGGAAGT GCTCTATATT GCCGGTGCGG TAATACAAGC ATTCCTCAAG 
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3541 GAAAGGGGCC TTACCCTATC AAAGGAAAAG ACGAAGATCG TACACATTGA AGAAGGGTTT 
3601 GACITTCTCG GATGGAACAT TCGCAAATAT GATGGGAAAC TGCTCATCAA ACCTGCGAAG 
3661 AAGAACGTTA AAGCGTTCCT CAAGAAAATC CGAGACACCT TAAGAGAACT TAGGACAGCA 
3721 CCCCAGGAGA TTGTGATAGA CACACTCAAC CCAATCATCA GAGGTTGGAC TAACTATCAC 
3781 AAAAATCAGG CATCCAAAGA AACCTTCGTC GGAGTGGACC ACCTCATATG GCAAAAATTA 
3841 TGGCGATGGG CAAGGCGCCG ACACCCAAGC AAATCTGTCC GATGGGTGAA GAGTAAGTAC 
3901 TTCATCCAAA TCGGGAACAG AAAATGGATG TTCGGAATAT GGACGAAAGA CAAAAACGGA 
3961 GACCCGTGGG CCAAGCATTT AATCAAAGCC TCGGAAATCC GAATCCAACG TCGCGGTAAA 
4021 ATCAAGGCAG ACGCCAACCC GTTTCTCCCA GAATGGGCAG AATACTTTGA GCAGCGCAAG 
40B1 AAACTCAAAG AGGCCCCTGC CCAATACCGG CGCACCCGTC GGGAATTGTG GAAGAAACAA 
4141 GGCGGCATCT GTCCAGTATG TGGGGGAGAA ATTGAGCAAG ACATGCTCAC CGAAATCCAC 
4201 CACATACTGC CCAAACACAA GGGTGGTACT GACGACCTGG ACAATCTTGT CCTAATCCAC 
4261 ACTAACTGCC ACAAACAGGT GCACAACCGA GATGGTCAGC ACAGCCGGTT CCTCTTGAAA 
4321 GAGGGGCTTT GACTGCAGGC AAGCTTGGCA CTGGCCGTCG TTTTACAACG TCGTGACTGG 
4381 GAAAACCCTG GCGTTACCCA ACTTAATCGC CTTGCAGCAC ATCCCCCTTT CGCCAGCTGG 
4441 CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC 
4501 GAATGGCAGC TTGGCTGTTT TGGCGGATGA GATAAGATTT TCAGCCTGAT ACAGATTAAA 
4561 TCAGAACGCA GAAGCGGTCT GATAAAACAG AATTTGCCTG GCGGCAGTAG CGCGGTGGTC 
4621 CCACCTGACC CCATGCCGAA CTCAGAAGTG AAACGCCGTA GCGCCGATGG TAGTGTGGGG 
4681 TCTCCCCATG CGAGAGTAGG GAACTGCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA 
4741 AGACTGGGCC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCCTGA GTAGGACAAA 
4801 TCCGCCGGGA GCGGATTTGA ACGTTGCGAA GCAACGGCCC GGAGGGTGGC GGGCAGGACG 
4861 CCCGCCATAA ACTGCCAGGC ATCAAATTAA GCAGAAGGCC ATCCTGACGG ATGGCCTTTT 
4921 TGCGTTTCTA CAAACTCTTT TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC 
4981 ATGAGACAAT AACCCTGATA AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT 
5041 CAACATTTCC GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT 
5101 CACCCAGAAA CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT 
5161 TACATCGAAC TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT 
5221 TCTCCAATGA TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTGTTGAC 
5281 GCCGGGCAAG AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC 
5341 TCACCAGTCA CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT 
5401 GCCATAACCA TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG 
5461 AAGGAGCTAA CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG 
5521 GAACCGGAGC TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGCA 
5581 ATGGCAACAA CGTTGCGCAA ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA 
5641 CAATTAATAG ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT 
5701 CCGGCTGGCT GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC 
5761 ATTGCAGCAC TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG 
5821 AGTCAGGCAA CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT 
5881 AAGCATTGGT AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA TTTACCCCGG 
5941 TTGATAATCA GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA 
6001 ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC 
6061 AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGACCGAG ATAGGGTTGA 
6121 GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG 
6181 GGCGAAAAAC CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT 
6241 TTTTGGGGTC GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA 
6301 GAGCTTGACG GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA GCGAAAGGAG 
6361 CGGGCGCTAG GGCGCTGGCA AGTGTAGCGG TCACGCTGCG CGTAACCACC ACACCCGCCG 
6421 CGCTTAATGC GCCGCTACAG GGCGCGTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT 
6481 CTCATGACCA AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA 
6541 AAGATCAAAG GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA 
6601 AAAAAACCAC CGCTACCAGC GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT 
6661 CCGAAGGTAA CTGGCTTCAG CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG 
6721 TAGTTAGGCC ACCACTTCAA GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC 
6781 CTGTTACCAG TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA 
6841 CGATAGTTAC CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC 
6901 AGCTTGGAGC GAACGACCTA CACCGAACTG AGATACCTAC AGCGTGAGCT ATGAGAAAGC 
6961 GCCACGCTTC CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA 
7021 GGAGAGCGCA CGAGGGAGCT TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG 
7081 TTTCGCCACC TCTGACTTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA 
7141 TGGAAAAACG CCAGCAACGC GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT 
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7201 CACATGTTCT TTCCTGCGTT ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCTTTGAG 
7261 TGAGCTGATA CCGCTCGCCG CAGCCGAACG ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA 
7321 GCGGAAGAGC GCCTGATGCG GTATTTTCTC CTTACGCATC TGTGCGGTAT TTCACACCGC 
7381 ATATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC CAGTATACAC 
7441 TCCGCTATCG CTACGTGACT GGGTCATGGC TGCGCCCCGA CACCCGCCAA CACCCGCTGA 
7501 CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC 
7561 CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GGCAGCTGCG 
7621 GTAAAGCTCA TCAGCGTGGT CGTGCAGCGA TTCACAGATG TCTGCCTGTT CATCCGCGTC 
7681 CAGCTCGTTG AGTTTCTCCA GAAGCGTTAA TGTCTGGCTT CTGATAAAGC GGGCCATGTT 
7741 AAGGGCGGTT TTTTCCTGTT TGGTCACTGA TGCCTCCGTG TAAGGGGGAT TTCTGTTCAT 
7801 GGGGGTAATG ATACCGATGA AACGAGAGAG GATGCTCACG ATACGGGTTA CTGATGATGA 
7861 ACATGCCCGG TTACTGGAAC GTTGTGAGGG TAAACAACTG GCGGTATGGA TGCGGCGGGA 
7921 CCAGAGAAAA ATCACTCAGG GTCAATGCCA GCGCTTCGTT AATACAGATG TAGGTGTTCC 
7981 ACAGGGTAGC CAGCAGCATC CTGCGATGCA GATCCGGAAC ATAATGGTGC AGGGCGCTGA 
8041 CTTCCGCGTT TCCAGACTTT ACGAAACACG GAAACCGAAG ACCATTCATG TTGTTGCTCA 
8101 GGTCGCAGAC GTTTTGCAGC AGCAGTCGCT TCACGTTCGC TCGCGTATCG GTGATTCATT 
8161 CTGCTAACCA GTAAGGCAAC CCCGCCAGCC TAGCCGGGTC CTCAACGACA GGAGCACGAT 
8221 CATGCGCACC CGTGGCCAGG ACCCAACGCT GCCCGAAATT 
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1 CCGACACCAT CGAATGGTGC AAAACCTTTC GCGGTATGGC ATGATAGCGC CCGGAAGAGA 
61 GTCAATTCAG GGTGGTGAAT GTGAAACCAG TAACGTTATA CGATGTCGCA GAGTATGCCG 
121 GTGTCTCTTA TCAGACCGTT TCCCGCGTGG TGAACCAGGC CAGCCACGTT TCTGCGAAAA 
181 CGCGGGAAAA AGTGGAAGCG GCGATGGCGG AGCTGAATTA CATTCCCAAC CGCGTGGCAC 
241 AACAACTGGC GGGCAAACAG TCGTTGCTGA TTGGCGTTGC CACCTCCAGT CTGGCCCTGC 
301 ACGCGCCGTC GCAAATTGTC GCGGCGATTA AATCTCGCGC CGATCAACTG GGTGCCAGCG 
361 TGGTGGTGTC GATGGTAGAA CGAAGCGGCG TCGAAGCCTG TAAAGCGGCG GTGCACAATC 
421 TTCTCGCGCA ACGCGTCAGT GGGCTGATCA TTAACTATCC GCTGGATGAC CAGGATGCCA 
481 TTGCTGTGGA AGCTGCCTGC ACTAATGTTC CGGCGTTATT TCTTGATGTC TCTGACCAGA 
541 CACCCATCAA CAGTATTATT TTCTCCCATG AAGACGGTAC GCGACTGGGC GTGGAGCATC 
601 TGGTCGCATT GGGTCACCAG CAAATCGCGC TGTTAGCGGG CCCATTAAGT TCTGTCTCGG 
661 CGCGTCTGCG TCTGGCTGGC TGGCATAAAT ATCTCACTCG CAATCAAATT CAGCCGATAG 
721 CGGAACGGGA AGGCGACTGG AGTGCCATGT CCGGTTTTCA ACAAACCATG CAAATGCTGA 
781 ATGAGGGCAT CGTTCCCACT GCGATGCTGG TTGCCAACGA TCAGATGGCG CTGGGCGCAA 
841 TGCGCGCCAT TACCGAGTCC GGGCTGCGCG TTGGTGCGGA TATCTCGGTA GTGGGATACG 
901 ACGATACCGA AGACAGCTCA TGTTATATCC CGCCGTTAAC CACCATCAAA CAGGATTTTC 
961 GCCTGCTGGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC CAGGCGGTGA 
1021 AGGGCAATCA GCTGTTGCCC GTCTCACTGG TGAAAAGAAA AACCACCCTG GCGCCCAATA 
1081 CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTIT 
1141 CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TAAGTTAGCT CACTCATTAG 
1201 GCACAATTCT CATGTTTGAC AGCTTATCAT CGACTGCACG GTGCACCAAT GCTTCTGGCG 
1261 TCAGGCAGCC ATCGGAAGCT GTGGTATGGC TGTGCAGGTC GTAAATCACT GCATAATTCG 
1321 TGTCGCTCAA GGCGCACTCC CGTTCTGGAT AATGTTTTTT GCGCCGACAT CATAACGGTT 
1381 CTGGCAAATA TTCTGAAATG AGCTGTTGAC AATTAATCAT CGGCTCGTAT AATGTGTGGA 
1441 ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCCAGT CCGTTTAGGT GTTTTCACGA 
1501 GCACTTCACC AACAAGGACC ATAGCATATG AAAATCGAAG AAGGTAAACT GGTAATCTGG 
1561 ATTAACGGCG ATAAAGGCTA TAACGGTCTC GCTGAAGTCG GTAAGAAATT CGAGAAAGAT 
1621 ACCGGAATTA AAGTCACCGT TGAGCATCCG GATAAACTGG AAGAGAAATT CCCACAGGTT 
1681 GCGGCAACTG GCGATGGCCC TGACATTATC TTCTGGGCAC ACGACCGCTT TGGTGGCTAC 
1741 GCTCAATCTG GCCTGTTGGC TGAAATCACC CCGGACAAAG CGTTCCAGGA CAAGCTGTAT 
1801 CCGTTTACCT GGGATGCCGT ACGTTACAAC GGCAAGCTGA TTGCTTACCC GATCGCTGTT 
1861 GAAGCGTTAT CGCTGATTTA TAACAAAGAT CTGCTGCCGA ACCCGCCAAA AACCTGGGAA 
1921 GAGATCCCGG CGCTGGATAA AGAACTGAAA GCGAAAGGTA AGAGCGCGCT GATGTTCAAC 
1981 CTGCAAGAAC CGTACTTCAC CTGGCCGCTG ATTGCTGCTG ACGGGGGTTA TGCGTTCAAG 
2041 TATGAAAACG GCAAGTACGA CATTAAAGAC GTGGGCGTGG ATAACGCTGG CGCGAAAGCG 
2101 GGTCTGACCT TCCTGGTTGA CCTGATTAAA AACAAACACA TGAATGCAGA CACCGATTAC 
2161 TCCATCGCAG AAGCTGCCTT TAATAAAGGC GAAACAGCGA TGACCATCAA CGGCCCGTGG 
2221 GCATGGTCCA ACATCGACAC CAGCAAAGTG AATTATGGTG TAACGGTACT GCCGACCTTC 
2281 AAGGGTCAAC CATCCAAACC GTTCGTTGGC GTGCTGAGCG CAGGTATTAA CGCCGCCAGT 
2341 CCGAACAAAG AGCTGGCAAA AGAGTTCCTC GAAAACTATC TGCTGACTGA TGAAGGTCTG 
2401 GAAGCGGTTA ATAAAGACAA ACCGCTGGGT GCCGTAGCGC TGAAGTCTTA CGAGGAAGAG 
2461 TTGGCGAAAG ATCCACGTAT TGCCGCCACT ATGGAAAACG CCCAGAAAGG TGAAATCATG 
2521 CCGAACATCC CGCAGATGTC CGCTTTCTGG TATGCCGTGC GTACTGCGGT GATCAACGCC 
2581 GCCAGCGGTC GTCAGACTGT CGATGCCGCC CTGGCCGCCG CGCAGACTGC CGCCGCCGCC 
2641 GCCATGGAGA CAAGGCAAAT GGCAGTGGAA CAAACCACTG GTGCGGTCAC CAACCAAACG 
2701 GAAACAAGCT GGCACAGCAT AGACTGGGCC AAAGCCAACC GTGAGGTAAA GAGGCTGCAA 
2761 GTGCGTATCG CAAAGGCTGT GAAGGAAGGA CGCTGGGGCA AAGTGAAAGC TTTGCAATGG 
2821 CTCCTGACCC ACTCGTTCTA CGGCAAAGCC CTCGCCGTGA AACGGGTAAC TGACAACTCG 
2881 GGCAGCAAAA CACCTGGTGT GGACGGGATA ACCTGGTCCA CACAAGAGCA GAAAGCCCAA 
2941 GCCATAAAGT CCCTCAGGAG AAGAGGCTAC AAACCCCAAC CCCTGAGGCG GGTATACATC 
3001 CCGAAAGCAA GCGGCAAGCA GCGCCCGCTA GGAATCCCGA CAACGAAGGA CAGGGCAATG 
3061 CAGGCATTAT ATGCCCTAGC TCTAGAACCT GTCGCGGAAA CCACAGCGGA TCGGAACTCA 
3121 TACGGGTTCC GTCAAGGACG GTGCACGGCA GATGCTGCCG GGCAGTGCTT CACTGTGCTA 
3181 GGCCGATCTG ACTGTGCAAA ATATATCCTT GATGCTGACA TCACCGGATG CTTTGACAAC 
3241 ATTAGCCACG AATGGCTACT AGACAACATC CCGCTGGACA AAGAGGTTCT GCGGAAGTGG 
3301 CTTAAATCTG GGTTCGTCTG GAAACAGCAA CTCTTCCCAA CCCATGCTGG GACACCTCAG 
3361 GGAGGGGTAA TCTCCCCAAT GCTGGCCAAT ATGACCCTAG ATGGGATGGA AGAATTGCTG 
3421 AAGAAACACC TCAGAAAACA AAAAGTCAAC CTCATACGAT ATGCAGACGA CTTTGTCGTA 
3481 ACTGGTGAAT CAAAGGAAAC CTTGGAAAAG GTTACAACTG TAATCCAAGA ATTCCTCAAG 
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3541 GAAAGGGGCC TTACCCTATC AGAAGAAAAG ACAAAGGTCG TTCATATCGA AGAAGGATTT 
3601 GACTTTCTTG GATGGAACAT TCGCAAATAT GGTGAGAAGC TTCTCATCAA ACCTGCGAAG 
3661 AAGAACATCA AGGCGTTCCA CAAGAAAATC CGAGACGCAC TGAAGGAACT CAGAACAGCC 
3721 ACCCAGGAAG CTGTGATAGA CACACTCAAC CCAATTATCA AAGGCTGGGC TAACTATCAC 
3781 AGAAACCAGG TTTCCAAAAG AATCTTCAAC AGAGCGGATG ACAATATCTG GCATAAATTA 
3841 TGGCGATGGG CAAAACGTCG GCACCCAAAC AAACCAGCCC GATGGACAAA GAACAAATAC 
3901 TTCATCAAAA TCGGGAATAG GCACTGGGTG TTTGGCACAT GGAAAAAGGA CAAAGAGGGA 
3961 AGGTTACGGT CCAGATACCT AATTAAAGCC GGAGATACTC GAATCCAACG TCATGTCAAA 
4021 ATCAAGGCAG ACGCCAATCC GTTTCTCCCA GAGTGGGCAG AATACTTTGA GGAACGCAAG 
4081 AAACTCAAAG AAGCCCCTGC TCAATATCGG CGCATCCGCC GAGAACTATG GAAGAAACAG 
4141 GGTGGTATCT GTCCAGTATG CGGGGGTGAA ATTGAGCAAG ACATGCTCAC TGAAATCCAC 
4201 CACATATTGC CCAAACACAA GGGTGGTTCT GACGACCTGG ATAATCTTGT CTTAATCCAC 
4261 GCCAACTGTC ACAAACAGGT GCACAGCCGA GACGGTCAGC ACAGCCGGTT CCTCTTGAAA 
4321 GAGGGGCTTT GACTGCAGGC AAGCTTGGCA CTGGCCGTCG TTTTACAACG TCGTGACTGG 
4381 GAAAACCCTG GCGTTACCCA ACTTAATCGC CTTGCAGCAC ATCCCCCTTT CGCCAGCTGG 
4441 CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC 
4501 GAATGGCAGC TTGGCTGTTT TGGCGGATGA GATAAGATTT TCAGCCTGAT ACAGATTAAA 
4561 TCAGAACGCA GAAGCGGTCT GATAAAACAG AATTTGCCTG GCGGCAGTAG CGCGGTGGTC 
4621 CCACCTGACC CCATGCCGAA CTCAGAAGTG AAACGCCGTA GCGCCGATGG TAGTGTGGGG 
4681 TCTCCCCATG CGAGAGTAGG GAACTGCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA 
4741 AGACTGGGCC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCCTGA GTAGGACAAA 
4801 TCCGCCGGGA GCGGATTTGA ACGTTGCGAA GCAACGGCCC GGAGGGTGGC GGGCAGGACG 
4861 CCCGCCATAA ACTGCCAGGC ATCAAATTAA GCAGAAGGCC ATCCTGACGG ATGGCCTTTT 
4921 TGCGTTTCTA CAAACTCTTT TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC 
4981 ATGAGACAAT AACCCTGATA AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT 
5041 CAACATTTCC GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT 
5101 CACCCAGAAA CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT 
5161 TACATCGAAC TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT 
5221 TCTCCAATGA TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTGTTGAC 
5281 GCCGGGCAAG AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC 
5341 TCACCAGTCA CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT 
5401 GCCATAACCA TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG 
5461 AAGGAGCTAA CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG 
5521 GAACCGGAGC TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGCA 
5581 ATGGCAACAA CGITGCGCAA ACTATTAACT GGCGAACTAC ITACTCTAGC TTCCCGGCAA 
5641 CAATTAATAG ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT 
5701 CCGGCTGGCT GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC 
5761 ATTGCAGCAC TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG 
5821 AGTCAGGCAA CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT 
5881 AAGCATTGGT AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA TTTACCCCGG 
5941 TTGATAATCA GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA 
6001 ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC 
6061 AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGACCGAG ATAGGGTTGA 
6121 GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG 
6181 GGCGAAAAAC CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT 
6241 TTTTGGGGTC GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA 
6301 GAGCTTGACG GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA GCGAAAGGAG 
6361 CGGGCGCTAG GGCGCTGGCA AGTGTAGCGG TCACGCTGCG CGTAACCACC ACACCCGCCG 
6421 CGCTTAATGC GCCGCTACAG GGCGCGTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT 
6481 CTCATGACCA AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA 
6541 AAGATCAAAG GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA 
6601 AAAAAACCAC CGCTACCAGC GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT 
6661 CCGAAGGTAA CTGGCTTCAG CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG 
6721 TAGTTAGGCC ACCACTTCAA GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC 
6781 CTGTTACCAG TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA 
6841 CGATAGTTAC CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC 
6901 AGCTTGGAGC GAACGACCTA CACCGAACTG AGATACCTAC AGCGTGAGCT ATGAGAAAGC 
6961 GCCACGCTTC CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA 
7021 GGAGAGCGCA CGAGGGAGCT TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG 
7081 TTTCGCCACC TCTGACTTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA 
7141 TGGAAAAACG CCAGCAACGC GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT 
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7201 CACATGTTCT TTCCTGCGTT ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCTTTGAG 
7261 TGAGCTGATA CCGCTCGCCG CAGCCGAACG ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA 
7321 GCGGAAGAGC GCCTGATGCG GTATTTTCTC CTTACGCATC TGTGCGGTAT TTCACACCGC 
7381 ATATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC CAGTATACAC 
7441 TCCGCTATCG CTACGTGACT GGGTCATGGC TGCGCCCCGA CACCCGCCAA CACCCGCTGA 
7501 CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC 
7561 CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GGCAGCTGCG 
7621 GTAAAGCTCA TCAGCGTGGT CGTGCAGCGA TTCACAGATG TCTGCCTGTT CATCCGCGTC 
7681 CAGCTCGTTG AGTTTCTCCA GAAGCGTTAA TGTCTGGCTT CTGATAAAGC GGGCCATGTT 
7741 AAGGGCGGTT TTTTCCTGTT TGGTCACTGA TGCCTCCGTG TAAGGGGGAT TTCTGTTCAT 
7801 GGGGGTAATG ATACCGATGA AACGAGAGAG GATGCTCACG ATACGGGTTA CTGATGATGA 
7861 ACATGCCCGG TTACTGGAAC GTTGTGAGGG TAAACAACTG GCGGTATGGA TGCGGCGGGA 
7921 CCAGAGAAAA ATCACTCAGG GTCAATGCCA GCGCTTCGTT AATACAGATG TAGGTGTTCC 
7981 ACAGGGTAGC CAGCAGCATC CTGCGATGCA GATCCGGAAC ATAATGGTGC AGGGCGCTGA 
8041 CTTCCGCGTT TCCAGACTTT ACGAAACACG GAAACCGAAG ACCATTCATG TTGTTGCTCA 
8101 GGTCGCAGAC GTTTTGCAGC AGCAGTCGCT TCACGTTCGC TCGCGTATCG GTGATTCATT 
8161 CTGCTAACCA GTAAGGCAAC CCCGCCAGCC TAGCCGGGTC CTCAACGACA GGAGCACGAT 
8221 CATGCGCACC CGTGGCCAGG ACCCAACGCT GCCCGAAATT 
FIG . 8 ( cont . ) 
U . S . Patent Dec . 11 , 2018 Sheet 12 of 24 US 10 , 150 , 955 B2 
m 
1 CCGACACCAT CGAATGGTGC AAAACCTTTC GCGGTATGGC ATGATAGCGC CCGGAAGAGA 
61 GTCAATTCAG GGTGGTGAAT GTGAAACCAG TAACGTTATA CGATGTCGCA GAGTATGCCG 
121 GTGTCTCTTA TCAGACCGTT TCCCGCGTGG TGAACCAGGC CAGCCACGTT TCTGCGAAAA 
181 CGCGGGAAAA AGTGGAAGCG GCGATGGCGG AGCTGAATTA CATTCCCAAC CGCGTGGCAC 
241 AACAACTGGC GGGCAAACAG TCGTTGCTGA TTGGCGTTGC CACCTCCAGT CTGGCCCTGC 
301 ACGCGCCGTC GCAAATTGTC GCGGCGATTA AATCTCGCGC CGATCAACTG GGTGCCAGCG 
361 TGGTGGTGTC GATGGTAGAA CGAAGCGGCG TCGAAGCCTG TAAAGCGGCG GTGC?CAATC 
421 TTCTCGCGCA ACGCGTCAGT GGGCTGATCA ITAACTATCC GCTGGATGAC CAGGATGCCA 
481 TTGCTGTGGA AGCTGCCTGC ACTAATGTTC CGGCGTTATT TCTTGATGTC TCTGACCAGA 
541 CACCCATCAA CAGTATTATT TTCTCCCATG AAGACGGTAC GCGACTGGGC GTGGAGCATC 
601 TGGTCGCATT GGGTCACCAG CAAATCGCGC TGTTAGCGGG CCCATTAAGT TCTGTCTCGG 
661 CGCGTCTGCG TCTGGCTGGC TGGCATAAAT ATCTCACTCG CAATCAAATT CAGCCGATAG 
721 CGGAACGGGA AGGCGACTGG AGTGCCATGT CCGGTTTTCA ACAAACCATG CAAATGCTGA 
781 ATGAGGGCAT CGTTCCCACT GCGATGCTGG TTGCCAACGA TCAGATGGCG CTGGGCGCAA 
841 TGCGCGCCAT TACCGAGTCC GGGCTGCGCG TTGGTGCGGA TATCTCGGTA GTGGGATACG 
901 ACGATACCGA AGACAGCTCA TGTTATATCC CGCCGTTAAC CACCATCAAA CAGGATTTTC 
961 GCCTGCTGGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC CAGGCGGTGA 
1021 AGGGCAATCA GCTGTTGCCC GTCTCACTGG TGAAAAGAAA AACCACCCTG GCGCCCAATA 
1081 CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT 
1141 CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TAAGTTAGCT CACTCATTAG 
1201 GCACAATTCT CATGTTTGAC AGCTTATCAT CGACTGCACG GTGCACCAAT GCTTCTGGCG 
1261 TCAGGCAGCC ATCGGAAGCT GTGGTATGGC TGTGCAGGTC GTAAATCACT GCATAATTCG 
1321 TGTCGCTCAA GGCGCACTCC CGTTCTGGAT AATGTTTTTT GCGCCGACAT CATAACGGTT 
1381 CTGGCAAATA TTCTGAAATG AGCTGTTGAC AATTAATCAT CGGCTCGTAT AATGTGTGGA 
1441 ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCCAGT CCGTTTAGGT GTTTTCACGA 
1501 GCACTTCACC AACAAGGACC ATAGCATATG AAAATCGAAG AAGGTAAACT GGTAATCTGG 
1561 ATTAACGGCG ATAAAGGCTA TAACGGTCTC GCTGAAGTCG GTAAGAAATT CGAGAAAGAT 
1621 ACCGGAATTA AAGTCACCGT TGAGCATCCG GATAAACTGG AAGAGAAATT CCCACAGGTT 
1681 GCGGCAACTG GCGATGGCCC TGACATTATC TTCTGGGCAC ACGACCGCTT TGGTGGCTAC 
1741 GCTCAATCTG GCCTGTTGGC TGAAATCACC CCGGACAAAG CGTTCCAGGA CAAGCTGTAT 
1801 CCGTTTACCT GGGATGCCGT ACGTTACAAC GGCAAGCTGA TTGCTTACCC GATCGCTGTT 
1861 GAAGCGTTAT CGCTGATTTA TAACAAAGAT CTGCTGCCGA ACCCGCCAAA AACCTGGGAA 
1921 GAGATCCCGG CGCTGGATAA AGAACTGAAA GCGAAAGGTA AGAGCGCGCT GATGTTCAAC 
1981 CTGCAAGAAC CGTACTTCAC CTGGCCGCTG ATTGCTGCTG ACGGGGGTTA TGCGTTCAAG 
2041 TATGAAAACG GCAAGTACGA CATTAAAGAC GTGGGCGTGG ATAACGCTGG CGCGAAAGCG 
2101 GGTCTGACCT TCCTGGTTGA CCTGATTAAA AACAAACACA TGAATGCAGA CACCGATTAC 
2161 TCCATCGCAG AAGCTGCCTT TAATAAAGGC GAAACAGCGA TGACCATCAA CGGCCCGTGG 
2221 GCATGGTCCA ACATCGACAC CAGCAAAGTG AATTATGGTG TAACGGTACT GCCGACCTTC 
2281 AAGGGTCAAC CATCCAAACC GTTCGTTGGC GTGCTGAGCG CAGGTATTAA CGCCGCCAGT 
2341 CCGAACAAAG AGCTGGCAAA AGAGTTCCTC GAAAACTATC TGCTGACTGA TGAAGGTCTG 
2401 GAAGCGGTTA ATAAAGACAA ACCGCTGGGT GCCGTAGCGC TGAAGTCTTA CGAGGAAGAG 
2461 TTGGCGAAAG ATCCACGTAT TGCCGCCACT ATGGAAAACG CCCAGAAAGG TGAAATCATG 
2521 CCGAACATCC CGCAGATGTC CGCTTTCTGG TATGCCGTGC GTACTGCGGT GATCAACGCC 
2581 GCCAGCGGTC GTCAGACTGT CGATGCCGCC CTGGCCGCCG CGCAGACTGC CGCCGCCGCC 
2641 GCCATGAAGG TAAACAAACT TGTCGTAAAA AGCGAACAGG ACTTGAGAAA CTGCTTGGAT 
2701 CTTCTTTATC AAGAAGCTAA AAAGGGAAAA CATTTTTACG GCATGCTTGA GTTGCTTCAA 
2761 AATGATGTTG TCATTTTAGA AGCTATTCGC AATATTAAAA GCAATAAAGG TAGCAAAACG 
2821 GCGGGGATTG ATCAGAAAAT AGTAGATGAT TATTTGCTTA TGCCAACGGA AAAGGTTTTC 
2881 GGGATGATAA AAGCCAAACT CAATGACTAT AAGCCTATAC CAGTGAGAAG GTGCAACAAG 
2941 CCCAAAGGAA ATGCCAAAAG CTCAAAAAGA AAAGGCAATA GTCCGAATGA GGAAGGGGAA 
3001 ACGAGGCCCT TAGGAATATC CGCAGTGACG GATAGAATCA TCCAAGAGAT GCTACGGATA 
3061 GTGCTCGAGC CGATTTTCGA AGCCCAATTC TATCCGCACA GITATGGGTT CAGACCGTAT 
3121 CGCTCCACCG AACATGCCTT AGCCTGGATG CTGAAAATCA TCAACGGAAG CAAACTGTAT 
3181 TGGGTTGTAA AAGGTGACAT TGAAAGTTAT TTTGATCACA TCAATCATAA GAAGCTTCTG 
3241 AACATCATGT GGAATATGGG CGTTAGGGAT AAACGGGTAC TATGCATCGT TAAGAAAATG 
3301 CTGAAGGCGG GGCAAGTGAT ACAAGGTAAA TTCTATCCAA CCGCTAAGGG GATTCCTCAG 
3361 GGAGGAATTA TTAGCCCGTT GTTGGCTAAT GTATATCTCA ACAGCTTTGA CTGGATGGTT 
3421 GGCCAAGAAT ATGAGTATCA CCCTAATAAC GCAAACTATC GGGAAAAGAA AAACGCATTA 
3481 GCGGCGTTAA GGAACAAGGG ACATCATCCC GTCTTTTACA TTCGTTATGC TGATGATTGG 
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3541 GTTATTCTTA CGGATACGAA AGAATATGCG GAAAAAATAA GGGAGCAATG TAAGCAGTAT 
3601 TTAGCCTGTG AGTTGCACTT AACTCTATCG GATGAGAAAA CGTTCATTGC AGATATCCGC 
3661 GAACAACGGG TTAAGTTTCT AGGCTTTTGT ATTGAGGCAG GAAAGCGGCG TTTTCATAAA 
3721 AAAGGATTCG CCGCTAGAAT GATTCCCGAT ATGGAAAAAG TCAATGCCAA GGTCAAAGAA 
3781 ATTAAGCGCG ATATTCGATT GTTAAGAACG AGAAAATCGG AATTAGAGAA AGCCCTTGAT 
3841 ATTGAAAACA TTAACACCAA AATTATAGGA TTAGCCAATC ATCTAAAAAT AGGCATTTCC 
3901 AAGTACATTA TGGGCAAAGT AGATCGCGTC ATTGAAGAGA CAGCCTACCG CACCTGGGTT 
3961 AAAATGTATG GGAAAGAAAA AGCGGCGCAA TATAAAAGGC CTGTGTCAGA GTTTCACAAT 
4021 CGGATTGACA GACATAAAGG CTATCAAATG AAACATTTTT CTGTCGTCAC AGAGGATGGC 
4081 ATAAGAGTAG GGATTACCCA TGCAAAAATA ACGCCTATAC AGTATGCAAC AGTATTCAAA 
4141 CAAGAAATGA CCCCATACAC TGCAGACGGC AGAAAAATGT ATGAAGAAAA GCATAGAAAA 
4201 ATACGATTGC CGGATAAAAT GAGTCTGTTC GATCACGATT CGATATTCAT CTACATTTTA 
4261 TCTGAGCATA ATGATGGGAA ATATAATCTT GAATATTTCT TAAATAGGGT GAATGTATTT 
4321 CACAGAGATA AAGGAAAATG CAAAATATGT GCCGTATACT TAAGTCCCGG TAACTTCCAC 
4381 TGCCATCATA TTGACCCGAG TAAACCTTTA AGTGAGATCA ATAAGACCGT TAATCTAATT 
4441 AGCTTATGCA ACCAATGCCA TAGGCTTGTC CATAGCAACC AAGAACCGCC GTTTACAGAA 
4501 CGAAAAATGT TTGACAAACT AACGAAATAT AGGAACAAGC TGAAAATATA AGGATCCTCT 
4561 AGCTGCAGGC AAGCTTGGCA CTGGCCGTCG TTTTACAACG TCGTGACTGG GAAAACCCTG 
4621 GCGTTACCCA ACTTAATCGC CTTGCAGCAC ATCCCCCTTT CGCCAGCTGG CGTAATAGCG 
4681 AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC GAATGGCAGC 
4741 TTGGCTGTTT TGGCGGATGA GATAAGATTT TCAGCCTGAT ACAGATTAAA TCAGAACGCA 
4801 GAAGCGGTCT GATAAAACAG AATTTGCCTG GCGGCAGTAG CGCGGTGGTC CCACCTGACC 
4861 CCATGCCGAA CTCAGAAGTG AAACGCCGTA GCGCCGATGG TAGTGTGGGG TCTCCCCATG 
4921 CGAGAGTAGG GAACTGCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA AGACTGGGCC 
4981 TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCCTGA GTAGGACAAA TCCGCCGGGA 
5041 GCGGATTTGA ACGTTGCGAA GCAACGGCCC GGAGGGTGGC GGGCAGGACG CCCGCCATAA 
5101 ACTGCCAGGC ATCAAATTAA GCAGAAGGCC ATCCTGACGG ATGGCCTTTT TGCGTTTCTA 
5161 CAAACTCTTT TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC ATGAGACAAT 
5221 AACCCTGATA AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT CAACATTTCC 
5281 GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT CACCCAGAAA 
5341 CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT TACATCGAAC 
5401 TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT TCTCCAATGA 
5461 TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTGTTGAC GCCGGGCAAG 
5521 AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC TCACCAGTCA 
5581 CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT GCCATAACCA 
5641 TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG AAGGAGCTAA 
5701 CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG GAACCGGAGC 
5761 TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGCA ATGGCAACAA 
5821 CGTTGCGCAA ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA CAATTAATAG 
5881 ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT CCGGCTGGCT 
5941 GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC ATTGCAGCAC 
6001 TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG AGTCAGGCAA 
6061 CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT AAGCATTGGT 
6121 AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA TTTACCCCGG TTGATAATCA 
6181 GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA ACGTTAATAT 
6241 TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC AATAGGCCGA 
6301 AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGACCGAG ATAGGGTTGA GTGTTGTTCC 
6361 AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG GGCGAAAAAC 
6421 CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT TTTTGGGGTC 
6481 GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA GAGCTTGACG 
6541 GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA GCGAAAGGAG CGGGCGCTAG 
6601 GGCGCTGGCA AGTGTAGCGG TCACGCTGCG CGTAACCACC ACACCCGCCG CGCTTAATGC 
6661 GCCGCTACAG GGCGCGTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT CTCATGACCA 
6721 AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA AAGATCAAAG 
6781 GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA AAAAAACCAC 
6841 CGCTACCAGC GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT CCGAAGGTAA 
6901 CTGGCTTCAG CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG TAGTTAGGCC 
6961 ACCACTTCAA GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC CTGTTACCAG 
7021 TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA CGATAGTTAC 
7081 CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC AGCTTGGAGC 
7141 GAACGACCTA CACCGAACTG AGATACCTAC AGCGTGAGCT ATGAGAAAGC GCCACGCTTC 
FIG . 9 ( cont . ) 
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7201 CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA GGAGAGCGCA 
7261 CGAGGGAGCT TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG TTTCGCCACC 
7321 TCTGACTTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA TGGAAAAACG 
7381 CCAGCAACGC GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT CACATGTTCT 
7441 TTCCTGCGTT ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCTTTGAG TGAGCTGATA 
7501 CCGCTCGCCG CAGCCGAACG ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA GCGGAAGAGC 
7561 GCCTGATGCG GTATTITCTC CTTACGCATC TGTGCGGTAT TTCACACCGC ATATATGGTG 
7621 CACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC CAGTATACAC TCCGCTATCG 
7681 CTACGTGACT GGGTCATGGC TGCGCCCCGA CACCCCCCAA CACCCGCTGA CGCGCCCTGA 
7741 CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC CGGGAGCTGC 
7801 ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GGCAGCTGCG GTAAAGCTCA 
7861 TCAGCGTGGT CGTGCAGCGA TTCACAGATG TCTGCCTGTT CATCCGCGTC CAGCTCGTTG 
7921 AGTTTCTCCA GAAGCGTTAA TGTCTGGCTT CTGATAAAGC GGGCCATGTT AAGGGCGGTT 
7981 TTTTCCTGTT TGGTCACTGA TGCCTCCGTG TAAGGGGGAT TTCTGTTCAT GGGGGTAATG 
8041 ATACCGATGA AACGAGAGAG GATGCTCACG ATACGGGTTA CTGATGATGA ACATGCCCGG 
8101 TTACTGGAAC GTTGTGAGGG TAAACAACTG GCGGTATGGA TGCGGCGGGA CCAGAGAAAA 
8161 ATCACTCAGG GTCAATGCCA GCGCTTCGTT AATACAGATG TAGGTGTTCC ACAGGGTAGC 
8221 CAGCAGCATC CTGCGATGCA GATCCGGAAC ATAATGGTGC AGGGCGCTGA CTTCCGCGTT 
8281 TCCAGACTTT ACGAAACACG GAAACCGAAG ACCATTCATG TTGTTGCTCA GGTCGCAGAC 
8341 GTTTTGCAGC AGCAGTCGCT TCACGTTCGC TCGCGTATCG GTGATTCATT CTGCTAACCA 
8401 GTAAGGCAAC CCCGCCAGCC TAGCCGGGTC CTCAACGACA GGAGCACGAT CATGCGCACC 
8461 CGTGGCCAGG ACCCAACGCT GCCCGAAATT 
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1 CCGACACCAT CGAATGGTGC AAAACCTTTC GCGGTATGGC ATGATAGCGC CCGGAAGAGA 
61 GTCAATTCAG GGTGGTGAAT GTGAAACCAG TAACGTTATA CGATGTCGCA GAGTATGCCG 
121 GTGTCTCTTA TCAGACCGTT TCCCGCGTGG TGAACCAGGC CAGCCACGTT TCTGCGAAAA 
181 CGCGGGAAAA AGTGGAAGCG GCGATGGCGG AGCTGAATTA CATTCCCAAC CGCGTGGCAC 
241 AACAACTGGC GGGCAAACAG TCGTTGCTGA TTGGCGTTGC CACCTCCAGT CTGGCCCTGC 
301 ACGCGCCGTC GCAAATTGTC GCGGCGATTA AATCTCGCGC CGATCAACTG GGTGCCAGCG 
361 TGGTGGTGTC GATGGTAGAA CGAAGCGGCG TCGAAGCCTG TAAAGCGGCG GTGCACAATC 
421 TTCTCGCGCA ACGCGTCAGT GGGCTGATCA TTAACTATCC GCTGGATGAC CAGGATGCCA 
481 TTGCTGTGGA AGCTGCCTGC ACTAATGTTC CGGCGTTATT TCTTGATGTC TCTGACCAGA 
541 CACCCATCAA CAGTATTATT TTCTCCCATG AAGACGGTAC GCGACTGGGC GTGGAGCATC 
601 TGGTCGCATT GGGTCACCAG CAAATCGCGC TGTTAGCGGG CCCATTAAGT TCTGTCTCGG 
661 CGCGTCTGCG TCTGGCTGGC TGGCATAAAT ATCTCACTCG CAATCAAATT CAGCCGATAG 
721 CGGAACGGGA AGGCGACTGG AGTGCCATGT CCGGTTTTCA ACAAACCATG CAAATGCTGA 
781 ATGAGGGCAT CGTTCCCACT GCGATGCTGG TTGCCAACGA TCAGATGGCG CTGGGCGCAA 
841 TGCGCGCCAT TACCGAGTCC GGGCTGCGCG TTGGTGCGGA TATCTCGGTA GTGGGATACG 
901 ACGATACCGA AGACAGCTCA TGTTATATCC CGCCGTTAAC CACCATCAAA CAGGATTTTC 
961 GCCTGCTGGG GCAAACCAGC GTGGACCGCT TGCTGCAACT CTCTCAGGGC CAGGCGGTGA 
1021 AGGGCAATCA GCTGTTGCCC GTCTCACTGG TGAAAAGAAA AACCACCCTG GCGCCCAATA 
1081 CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA CGACAGGTTT 
1141 CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TAAGTTAGCT CACTCATTAG 
1201 GCACAATTCT CATGTTTGAC AGCTTATCAT CGACTGCACG GTGCACCAAT GCTTCTGGCG 
1261 TCAGGCAGCC ATCGGAAGCT GTGGTATGGC TGTGCAGGTC GTAAATCACT GCATAATTCG 
1321 TGTCGCTCAA GGCGCACTCC CGTTCTGGAT AATGTTTTTT GCGCCGACAT CATAACGGTT 
1381 CTGGCAAATA TTCTGAAATG AGCTGTTGAC AATTAATCAT CGGCTCGTAT AATGTGTGGA 
1441 ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCCAGT CCGTTTAGGT GTTTTCACGA 
1501 GCACTTCACC AACAAGGACC ATAGCATATG AAAATCGAAG AAGGTAAACT GGTAATCTGG 
1561 ATTAACGGCG ATAAAGGCTA TAACGGTCTC GCTGAAGTCG GTAAGAAATT CGAGAAAGAT 
1621 ACCGGAATTA AAGTCACCGT TGAGCATCCG GATAAACTGG AAGAGAAATT CCCACAGGTT 
1681 GCGGCAACTG GCGATGGCCC TGACATTATC TTCTGGGCAC ACGACCGCTT TGGTGGCTAC 
1741 GCTCAATCTG GCCTGTTGGC TGAAATCACC CCGGACAAAG CGTTCCAGGA CAAGCTGTAT 
1801 CCGTTTACCT GGGATGCCGT ACGTTACAAC GGCAAGCTGA TTGCTTACCC GATCGCTGTT 
1861 GAAGCGTTAT CGCTGATTTA TAACAAAGAT CTGCTGCCGA ACCCGCCAAA AACCTGGGAA 
1921 GAGATCCCGG CGCTGGATAA AGAACTGAAA GCGAAAGGTA AGAGCGCGCT GATGTTCAAC 
1981 CTGCAAGAAC CGTACTTCAC CTGGCCGCTG ATTGCTGCTG ACGGGGGTTA TGCGTTCAAG 
2041 TATGAAAACG GCAAGTACGA CATTAAAGAC GTGGGCGTGG ATAACGCTGG CGCGAAAGCG 
2101 GGTCTGACCT TCCTGGTTGA CCTGATTAAA AACAAACACA TGAATGCAGA CACCGATTAC 
2161 TCCATCGCAG AAGCTGCCTT TAATAAAGGC GAAACAGCGA TGACCATCAA CGGCCCGTGG 
2221 GCATGGTCCA ACATCGACAC CAGCAAAGTG AATTATGGTG TAACGGTACT GCCGACCTTC 
2281 AAGGGTCAAC CATCCAAACC GTTCGTTGGC GTGCTGAGCG CAGGTATTAA CGCCGCCAGT 
2341 CCGAACAAAG AGCTGGCAAA AGAGTTCCTC GAAAACTATC TGCTGACTGA TGAAGGTCTG 
2401 GAAGCGGTTA ATAAAGACAA ACCGCTGGGT GCCGTAGCGC TGAAGTCTTA CGAGGAAGAG 
2461 TTGGCGAAAG ATCCACGTAT TGCCGCCACT ATGGAAAACG CCCAGAAAGG TGAAATCATG 
2521 CCGAACATCC CGCAGATGTC CGCTTTCTGG TATGCCGTGC GTACTGCGGT GATCAACGCC 
2581 GCCAGCGGTC GTCAGACTGT CGATGCCGCC CTGGCCGCCG CGCAGACTGC CGCCGCCGCC 
2641 GCCATGGCTT TGTTGGAACG CATCTTAGCG AGAGACAACC TCATCACGGC GCTCAAACGG 
2701 GTCGAAGCCA ACCAAGGAGC ACCGGGAATC GACGGAGTAT CAACCGATCA ACTCCGTGAT 
2761 TACATCCGCG CTCACTGGAG CACGATCCAC GCCCAACTCT TGGCGGGAAC CTACCGGCCG 
2821 GCGCCTGTCC GCAGGGTCGA AATCCCGAAA CCGGGCGGCG GCACACGGCA GCTAGGCATT 
2881 CCCACCGTGG TGGACCGGCT GATCCAACAA GCCATTCTTC AAGAACTCAC ACCCATTTTC 
2941 GATCCAGACT TCTCCTCTTC CAGCTTCGGA TTCCGTCCGG GCCGCAACGC CCACGATGCC 
3001 GTGCGGCAAG CGCAAGGCTA CATCCAGGAA GGGTATCGGT ACGTGGTCGA CATGGACCTG 
3061 GAAAAGTTCT TTGATCGGGT CAACCATGAC ATCTTGATGA GTCGGGTGGC CCGAAAAGTC 
3121 AAGGATAAAC GCGTGCTGAA ACTGATCCGT GCCTACCTGC AAGCCGGCGT TATGATCGAA 
3181 GGGGTGAAGG TGCAGACGGA GGAAGGGACG CCGCAAGGCG GCCCCCTCAG CCCCCTGCTG 
3241 GCGAACATCC TTCTCGACGA TTTAGACAAG GAATTGGAGA AGCGAGGATT GAAATTCTGC 
3301 CGTTACGCAG ATGACTGCAA CATCTATGTG AAAAGTCTGC GGGCAGGACA ACGGGTGAAA 
3361 CAAAGCATCC AACGGTTCTT GGAGAAAACG CTCAAACTCA AAGTAAACGA GGAGAAAAGT 
3421 GCGGTGGACC GCCCGTGGAA ACGGGCCTTT CTGGGGTTTA GCTTCACACC GGAACGAAAA 
3481 GCGCGAATCC GGCTCGCCCC AAGGTCGATT CAACGTCTGA AACAGCGGAT TCGACAGCTG 
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3541 ACCAACCCAA ACTGGAGCAT ATCGATGCCA GAACGAATTC ATCGCGTCAA TCAATACGTC 
3601 ATGGGATGGA TCGGGTATTT TCGGCTCGTC GAAACCCCGT CTGTCCTTCA GACCATCGAA 
3661 GGATGGATTC GGAGGAGGCT TCGACTCTGT CAATGGCTTC AATGGAAACG GGTCAGAACC 
3721 AGAATCCGTG AGTTAAGAGC GCTGGGGCTG AAAGAGACAG CGGTGATGGA GATCGCCAAT 
3781 ACCCGAAAAG GAGCTTGGCG AACAACGAAA ACGCCGCAAC TCCACCAGGC CCTGGGCAAG 
3841 ACCTACTGGA CCGCTCAAGG GCTCAAGAGT TTGACGCAAC GATATTTCGA ACTCCGTCAA 
3901 GGTTGACTGC AGGCAAGCTT GGCACTGGCC GTCGTTTTAC AACGTCGTGA CTGGGAAAAC 
3961 CCTGGCGTTA CCCAACTTAA TCGCCTTGCA GCACATCCCC CTTTCGCCAG CTGGCGTAAT 
4021 AGCGAAGAGG CCCGCACCGA TCGCCCTTCC CAACAGTTGC GCAGCCTGAATGGCGAATGG 
4081 CAGCTTGGCT GTTTTGGCGG ATGAGATAAG ATTITCAGCC TGATACAGAT TAAATCAGAA 
4141 CGCAGAAGCG GTCTGATAAA ACAGAATTTG CCTGGCGGCA GTAGCGCGGT GGTCCCACCT 
4201 GACCCCATGC CGAACTCAGA AGTGAAACGC CGTAGCGCCG ATGGTAGTGT GGGGTCTCCC 
4261 CATGCGAGAG TAGGGAACTG CCAGGCATCA AATAAAACGA AAGGCTCAGT CGAAAGACTG 
4321 GGCCTTTCGT TTTATCTGTT GTTTGTCGGT GAACGCTCTC CTGAGTAGGA CAAATCCGCC 
4381 GGGAGCGGAT TTGAACGTTG CGAAGCAACG GCCCGGAGGG TGGCGGGCAG GACGCCCGCC 
4441 ATAAACTGCC AGGCATCAAA TTAAGCAGAA GGCCATCCTG ACGGATGGCC TTTTTGCGTT 
4501 TCTACAAACT CTTTTTGTTT ATTTTTCTAA ATACATTCAA ATATGTATCC GCTCATGAGA 
4561 CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA AGAGTATGAG TATTCAACAT 
4621 TTCCGTGTCG CCCTTATTCC CTTTTTTGCG GCATTTTGCC TTCCTGTTTT TGCTCACCCA 
4681 GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG GTGCACGAGT GGGTTACATC 
4741 GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC GCCCCGAAGA ACGTTCTCCA 
4801 ATGATGAGCA CTTTTAAAGT TCTGCTATGT GGCGCGGTAT TATCCCGTGT TGACGCCGGG 
4861 CAAGAGCAAC TCGGTCGCCG CATACACTAT TCTCAGAATG ACTTGGTTGA GTACTCACCA 
4921 GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG AATTATGCAG TGCTGCCATA 
4981 ACCATGAGTG ATAACACTGC GGCCAACITA CTTCTGACAA CGATCGGAGG ACCGAAGGAG 
5041 CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC GCCTTGATCG TTGGGAACCG 
5101 GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA CGATGCCTGT AGCAATGGCA 
5161 ACAACGTTGC GCAAACTATT AACTGGCGAA CTACTTACTC TAGCTTCCCG GCAACAATTA 
5221 ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC TGCGCTCGGC CCTTCCGGCT 
5281 GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG GGTCTCGCGG TATCATTGCA 
5341 GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA TCTACACGAC GGGGAGTCAG 
5401 GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG GTGCCTCACT GATTAAGCAT 
5461 TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA TTGATTTACC CCGGTTGATA 
5521 ATCAGAAAAG CCCCAAAAAC AGGAAGATTG TATAAGCAAA TATTTAAATT GTAAACGTTA 
5581 ATATTTTGTT AAAATTCGCG TTAAATTTTT GTTAAATCAG CTCATTTTTT AACCAATAGG 
5641 CCGAAATCGG CAAAATCCCT TATAAATCAA AAGAATAGAC CGAGATAGGG TTGAGTGTTG 
5701 TTCCAGTTTG GAACAAGAGT CCACTATTAA AGAACGTGGA CTCCAACGTC AAAGGGCGAA 
5761 AAACCGTCTA TCAGGGCGAT GGCCCACTAC GTGAACCATC ACCCAAATCA AGTTTTTTGG 
5821 GGTCGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG GAGCCCCCGA TTTAGAGCTT 
5881 GACGGGGAAA GCCGGCGAAC GTGGCGAGAA AGGAAGGGAA GAAAGCGAAA GGAGCGGGCG 
5941 CTAGGGCGCT GGCAAGTGTA GCGGTCACGC TGCGCGTAAC CACCACACCC GCCGCGCTTA 
6001 ATGCGCCGCT ACAGGGCGCG TAAAAGGATC TAGGTGAAGA TCCTTTTTGA TAATCTCATG 
6061 ACCAAAATCC CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC 
6121 AAAGGATCTT CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA 
6181 CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG 
6241 GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC TTCTAGTGTA GCCGTAGTTA 
6301 GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT AATCCTGTTA 
6361 CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG 
6421 TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG 
6481 GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG 
6541 CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG 
6601 CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT CGGGTTTCGC 
6661 CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA 
6721 AACGCCAGCA ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG 
6781 TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT TGAGTGAGCT 
6841 GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT CAGTGAGCGA GGAAGCGGAA 
6901 GAGCGCCTGA TGCGGTATTT TCTCCTTACG CATCTGTGCG GTATTTCACA CCGCATATAT 
6961 GGTGCACTCT CAGTACAATC TGCTCTGATG CCGCATAGTT AAGCCAGTAT ACACTCCGCT 
7021 ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG CTGACGCGCC 
7081 CTGACGGGCT TGTCTGCTCC CGGCATCCGC ITACAGACAA GCTGTGACCG TCTCCGGGAG 
7141 CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC TGCGGTAAAG 
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7201 CTCATCAGCG TGGTCGTGCA GCGATTCACA GATGTCTGCC TGTTCATCCG CGTCCAGCTC 
7261 GTTGAGTTTC TCCAGAAGCG TTAATGTCTG GCTTCTGATA AAGCGGGCCA TGTTAAGGGC 
7321 GGTTTTTTCC TGTTTGGTCA CTGATGCCTC CGTGTAAGGG GGATTTCTGT TCATGGGGGT 
7381 AATGATACCG ATGAAACGAG AGAGGATGCT CACGATACGG GTTACTGATG ATGAACATGC 
7441 CCGGTTACTG GAACGTTGTG AGGGTAAACA ACTGGCGGTA TGGATGCGGC GGGACCAGAG 
7501 AAAAATCACT CAGGGTCAAT GCCAGCGCTT CGTTAATACA GATGTAGGTG TTCCACAGGG 
7561 TAGCCAGCAG CATCCTGCGA TGCAGATCCG GAACATAATG GTGCAGGGCG CTGACTTCCG 
7621 CGTTTCCAGA CTTTACGAAA CACGGAAACC GAAGACCATT CATGTTGTTG CTCAGGTCGC 
7681 AGACGTTTTG CAGCAGCAGT CGCTTCACGT TCGCTCGCGT ATCGGTGATT CATTCTGCTA 
7741 ACCAGTAAGG CAACCCCGCC AGCCTAGCCG GGTCCTCAAC GACAGGAGCA CGATCATGCG 
7801 CACCCGTGGC CAGGACCCAA CGCTGCCCGA AATT 
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SEQ ID NO : 21 
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STABILIZED REVERSE TRANSCRIPTASE philus reverse transcriptase . In another embodiment , the 
FUSION PROTEINS thermostable reverse transcriptase exhibits high fidelity 
cDNA synthesis . In yet another embodiment , the thermo 
CONTINUING APPLICATION DATA stable reverse transcriptase includes a polypeptide with an 
5 amino acid sequence identity that is substantially similar to 
This application is a divisional of Ser . No . 13 / 254 , 223 , a sequence selected from the group consisting of SEQ ID 
filed Sep . 1 , 2011 , which is a 371 of PCT / US10 / 26165 , filed NO : 1 . SEQ ID NO : 2 , SEQ ID NO : 3 . SEQ ID NO : 4 , or 
Mar . 4 , 2010 , which claims the benefit of 61 / 157 , 332 , filed SEQ ID NO : 5 . 
Mar . 4 , 2009 , which is incorporated by reference herein . The stabilized reverse transcriptase fusion protein 10 includes a stabilizer protein that , when linked to the reverse 
GOVERNMENT FUNDING transcriptase , enhances the shelf life and / or the thermal 
stability and / or the solubility of the thermostable reverse 
This invention was made with government support under transcriptase . In certain embodiments , the stabilizer protein 
grant no . R01 GM037949 awarded by the National Institutes is an affinity protein or a solubility - enhancing protein ( e . g . , 
of Health . The government has certain rights in the inven - 15 a maltose binding protein or N - utilization substance A 
tion . protein ) . In additional embodiments , the stabilizer protein is 
modified by replacing certain charged amino acids with 
BACKGROUND OF THE INVENTION uncharged amino acids . 
The stabilized reverse transcriptase fusion protein can 
Reverse transcription polymerase chain reaction , abbre - 20 also include a linker peptide that connects the thermostable 
viated as RT - PCR , is a well known technique for amplifying reverse transcriptase to the stabilizer protein . In some 
RNA . In RT - PCR , an RNA strand is reverse transcribed into embodiments , this linker peptide is a non - cleavable linker , 
complementary DNA ( cDNA ) , which is then amplified while in other embodiments it is a non - cleavable rigid linker . 
using DNA polymerase in the polymerase chain reaction . In In some embodiments , the linker peptide consists of 1 to 20 
the first step of this process , cDNA is made from an RNA 25 amino acids , while in other embodiments the linker peptide 
template using deoxyribonucleotide phosphates and reverse consists of 1 to 5 or 3 to 5 amino acids . For example , a rigid 
transcriptase together with a DNA primer . non - cleavable linker peptide can include 5 alanine amino 
Synthesis of cDNA from the RNA template can be acids . 
hindered by RNA secondary and tertiary structures , which In additional embodiments , the stabilized reverse tran 
consist of helices and various other kinds of kinks in the 30 scriptase fusion protein has an amino acid sequence that 
RNA strand . RNA secondary and tertiary structure can be includes a polypeptide with an amino acid sequence identity 
decreased by carrying out the reaction at a higher tempera - that is substantially similar to a sequence selected from the 
ture ( e . g . , above 50° C . ) or by adding denaturing additives . group consisting of SEQ ID NO : 6 , SEQ ID NO : 7 , SEQ ID 
However , the addition of denaturing additives is undesirable NO : 8 , SEQ ID NO : 9 , or SEQ ID NO : 10 . In some 
because it often reduces reverse transcriptase activity . 35 embodiments , the stabilized reverse transcriptase fusion 
Higher temperatures also provide the advantage of increas - protein is a high fidelity reverse transcriptase capable of 
ing the specificity of DNA synthesis by decreasing non - carrying out reverse transcription with an error frequency of 
specific primer binding . Unfortunately , only a limited num - 2 . 0x10 or less at a temperature from about 45° to about 65° 
ber of reverse transcriptases capable of operating at high C . In further embodiments , the stabilized reverse tran 
temperature are currently available , and these exhibit rela - 40 scriptase fusion protein is capable of carrying out substantial 
tively low fidelity DNA polymerization . For example , com - levels of reverse transcription at temperatures up to about 
mercially available Avian Myeloblastosis Virus reverse tran - 81° C . 
scriptase includes RNase H activity and can function at 37° Another aspect of the invention provides a method for 
C . , but has a fidelity of only about 1 . 7x10 - 4 . RNase H preparing a cDNA from an RNA molecule that includes the 
activity competes with the DNA polymerase activity and the 45 steps of : ( a ) adding a primer nucleotide sequence to an RNA 
primer binding site and , therefore , cDNA yield is lower . molecule and ( b ) incubating the RNA molecule in the 
Accordingly , there is a need for reverse transcriptase presence of one or more modified or unmodified deoxy or 
enzymes that are able to carry out reverse transcription at dideoxyribonucleoside triphosphates and a stabilized 
higher temperatures , including those that have high fidelity reverse transcriptase fusion protein that includes a thermo 
and processivity . Such enzymes are beneficial because 50 stable reverse transcriptase connected to a stabilizer protein 
higher temperatures decrease obstructing RNA secondary under conditions sufficient to synthesize a cDNA molecule 
and tertiary structure and increase the specificity of reverse complementary to all or a portion of the RNA molecule . In 
transcription by allowing the use of longer and more specific particular embodiments , the thermostable reverse tran 
primers . scriptase is connected to the stabilizer protein by a linker 
55 peptide ( e . g . , a non - cleavable or rigid non - cleavable linker 
SUMMARY OF THE INVENTION peptide ) . Preferably , the reverse transcription is performed 
within a temperature range where RNA includes a substan 
In one aspect , the invention provides a stabilized reverse tially decreased amount of obstructing stable secondary or 
transcriptase ( RT ) fusion protein that includes a thermo - tertiary structure . Embodiments of this method include ones 
stable reverse transcriptase connected to a stabilizer protein . 60 in which the thermostable reverse transcriptase is a group II 
In one embodiment of the stabilized reverse transcriptase intron - derived reverse transcriptase . In further embodiments 
fusion protein , the thermostable reverse transcriptase is a of the method , the thermostable reverse transcriptase 
bacterial reverse transcriptase . In a further embodiment , the includes a polypeptide with an amino acid sequence identity 
bacterial reverse transcriptase is a group II intron - derived that is substantially similar to a sequence selected from the 
reverse transcriptase . Examples of thermostable bacterial 65 group consisting of SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID 
reverse transcriptases include Thermosynechococcus elon - NO : 3 , SEQ ID NO : 4 , or SEQ ID NO : 5 , a non - cleavable 
gatus reverse transcriptase and Geobacillus stearothermo - linker consists of 1 to 20 amino acids , and the stabilizer 
US 10 , 150 , 955 B2 
cell . 
protein is an affinity protein or a solubility - enhancing pro residues 373 - 1008 represent the Geobacillus stearothermo 
tein . In yet further embodiments of the method , the reverse philus GsI1 ORF ( SEQ ID NO : 4 ) . 
transcription is performed with an error frequency of 2 . 0x FIG . 5 is a listing of the amino acid sequence of a reverse 
10 - or less at a temperature from about 450 to about 65° C . transcriptase from Geobacillus stearothermophilus bound to 
Another aspect of the invention provides a DNA expres - 5 a maltose binding protein by a rigid linker ( SEQ ID NO : 10 ) . 
sion vector for producing a stabilized reverse transcriptase Amino acid residues 1 - 367 represent the maltose binding 
fusion protein that includes a nucleic acid that encodes a protein ( SEQ ID NO : 11 ) ; amino acid residues 368 - 372 
polypeptide with an amino acid sequence identity that is represent the rigid linker ( SEQ ID NO : 12 ) ; and amino acid 
substantially similar to a sequence selected from the group residues 373 - 792 represent the Geobacillus stearothermo 
consisting of SEQ ID NO : 6 , SEQ ID NO : 7 , SEQ ID NO : 10 philus GSI2 ORF ( SEQ ID NO : 5 ) . 
8 , SEQ ID NO : 9 , or SEQ ID NO : 10 . FIG . 6 is a listing of the nucleotide sequence of the 
Another aspect of the invention provides a method of MalE - Tel4c open reading frame ( ORF ) rigid fusion of 
producing a stabilized reverse transcriptase fusion protein reverse transcriptase from Thermosynechococcus elongatus 
that includes the steps of : ( a ) culturing a host cell that in the PMAL expression construct ( SEQ ID NO : 13 ) . 
includes a DNA expression vector for producing a stabilized 15 FIG . 7 is a listing of the nucleotide sequence of the 
reverse transcriptase fusion protein that includes a nucleic MalE - Tel4f ORF rigid fusion of a reverse transcriptase from 
acid that encodes a polypeptide with an amino acid sequence Thermosynechococcus elongatus in the pMAL expression 
identity that is substantially similar to a sequence selected construct ( SEQ ID NO : 14 ) . 
from the group consisting of SEQ ID NO : 6 , SEQ ID NO : FIG . 8 is a listing of the nucleotide sequence of the 
7 , SEQ ID NO : 8 , SEQ ID NO : 9 , or SEQ ID NO : 10 ; ( b ) 20 MalE - Tel4h * ORF rigid fusion of a reverse transcriptase 
expressing the stabilized reverse transcriptase fusion protein from Thermosynechococcus elongatus in the PMAL expres 
encoded by the DNA expression vector , and ( c ) isolating the sion construct ( SEQ ID NO : 15 ) . 
stabilized reverse transcriptase fusion protein from the host FIG . 9 is a listing of the nucleotide sequence of the 
MalE - GSI1 ORF rigid fusion of a reverse transcriptase from 
The stabilized reverse transcriptase fusion protein can 25 Geobacillus stearothermophilus in the PMAL expression 
facilitate cDNA synthesis at higher temperature , and / or with construct ( SEQ ID NO : 16 ) . 
higher processivity , and / or allow the use of longer , more FIG . 10 is a listing of the nucleotide sequence of the 
stable , primers that increase the specificity ( i . e . , fidelity ) of MalE - GSI2 ORF rigid fusion of a reverse transcriptase from 
reverse transcription . The stabilized RT fusion protein of the Geobacillus stearothermophilus in the PMAL expression 
invention can therefore be useful for a number of applica - 30 construct ( SEQ ID NO : 17 ) . 
tions , such as research applications . FIG . 11 provides a graph showing the poly ( rA ) 
It is to be understood that both the foregoing general oligo ( dT ) 42 assay of reverse transcriptase ( RT ) activity at 
description and the following detailed description are exem different temperatures . The enzymes assayed were MalE 
plary and explanatory only and are not restrictive of the RF - Gs11 , MalE - RF - Gs12 , MalE - RF - Tel4c , MalE - RF - Tel4f , 
invention , as claimed . 35 MalE - RF - Tel4h * , LtrA , and MalE - RF - LtrA . Reactions were 
done by incubating the RT ( 50 nM for Tel4c and 100 nM for 
BRIEF DESCRIPTION OF THE FIGURES all other RTs ) with 100 nM poly ( rA ) / oligo ( dT ) 42 and 5 ul 
[ a - p ] - dITP ( 3 , 000 Ci / mmol ) in 75 mM KC1 , 10 mm 
FIG . 1 is a listing of the amino acid sequence of a reverse MgCl2 , 20 mM Tris - HCl , pH 7 . 5 , and 1 mM DTI . After 
transcriptase from Thermosynechococcus elongatus bound 40 preincubating the RT with poly ( rA ) / oligo ( dT ) 42 in the reac 
to a maltose binding protein by a rigid linker ( SEQ ID NO : tion medium for 1 min at the indicated temperature , the 
6 ) . Amino acid residues 1 - 367 represent the modified malt reaction was initiated by adding [ a - 32P ] - DTTP , incubated for 
ose binding protein ( SEQ ID NO : 11 ) : amino acid residues times verified to be within the linear range ( 90 sec for Tel4c 
368 - 372 represent the rigid linker ( SEQ ID NO : 12 ) ; and RT and 5 min for all other RTs ) , and stopped by adding 
amino acid residues 373 - 935 represent the TeI4c ORF ( SEQ 45 EDTA to a final concentration of 250 mM . The polymer 
ID NO : 1 ) . ization of [ a - 32P ] - dTTP into high - molecular weight material 
FIG . 2 is a listing of the amino acid sequence of a reverse was quantified by spotting the reaction products onto What 
transcriptase from Thermosynechococcus elongatus bound man DE81 chromatography paper ( GE Health care Biosci 
to a maltose binding protein by a rigid linker ( SEO ID NO : ences Corp ) , washing with 0 . 3 M NaCl and 0 . 03 M sodium 
7 ) . Amino acid residues 1 - 367 represent the maltose binding 50 citrate , and scanning with a PhosphorImager to quantify 
protein ( SEQ ID NO : 11 ) : amino acid residues 368 - 372 radioactivity bound to the filter , as described in Materials 
represent the rigid linker ( SEQ ID NO : 12 ) ; and amino acid and Methods . The plot shows radioactivity bound to the 
residues 373 - 935 represent the Tel4f ORF ( SEQ ID NO : 2 ) . filter ( PhosphorImager units ) as a function of reaction tem 
FIG . 3 is a listing of the amino acid sequence of a reverse perature . 
transcriptase from Thermosynechococcus elongatus bound 55 FIG . 12 shows schematic representations of Group II 
to a maltose binding protein by a rigid linker ( SEQ ID NO : intron RTs and fusion proteins . Section 12 ( A ) provides 
8 ) . Amino acid residues 1 - 367 represent the maltose binding comparison of group II intron - encoded and retroviral RTS . 
protein ( SEQ ID NO : 11 ) ; amino acid residues 368 - 372 Group II intron RTs exemplified by the LtrA protein encoded 
represent the rigid linker ( SEQ ID NO : 12 ) ; and amino acid by the Ll . LtrB intron generally contains four major domains : 
residues 373 - 935 represent the Tel4h * ORF ( SEQ ID NO : 60 RT , with conserved sequence blocks RT - 1 - 7 ; X / thumb ; DNA 
3 ) . binding ( D ) , and DNA endonuclease ( En ) . The RT and 
FIG . 4 is a listing of the amino acid sequence of a reverse thumb domains of group II intron RTs are homologous to 
transcriptase from Geobacillus stearothermophilus bound to those of retroviral RTs exemplified by HIV - 1 RT , but are 
a maltose binding protein by a rigid linker ( SEQ ID NO : 9 ) . larger due to an N - terminal extension and insertions 
Amino acid residues 1 - 367 represent the maltose binding 65 upstream ( RT - O ) and between the conserved RT sequence 
protein ( SEQ ID NO : 11 ) ; amino acid residues 368 - 372 blocks ( e . g . , RT - 2a , 3a , 4a , and 7a and thumb domain 
represent the rigid linker ( SEQ ID NO : 12 ) ; and amino acid insertion ti in LtrA ; Blocker et al . , RNA 11 , 14 - 28 , 2005 ) . 
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The positions of three a - helices characteristic of the thumb as size markers . Schematics of two template primer sub 
domains of retroviral RTs are shown for both LtrA and strates are shown at the bottom of the figure . 
HIV - RT . The group II intron RTs used in this work all FIG . 15 is a listing of the nucleotide sequence of the 
contain the En domain , except for the Gs12 RT , which lacks 1 . 2 - kb kanR RNA template ( SEQ ID NO : 21 ) . 
the En domain . Section 12 ( B ) shows group II intron RT 5 FIG . 16 provides semi - log plots obtained from qRT - PCR 
fusion proteins . Group II intron RTS ( IEPs ) were expressed to compare amounts of cDNA synthesis at different tem 
with fused N - terminal MalE or NusA solubility tags . Initial peratures by MalE - RF - Tel4c RT and SuperScript III RT . 
constructs contained the MalE solubility tag in expression cDNA was synthesized with MalE - RF - Te14c RT or Super 
vector pMalE - c2t fused to the N - terminus of the RT via a Script III RT ( SSIII RT ) using the 1 . 2 - kb kanR RNA with 
flexible linker with a TEV protease cleavage site ( under - 10 annealed primer P078 ( Tm = 80° C . ) and detected with 
lined ) . These are shown as primer / probe sets at nt 188 - 257 and nt 562 - 634 ( the data for 
TVDEALKDAQTNS3N10LENLYFQGEF ( SEQ ID NO : detection with primer set nt 188 - 257 are shown in the figure ; 
19 ) and TVDEALKDAQTNS3N10L ( SEQ ID NO : 44 ) . A the data obtained with the primer set nt 562 - 634 are shown 
variant of these initial constructs tested in FIG . 11 contained in FIG . 17 ) . The qPCR amplification curves show a semi - log 
the pMalE - c2t linker with the TEV protease cleavage site 15 plot of fluorescence ( ARN ) versus cycle number . For each 
deleted . Improved constructs used modified MalE or Nusa sample , duplicate wells were analyzed and are depicted in 
tags fused to the N - terminus of the RT via a rigid linker each amplification plot . The cycle threshold ( C ) values ( the 
containing 5 alanine residues ( underlined ) . These are shown cycle at which the fluorescence crosses the threshold 0 . 4 ) for 
as TVDAALAAAQTAAAAA ( SEQ ID NO : 20 ) and each cDNA synthesis reaction by MalE - RF - Tel4c or Super 
MAARNICWFGAAAAA ( SEQ ID NO : 46 ) The modified 20 Script III RT are indicated below the curves . Lower Cr 
MalE tag has charged amino acid residues changed to values indicate a larger number of cDNAs synthesized 
alanines ( italics ) , and the modified NusA tag is missing the FIG . 17 provides semi -log plots obtained from qRT - PCR 
two C - terminal amino acid residues . to compare processivity of cDNA synthesis by MalE - RF 
FIG . 13 provides graphs showing the RT activity of Tel4c RT and SuperScript III RT . cDNA was synthesized 
derivatives of MalE - RF - Tel4c RT with different rigid fusion 25 with MalE - RF - Tel4c or SuperScript III RT using the 1 . 2 - kb 
linker or solubility tag sequences . Panel 13 ( A ) provides a kanR RNA with annealed primer P078 ( Tm = 80° C . ) and 
bar graph showing RT activity at 60° C . Reaction with detected with primer / probe sets at nt 188 - 257 and nt 562 
MalE - RF - TeI4c RT ( left bar ) or variants containing different 634 . cDNA samples were obtained at 60° C . ( A , B ) and 650 
tag or linker sequences ( right bars ) were done as in FIG . 11 C . ( C , D ) . For each sample , triplicates were analyzed and are 
using 50 nM protein and 100 nM poly ( rA ) / oligo ( dT ) 42 and 30 depicted in each amplification plot . Average copy numbers 
incubating for 90 sec . Values are the mean for three deter are derived from a standard curve of quantitated and diluted 
minations with error bars indicating the standard deviation . PET9 plasmid . Detection of similar numbers of cDNA 
Panel 13 ( B ) provides a graph showing the temperature copies with the two primer sets , as seen for MalE - RF - Tel4c 
profile of RT activity for NusA - RF - Tel4c RT . RT activity RT . shows that most cDNAs extend to near the end of the 
was assayed as in FIG . 11 using 50 nM protein and 100 nM 35 RNA template , indicative of high processivity . A lower 
poly ( rA ) / oligo ( dT ) 42 and incubating for 2 min at the indi - number of cDNA copies detected with number of cDNA copies detected with the primer set near 
cated temperature . The y - axis shows radioactivity bound to the 5 ' end ( nt 188 - 257 ) compared to the primer set closer to 
the filter ( PhosphorImager units ) for each protein ( panel A ) the 3 ' end ( nt 562 - 634 ) , as seen for SuperScript III RT , 
or for NusA - RF - Tel4c RT as a function of reaction tem indicates that the RT falls off or is in some other way perature ( panel B ) . 40 impeded from reaching the 5 ' end of the RNA template . 
FIG . 14 provides graphs and autoradiograms that provide FIG . 18 is a listing of the amino acid sequence of the 
a comparison of cDNA synthesis by MalE - RF - Te14c , MalE - NusA solubility - enhancing protein ( SEQ ID NO : 38 ) . 
RF - Gs12 , and SuperScript III RT activity at different tem 
peratures . In panels ( A - C ) , the substrate was a 531 - nt RNA DETAILED DESCRIPTION OF THE 
transcribed from AflIII - digested PBS KS ( + ) with an 45 INVENTION 
annealed 5 ' - labeled 37 - nt primer , and in panels ( D - F ) , the 
substrate was a 1 . 2 - kb kanR RNA with an annealed 5 - la - Unless otherwise defined , all technical and scientific 
beled 44 - nt DNA primer . Reactions were done by incubating terms used herein have the same meaning as commonly 
100 nM of annealed template / primer with 200 nM enzyme understood by one of ordinary skill in the art to which this 
in 100 mM KC1 , 20 mM Tris HCI PH 7 . 5 , 10 mM MgCl2 and 50 invention belongs . The terminology used in the description 
10 mM DTT for MalE - RF - Tel4c RT ( panels A and D ) and of the invention herein is for describing particular embodi 
MalE - RF - GSI2 RT ( panels B and E ) and in the manufactur - ments only and is not intended to be limiting of the inven 
er ' s buffer for SuperScript III RT ( panels C and F ) . Reac - tion . All publications , patent applications , patents , and other 
tions were initiated by adding dNTPs to a final concentration references mentioned herein are incorporated by reference in 
of 1 . 25 mM , incubated for 30 min at the indicated tempera - 55 their entirety . 
ture , and terminated by adding 0 . 1 % SDS / 250 mM EDTA 
( final concentrations ) followed by phenol - CIA extraction . Definitions 
The products were analyzed by electrophoresis in a dena 
turing 6 % polyacrylamide gel , which was dried and quan As used in the description of the invention and the 
tified with a PhosphorImager . In each panel , the top and 60 appended claims , the singular forms " a , " " an , ” and “ the ” are 
bottom autoradiograms show portions of the gel containing intended to include the plural forms as well , unless the 
the full - length product ( arrow ) and unextended or partially context clearly indicates otherwise . In addition , the recita 
extended primer , respectively , and the bar graphs show the tions of numerical ranges by endpoints include all numbers 
percentage of primer that was extended to full - length cDNA subsumed within that range ( e . g . , 1 to 5 includes 1 , 1 . 5 , 2 , 
based on PhosphorImager quantitation . " ? " indicates 65 2 . 75 , 3 , 3 . 80 , 4 , 5 , etc . ) . 
unidentified bands not used in quantitation of full - length As used herein , " polypeptide ” refers to a polymer of 
product . A 5 - labeled 10 - bp ladder ( InvitrogenTM ) was used amino acids and does not imply a specific length of a 
US 10 , 150 , 955 B2 
polymer of amino acids . Thus , for example , the terms polymerase . Transcriptional promoters may comprise one or 
peptide , oligopeptide , protein , antibody , and enzyme are more of a number of different sequence elements as follows : 
included within the definition of polypeptide . This term also 1 ) sequence elements present at the site of transcription 
includes polypeptides with post - expression modification , initiation ; 2 ) sequence elements present upstream of the 
such as glycosylation ( e . g . , the addition of a saccharide ) , 5 transcription initiation site and , 3 ) sequence elements down 
acetylation , phosphorylation , and the like . stream of the transcription initiation site . The individual 
An " isolated ” polypeptide or polynucleotide , as used sequence elements function as sites on the DNA , where 
herein , means a polypeptide or polynucleotide that has been RNA polymerases and transcription factors that facilitate 
either removed from its natural environment , produced positioning of RNA polymerases on the DNA bind . 
using recombinant techniques , or chemically or enzymati - 10 As used herein , the term “ polymerase chain reaction ” 
cally synthesized . Preferably , a polypeptide or polynucle - ( “ PCR ” ) refers to a method for increasing the concentration 
otide of this invention is purified , i . e . , essentially free from of a segment of a target sequence in a mixture of genomic 
any other polypeptide or polynucleotide and associated DNA without cloning or purification . See for example 
cellular products or other impurities . Bartlett et al . , Methods Mol . Biol . 226 : 3 - 6 ( 2003 ) , which 
" Amino acid ” is used herein to refer to a chemical 15 provides an overview of PCR and its development . This 
compound with the general formula : NH2 CRH COOH , process for amplifying the target sequence typically consists 
where R , the side chain , is H or an organic group . Where R of introducing a large excess of two oligonucleotide primers 
is organic , R can vary and is either polar or nonpolar ( i . e . , to the DNA mixture containing the desired target sequence , 
hydrophobic ) . The following abbreviations are used followed by a precise sequence of thermal cycling in the 
throughout the application : A = Ala = Alanine , 20 presence of a DNA polymerase . The two primers are 
T = Thr = Threonine , V = Val = Valine , C = Cys = Cysteine . complementary to their respective strands of the double 
L = Leu = Leucine , Y = Tyr = Tyrosine , I = Ile = Isoleucine , stranded target sequence . To effect amplification , the mix 
N = Asn = Asparagine , P = Pro = Proline , Q = Gin = Glutamine , ture is denatured and the primers then annealed to their 
F = Phe = Phenylalanine , D = Asp = Aspartic Acid , complementary sequences within the target molecule . Fol 
W = Trp = Tryptophan , E = Glu = Glutamic Acid , 25 lowing annealing , the primers are extended with a poly 
M = Met = Methionine , K = Lys = Lysine , G = Gly = Glycine , merase so as to form a new pair of complementary strands . 
R = Arg = Arginine , S = Ser = Serine , H = His = Histidine . Unless The steps of denaturation , primer annealing and polymerase 
otherwise indicated , the term “ amino acid ” as used herein extension can be repeated many times to obtain a high 
also includes amino acid derivatives that nonetheless retain concentration of an amplified segment of the desired target 
the general formula . 30 sequence . Unless otherwise noted , PCR , as used herein , also 
A nucleotide consists of a phosphate group linked by a includes variants of PCR such as allele - specific PCR , asym 
phosphoester bond to a pentose ( ribose in RNA , and deoxy - metric PCR , hot - start PCR , ligation - mediated PCR , multi 
ribose in DNA ) that is linked in turn to an organic base . The plex - PCR , reverse transcription PCR , or any of the other 
monomeric units of a nucleic acid are nucleotides . Naturally PCR variants known to those skilled in the art . 
occurring DNA and RNA each contain four different nucleo - 35 As used in this specification , whether in a transitional 
tides : nucleotides having adenine , guanine , cytosine and phrase or in the body of the claim , the terms “ comprise ( s ) " 
thymine bases are found in naturally occurring DNA , and and “ comprising ” are to be interpreted as having an open 
nucleotides having adenine , guanine , cytosine and uracil ended meaning . That is , the terms are to be interpreted 
bases found in naturally occurring RNA . The bases adenine , synonymously with the phrases “ having at least ” or “ includ 
guanine , cytosine , thymine , and uracil often are abbreviated 40 ing at least ” . When used in the context of a process , the term 
A , G , C , T and U , respectively . " comprising ” means that the process includes at least the 
Nucleotides include free mono - , di - and triphosphate recited steps , but may include additional steps . When used 
forms ( i . e . , where the phosphate group has one , two or three in the context of a compound or composition , the term 
phosphate moieties , respectively ) . Thus , nucleotides include " comprising ” means that the compound or composition 
ribonucleoside triphosphates ( e . g . , ATP , UTP , CTG and 45 includes at least the recited features or components , but may 
GTP ) and deoxyribonucleoside triphosphates ( e . g . , dATP , also include additional features or components . 
dCTP , dITP , DGTP and dTTP ) , and derivatives thereof . A “ fusion protein , ” as used herein , refers to a protein 
Nucleotides also include dideoxyribonucleoside triphos - having at least two heterologous polypeptides covalently 
phates ( ddNTPs , including ddATP , ddCTP , ddGTP , ddITP linked in which one polypeptide comes from one protein 
and ddTTP ) , and derivatives thereof . 50 sequence or domain and the other polypeptide comes from 
" Substantially similar ” means that a given nucleic acid or a second protein sequence or domain . 
amino acid sequence shares at least 85 % , more preferably at Stabilized Reverse Transcriptase Fusion Protein 
least 90 % , and even more preferably at least 95 % identity The invention provides a stabilized reverse transcriptase 
with a reference sequence . Furthermore , only sequences fusion protein that includes a thermostable reverse tran 
describing or encoding proteins in which only conservative 55 scriptase connected to a stabilizer protein . In many embodi 
substitutions are made in the conserved regions are substan - ments , the thermostable reverse transcriptase is connected to 
tially similar overall . Preferable , substantially similar the stabilizer protein via a linker peptide . However , the 
sequences also retain the distinctive activity of the polypep - thermostable reverse transcriptase and the stabilizer protein 
tide . Substitutions typically seen as conservative substitu - can also be directly fused to one another . The polypeptides 
tions are the replacements , one for another , among the 60 that comprise the fusion protein are preferably linked N - ter 
aliphatic amino acids Ala , Val , Leu and Ile ; interchange of minus to C - terminus . However , the reverse transcriptase and 
the hydroxyl residues Ser and Thr , exchange of the acidic the stabilizer protein can be connected together in either 
residues Asp and Glu , substitution between the amide resi - order . For example , the two peptide sequences can be 
dues Asn and Gin , exchange of the basic residues Lys and connected from the C - terminus to N - terminus or N - terminus 
Arg and replacements among the aromatic residues Phe , Tyr . 65 to the C - terminus . In some embodiments , a linker peptide is 
A “ promoter , " as used herein , refers to a sequence in DNA included between the connecting C - terminus and N - termi 
that mediates the initiation of transcription by an RNA nus of the reverse transcriptase and stabilizer protein . 
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Attaching a stabilizer protein to the thermostable reverse extension reactions , 5 ' RACE , detection of chemical modi 
transcriptase can provide one or more advantages . A stabi - fications or other techniques that require synthesis of DNA 
lized reverse transcriptase fusion protein can have one or using an RNA template . 
more of the following advantages : ( a ) increased stability at The term “ thermostable ” refers to the ability of an enzyme 
elevated temperatures ; ( b ) higher processivity , ( c ) increased 5 or protein ( e . g . , reverse transcriptase ) to be resistant to 
solubility , and / or ( d ) higher fidelity . In some embodiments , inactivation by heat . Typically such enzymes are obtained 
a reverse transcriptase of the invention may have a plurality from a thermophilic organism ( i . e . , a thermophile ) that has 
of the properties listed above . For example , a stabilized evolved to grow in a high temperature environment . Ther 
reverse transcriptase fusion protein may have increased mophiles , as used herein , are organisms with an optimum 
thermostability and increased fidelity . The advantages may 10 growth temperature of 45° C . or more , and a typical maxi 
sometimes derive from one another . For example , by pro mum growth temperature of 70° C . or more . In general , a thermostable enzyme is more resistant to heat inactivation viding increased solubility , the stabilized reverse tran than a typical enzyme , such as one from a mesophilic scriptase fusion protein can provide a product able to organism . Thus , the nucleic acid synthesis activity of a provide increased fidelity of transcription as a result of 15 thermostable reverse transcriptase may be decreased by heat solubilizing a previously insoluble high fidelity thermo treatment to some extent , but not as much as would occur for stable reverse transcriptase . The use of a stabilizer protein in a reverse transcriptase from a mesophilic organism . “ Ther 
the fusion protein can also provide other advantages such as mostable ” also refers to an enzyme which is active at 
increased protein expression and improved protein folding . temperatures greater than 38° C . , preferably between about 
Inclusion of a linker peptide between the stabilizer protein 20 38 - 100° C . , and more preferably between about 40 - 81° C . A 
and the thermostable reverse transcriptase can further particularly preferred temperature range is from about 45° 
enhance these advantages . C . to about 65° C . 
The stabilized reverse transcriptase fusion protein In some embodiments , a thermostable reverse tran 
includes a thermostable reverse transcriptase and a stabilizer scriptase retains at least 50 % ( e . g . , at least 60 % , at least 
protein , as described herein . The stabilized reverse tran - 25 70 % , at least 80 % , at least 90 % , or at least 95 % ) of its 
scriptase fusion protein can also includes a linker peptide . nucleic acid synthetic activity after being heated in a nucleic 
For example , the stabilized reverse transcriptase fusion acid synthesis mixture at 90° C . for 30 seconds . In contrast , 
protein can have an amino acid sequence as set forth in SEQ t ypical reverse transcriptases will not work at elevated 
ID NO : 6 , SEQ ID NO : 7 , SEQ ID NO : 8 , SEQ ID NO : 9 , temperatures , and lose most of their nucleic acid synthetic 
or SEQ ID NO : 10 , shown in FIGS . 1 - 5 , respectively . 30 activity after such heat treatment . Thermostable reverse 
Alternately , the stabilized reverse transcriptase fusion pro - transcriptases typically also have a higher optimum nucleic 
tein can have an amino acid sequence that is substantially acid polymerization temperature . 
similar to one or more of the sequences as set forth in SEQ S ome reverse transcriptases are thermostable and there 
ID NO : 6 , SEQ ID NO : 7 , SEQ ID NO : 8 , SEQ ID NO : 9 , fore remain substantially active at temperatures commonly 
or SEQ ID NO : 10 . A stabilized reverse transcriptase fusion 35 used in PCR - based nucleic acid synthesis . This provides the 
protein amino acid sequence that is “ substantially similar ” to advantage of being able to carry out both reverse transcrip 
the fusion proteins provided by sequences 6 - 10 will share at tion and DNA amplification in a single reaction environ 
least 85 % identity , more preferably 90 % identity and even ment . Such temperatures vary depending upon reaction 
more preferably 95 % identity , and will include only conser parameters , including pH , template and primer nucleotide 
vative amino acid substitutions in conserved regions . 40 composition , primer length , and salt concentration . Thermo 
Thermostable Reverse Transcriptases stable reverse transcriptases include Thermosynechococcus 
The present invention provides a reverse transcriptase elongatus ( Te ) RT , Geobacillus stearothermophilus ( Gs ) RT , 
fusion protein that includes a thermostable reverse tran - modified forms of these RTs , and engineered variants of 
scriptase . The term “ reverse transcriptases ” ( i . e . , RNA Avian myoblastosis virus ( AMV ) RT , Moloney murine 
directed DNA polymerases ) refers to a group of enzymes 45 leukemia virus ( M - MLV ) RT , and Human immunodefi 
having reverse transcriptase activity ( i . e . , that catalyze syn - ciency virus ( HIV ) RT . A reverse transcriptase obtained from 
thesis of DNA from an RNA template ) . In general , such an organism living in an elevated temperature environment 
enzymes include , but are not limited to , retroviral reverse ( i . e . , greater than 37° C . ) can be expected to be stable at the 
transcriptase , retrotransposon reverse transcriptase , and bac - living temperature of the organism , and to a reasonable 
terial reverse transcriptases such as group 11 intron - derived 50 degree above . 
reverse transcriptase , and mutants , variants or derivatives A class of reverse transcriptases that is particularly suit 
thereof . Examples of bacterial reverse transcriptase include able for use in stabilized reverse transcriptase fusion pro 
Lactococcus lactis reverse transcriptase , Thermosynechoc - teins are group II intron - derived reverse transcriptases . A 
occus elongatus reverse transcriptase , or Geobacillus wide variety of group II intron - derived reverse transcriptases 
stearothermophilus reverse transcriptase . Further bacterial 55 are known . See for example the Zimmerly Lab Website for 
reverse transcriptases are described by Simon et al . , Nucleic Mobile Group II Introns that describes 105 full length group 
Acids Research , 36 , p . 7219 - 29 ( 2008 ) , and Kojima and II intron - derived reverse transcriptases . The use of this 
Kanehisa , Molecular Biology and Evolution , 25 , p . 1395 - 04 website is described by Dai et al . , Nucleic Acids Research , 
( 2008 ) which describe many classes of reverse transcriptases 31 , p . 424 - 26 ( 2003 ) . 
( i . e . , retrons , group II introns , and diversity - generating ret - 60 In certain embodiments the thermostable reverse tran 
roelements among others ) . Reverse transcriptase has been scriptase is one that was encoded by a group II intron . Group 
used primarily to transcribe RNA into cDNA , which can II intron RTs typically consist of four conserved domains : 
then be cloned into a vector for further manipulation or used RT , which contains seven conserved sequence blocks ( RT1 
in various amplification methods such as polymerase chain 7 ) characteristic of the fingers and palm regions of retroviral 
reaction , nucleic acid sequence - based amplification 65 RTs ; X , a region required for RNA splicing activity corre 
( NASBA ) , transcription mediated amplification ( TMA ) , sponding at least in part to the thumb domain of retroviral 
self - sustained sequence replication ( 3SR ) , diverse primer RTs ; D , a DNA - binding domain involved in DNA target site 
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recognition ; and En , a DNA endonuclease domain that 11 intron - derived RTs , see Conlan et al . , Nucleic Acids 
cleaves the DNA target site to generate the primer for Research . 33 , p . 5262 - 70 ( 2005 ) . 
reverse transcription ( FIG . 12A ; Blocker et al . , RNA 11 , Examples of suitable group II - derived intron reverse 
14 - 28 , 2005 ) . The En domain is missing in some group II transcriptases include the reverse transcriptases set forth in 
intron RTs , which instead use nascent strands at DNA 5 SEQ ID NO : 1 , SEQ ID NO : 2 . SEQ ID NO : 3 . SEQ ID NO : 
replication forks to prime reverse transcription ( Zhong et al . , 4 , and SEQ ID NO : 5 , which are obtained from Thermos 
EMBO J . 22 , 4555 - 4565 , 2003 ) . The RT and X / thumb ynechococcus elongatus ( Tel4c , f , and h * ) and Geobacillus 
domains of group II intron RTs are larger than those of stearothermophilus ( Gs11 and Gs12 ) . These sequences are 
retroviral RTs due to an N - terminal extension , an additional shown in FIGS . 1 - 5 . The invention also encompasses group 
N - terminal conserved sequence block ( RT - 0 ) , and insertions 10 II intron derived reverse transcriptases that are substantially 
between the conserved sequence blocks in the RT and similar to those set forth in SEQ ID NO : 1 , SEQ ID NO : 2 . 
X / thumb domain , some of which are shared with non - LTR - SEQ ID NO : 3 . SEQ ID NO : 4 , and SEQ ID NO : 5 . A reverse 
retrotransposon RTs . It has been suggested that the larger - transcriptase that is “ substantially similar ” to the reverse 
sized RT and thumb domains of group II intron and related transcriptases provided by sequences 1 - 5 will share at least 
RTs enable tighter binding of template RNAs leading to 15 85 % identity , more preferably 90 % identity and even more 
higher processivity and fidelity during reverse transcription . preferably 95 % identity , and will include only conservative 
Unlike retroviral RTs , group II intron RTs lack an RNase H amino acid substitutions in conserved regions . The thermo 
domain and typically have very low DNA - dependent DNA stability of a number of group II intron - derived RTs is shown 
polymerase activity ( Smith et al . , Genes and Development in FIG . 11 , which demonstrates that stabilized reverse tran 
19 , 2477 - 2487 , 2005 ) . 20 scriptase fusion proteins including the reverse transcriptases 
Group II introns encode a class of RNAs known for their as set forth in SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 
self - splicing reaction . Under certain in vitro conditions , 3 , SEQ ID NO : 4 , and SEQ ID NO : 5 have higher thermo 
group II intron - encoded RNAs can excise themselves from stability than mesophilic L1 . LtrB reverse transcriptase , 
precursor mRNAs and ligate together their flanking exons , whether or not it is part of a fusion protein , when evaluated 
without the aid of a protein . The splicing reaction mecha - 25 as shown in FIG . 11 . The mesophilic Ll . LtrB showed a 
nism is similar to the splicing of nuclear pre - mRNA introns . temperature optimum of about 35° C . either alone or as part 
A number of group II introns also encode reverse tran - of a fusion protein . 
scriptase ( RT ) open reading frames ( ORF ) and are active As noted herein , modified forms of thermostable group II 
mobile elements . The ORF is typically found in domain DIV intron - derived RTs can also be used . For example , SEQ ID 
of the group II intron encoded RNA . The group II intron RT 30 NO : 3 , the Tel4h * RT , does not represent a native form of 
assists RNA splicing by stabilizing the catalytically active reverse transcriptase , but rather is a derivative in which the 
RNA structure and then remains bound to the excised intron active site was modified from the amino acid sequence 
RNA in a ribonucleoprotein ( RNP ) that promotes intron YAGD to the amino acid sequence YADD , to more closely 
mobility by a process termed “ retrohoming . ” Retrohoming resemble the active site of other active group II intron 
occurs by a mechanism in which the excised intron RNA in 35 derived RTs . 
the RNPs inserts directly into a DNA target site and is The amount by which a given amino acid sequence is 
reverse transcribed by the RT . During retrohoming , in which " substantially similar ” to a reference sequence can be deter 
the group II intron facilitates targeting of the intron to mined for example , by comparing sequence information 
appropriate DNA sequences , the group II intron RT must using sequence analysis software such as the Blastp pro 
produce an accurate cDNA copy of the intron RNA , which 40 gram , version 2 . 2 . 10 , of the BLAST 2 search algorithm , as 
is typically 2 - 2 . 5 kb long and folds into highly stable and described by Tatusova et al . ( FEMS Microbiology Letters , 
compact secondary and tertiary structures . Thus , group II 174 , p . 247 - 50 ( 1999 ) ) , and available on the world wide web 
intron RTs must have high processivity and fidelity in order at the National Center for Biotechnology Information web 
to carry out their biological function . Group II intron - site , under BLAST in the Molecular Database section . 
derived RTs also lack RNase H activity , which can be 45 Preferably , the default values for all BLAST 2 search 
beneficial because RNase H specifically degrades the RNA parameters are used , including matrix = BLOSUM62 ; open 
of RNA : DNA hybrids , which allows any RNA to be copied gap penalty = 11 , extension gap penalty = 1 , gap 
only once and can lead to reduced yields of full length x _ dropoff = 50 , expect = 10 , wordsize = 3 , and optionally , filter 
cDNA . on . In the comparison of two amino acid sequences using the 
Based on the group II intron - derived reverse tran - 50 BLAST search algorithm , structural similarity is referred to 
scriptases so far evaluated , these RTs typically exhibit as " similarity ” and identity is referred to as “ identity . ” 
relatively high fidelity and high processivity . The fidelity of Amino acid identity is defined in the context of a com 
reverse transcription refers to the reliability of nucleotide parison between a candidate polypeptides and a reference 
incorporation during reverse transcription of RNA to DNA , amino acid sequence , and is determined by aligning the 
with higher fidelity describing nucleotide copying with a 55 residues of the two amino acid sequences ( i . e . , a candidate 
low number of errors ( e . g . , misincorporations ) . Higher amino acid sequence and the reference amino acid sequence ) 
specificity can be provided by using longer and more to optimize the number of identical amino acids along the 
specific primers , which requires the ability to carry out l engths of their sequences ; gaps in either or both sequences 
reverse transcription at higher temperatures . For example , a are permitted in making the alignment in order to optimize 
group II intron reverse transcriptase can provide reverse 60 the number of identical amino acids , although the amino 
transcription with an error frequency of 2 . 0x10 or less , acids in each sequence must nonetheless remain in their 
wherein the error frequency represents the proportion of proper order . 
nucleotide copying errors that occur relative to the number Information is available to support a structure - function 
of nucleotide copying events that occur without error . Other correlation for group II intron - derived reverse transcriptases . 
examples of high fidelity transcription include error frequen - 65 See for example Simon et al . , Nucleic Acids Research , 36 , 
cies of 1x10 - 4 , 7 . 5x10 - 5 , 5x10 - 5 , 2 . 5x10 - 5 , 1x10® , and p . 7219 - 29 ( 2008 ) , which classifies and aligns the RT 
5x10 - . For further description of the high fidelity of group domains of bacterial reverse transcriptases , and Xiong et al . , 
14 
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EMBO J . , 9 , p . 3353 - 62 ( 1990 ) , which provides an align - a tag binds to a ligand within an affinity column . Suitable 
ment of 82 RT sequences showing seven conserved domains affinity proteins are known in the art . See for example 
and 42 conserved positions . See also Blocker et al , RNA , 11 , Waugh , D . , Trends in Biotechnology , 23 , p . 316 - 320 ( 2005 ) , 
p . 14 - 28 ( 2005 ) , which provides a three - dimensional model which describes a number of suitable affinity proteins , 
of Lactococcus lactis Ll . LtrB intron RT ( the LtrA protein ) , 5 including glutathione S - transferase , maltose - binding pro 
describes the proteolytic cleavage sites and conserved tein , FLAG - tag peptide , biotin acceptor peptide , streptavi regions , and provides a sequence alignment analysis of LtrA din - binding peptide , and calmodulin - binding peptide . For 
relative to HIV - 1 RT . Accordingly , a variety of stabilized the preparation and use of fusion proteins that include an reverse transcriptase fusion proteins that are substantially affinity protein , see for example U . S . Pat . Nos . 5 , 643 , 758 , similar to those set forth in SEQ ID NO . 6 - 10 can readily be 10 5 , 654 , 176 , and 7 , 001 , 745 . obtained by modification of amino acids outside of the The stabilizer protein can also be a solubility - enhancing conserved regions , and only conservative modification of protein . Recombinantly - expressed fusion proteins can amino acids within the known conserved regions . exhibit low solubility in their host cells and / or in subsequent In one embodiment , the present invention provides a 
stabilized reverse transcriptase fusion protein having a 15 5 method applications , which can be ameliorated through 
reverse transcriptase activity that has a half - life of greater inclusion of a solubility - enhancing protein in the fusion 
than that of the corresponding unbound reverse transcriptase protein that substantially increases the solubility of the 
at an elevated temperature , i . e . , greater than 37° C . In some fusion protein in aqueous environments . Some solubility 
embodiments , the half - life of a reverse transcriptase of the enhancing proteins used are also affinity proteins , and can 
present invention may be 5 minutes or greater and preferably 20 therefore be described as solubility - enhancing affinity pro 
10 minutes or greater at 50° C . In some embodiments , the teins . Examples of solubility - enhancing proteins include 
reverse transcriptases of the invention may have a half - life sugar binding proteins such as arabinose binding protein , 
( e . g . , at 50° C . ) equal to or greater than about 25 minutes , chitin binding protein , cellulose binding protein , and malt 
preferably equal to or greater than about 50 minutes , more ose binding protein . Other examples of solubility - enhancing 
preferably equal to or greater than about 100 minutes , and 25 proteins include the NusA and Dsb solubility tags provided 
most preferably , equal to or greater than about 200 minutes . by Novagen® , and the solubility enhancing tag ( SET ) 
Stabilizer Proteins provided by InvitrogenTM . Harrison has demonstrated the 
The stabilized reverse transcriptase fusion protein of the very high solubility provided by the NusA solubility tag , 
present invention also includes a stabilizer protein . A stabi while the solubility enhancement of Dsb is described by 
lizer protein , as defined herein , is a protein forming part of 30 Collins - Racie . See Harrison , R . G . , inNovations , 11 , p . 4 - 7 
the fusion protein that functions to increase the overall ( 2000 ) , and Collins - Racie et al . , Biotechnology , 13 , p . 
stability of the fusion protein . Stability includes the ability 982 - 87 ( 1995 ) . 
of the protein to retain its conformation and activity . In In some embodiments , stabilizer proteins such as solubil 
addition , the stabilizer protein preferably enhances the solu - ity - enhancing proteins or affinity proteins can be modified to 
bility of the fusion protein , as further described herein with 35 improve their performance . Modification can include pro 
regard to solubility - enhancing proteins . This can be particu - viding one or more substitutions , additions or deletions of 
larly helpful with regard to group II intron RTs , which have amino acids within the protein sequence of the stabilizer 
been found to be poorly expressed and insoluble in the protein as compared to the normal , wild - type sequence of 
absence of the intron RNA to which they are ordinarily the protein . For example , a stabilizer protein such as an 
tightly bound in RNPs . ( Vellore et al . Appl . Environ . Micro - 40 affinity protein or a solubility - enhancing protein can be 
biol . 70 , 7140 - 7147 , 2004 ; Ng et al . , Gene 393 , 137 - 144 , modified by replacing the charged amino acids with 
2007 ) Effective stabilizer proteins include those that include uncharged amino acids in certain regions of the protein . 
an independent folding domain and / or do not fold into Charged amino acids include amino acids with positively or 
long - lived misfolded intermediates that can influence the negatively charged side chains . Examples of amino acids 
propensity of proteins to aggregate . Proteins that will pro - 45 with positively charged side chains include arginine , histi 
vide an independent folding domain are described by Janin dine , lysine , and the like . Examples of amino acids with 
et al . , Progress in Biophysics and Molecular Biology , 42 , p . negatively charged side chains include aspartic acid and 
21 - 78 ( 1983 ) , and proteins that do not fold into long - lived glutamic acid , and the like . Uncharged amino acids include , 
misfolded intermediates are described by Idicula et al . , but are not limited to , alanine , serine , threonine , glutamine , 
Protein Science , 14 , p . 582 - 592 ( 2005 ) . For example , the 50 valine , leucine , isoleucine , phenylalanine , and tyrosine . For 
stabilizer protein can be a protein that includes 50 or more example , a maltose binding protein can be modified by 
amino acids . In other embodiments , the stabilizer protein replacing one or more of the charged amino acids with 
can be a larger protein including 100 or more amino acids . alanine . 
As exemplified by the maltose binding protein and Nusa Examples of suitable affinity proteins include the maltose 
proteins provided herein , the stabilizer proteins can also 55 binding protein amino acid sequence set forth in SEQ ID 
have a size from about 250 amino acids to about 400 amino NO : 11 , shown in FIGS . 1 - 5 , and sequences substantially 
acids . The stabilizer protein can also be a thermostable similar to SEO ID NO : 11 . Note that while modification of 
protein . the affinity protein is not necessary , the maltose binding 
The stabilizer protein can also be or include an affinity protein set forth in SEQ ID NO : 11 was modified to replace 
protein . The term affinity protein , as used herein , refers to a 60 three charged amino acids with alanine near the C - terminus . 
protein for which there is a readily available ligand that Another suitable protein , in this case a solubilizing protein , 
exhibits a high binding constant ( i . e . , " affinity ” ) for the is the N - utilization substance A ( NusA ) protein , which has 
protein . Affinity proteins are often used in the role of an the amino acid sequence set forth in SEQ ID NO : 38 , shown 
affinity tag . Affinity proteins , as is known to those skilled in in FIG . 18 . In additional embodiments of the invention , 
the art , can be provided in fusion proteins to facilitate the 65 fusion proteins described herein that include the maltose 
purification of the protein connected or fused to the affinity binding proteins can have the maltose binding protein 
protein by techniques such as affinity purification , in which replaced with N - utilization substance A proteins . 
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Linker Peptides used if it is desirable to remove the stabilizer protein during 
In some embodiments , the stabilized reverse transcriptase a subsequent step and exposure to the cleaving protease is 
fusion protein also includes a linker peptide positioned avoided during use of the fusion protein . 
between the stabilizer protein and the thermostable reverse Use of Stabilized Reverse Transcriptase Fusion Proteins 
transcriptase . Preferably , the linker peptide is a non - cleav - 5 The invention also provides a method for preparing a 
able linker peptide . By " positioned between , ” it is meant that cDNA from an RNA ( e . g . , mRNA , rRNA , TRNA , and the linker peptide is connected by a chemical linkage ( e . g . , miRNA ) , which is required for other methods such as the an amide linkage ) to the N or C terminal of each of the reverse transcription polymerase chain reaction ( RT - PCR ) . stabilizer protein and the reverse transcriptase , as described As used herein , the term “ RT - PCR ” refers to the replication in regard to fusion proteins herein . For example , the linker 10 and amplification of RNA sequences . In this method , reverse peptide can be connected through an amide linkage to the C transcription is coupled to PCR , e . g . , as described in U . S . terminal region of the stabilizer protein and the N terminal Pat . No . 5 , 322 , 770 . In RT - PCR , the RNA template is con region of the thermostable reverse transcriptase . By non 
cleavable , it is meant that the linker peptide is not readily verted to cDNA due to the reverse transcriptase activity of an enzyme , and then amplified using the polymerizing susceptible to cleavage by a protease . 
In additional embodiments , the linker peptide is a rigid activity of the same or a different enzyme . 
linker peptide ; i . e . , a relatively non - flexible peptide linker . In the practice of the invention , cDNA molecules may be 
Rigid linker peptides are not required to completely lack produced by mixing one or more nucleic acid molecules 
flexibility , but rather are significantly less flexible than ( e . g . , RNA ) obtained from cells , tissues , or organs using 
flexible linker peptides such as glycine - rich peptide linkers . 20 methods that are well known in the art , with the composition 
Rigid linker peptides , as a result of their relative lack of of the invention , under conditions favoring the reverse 
flexibility , decrease the movement of the two protein transcription of the nucleic acid molecule by the action of 
domains attached together by the rigid linker peptide , which the enzymes of the compositions to form a cDNA molecule 
in the present case are the stabilizer protein and the ther ( single - stranded or double - stranded ) . Thus , the method of 
mostable reverse transcriptase . Linker peptides that provide 25 the invention comprises ( a ) mixing one or more nucleic acid 
ordered chains such as alpha helical structure can provide templates ( preferably one or more RNA or mRNA tem 
rigid linker peptides . For example , Arginine , Leucine , Glu - plates , such as a population of mRNA molecules ) with 
tamate , Glutamine , and Methionine all show a relatively stabilized RT fusion protein of the invention and ( b ) incu 
high propensity for helical linker formation . However , a bating the mixture under conditions sufficient to permit 
non - helical linker including many proline residues can 30 DNA synthesis of all or a portion of the one or more nucleic 
exhibit significant rigidity as well . Examples of rigid linkers acid templates . 
include polylysine and poly - DL - alaninepolylysine . Further In one aspect , the method includes the steps of ( a ) adding 
description of rigid peptide linkers is provided by Wriggers a primer to an RNA molecule and ( b ) incubating the RNA 
et al . , Biopolymers , 80 , p . 736 - 46 ( 2005 ) . In addition , rigid molecule in the presence of one or more deoxy or dideoxy 
linker peptides are described at the linker database described 35 ribonucleoside triphosphates and a stabilized reverse tran 
by George et al . , Protein Engineering , 15 , p . 871 - 79 ( 2003 ) . scriptase fusion protein comprising a thermostable reverse 
Preferably , the rigid linker peptide is also a non - cleavable transcriptase connected to a stabilizer protein under condi 
linker peptide ; i . e . , a non - cleavable , rigid linker peptide . tions sufficient to synthesize a cDNA molecule complemen 
Relatively short polypeptides are preferred for use as tary to all or a portion of the RNA molecule . Adding the 
linker peptides . For example , linker peptides can include 40 primer to an RNA molecule may include hybridizing the 
from 1 to 20 amino acids . Linker peptides can also include primer to the RNA molecule . In some embodiments , the 
from 1 to 15 , from 1 to 10 , from 1 to 5 , or from 3 to 5 amino stabilized reverse transcriptase fusion protein can also 
acids . Examples of specific sequences that can be used as include a linker peptide connecting the stabilizer protein to 
linker peptides include dipeptides , tripeptides , tetrapeptides , the thermostable reverse transcriptase . Preferably , the 
and pentapeptides formed of alanine amino acids . One 45 reverse transcription is performed within a temperature 
suitable rigid linker peptide is AAAAA ( SEQ ID NO : 12 ) , range where the RNA includes a substantially decreased 
while another suitable rigid linker peptide is AAAEF ( SEQ amount of obstructing stable secondary or tertiary structure . 
ID NO : 18 ) . Use of a linker peptide ( e . g . , a rigid linker This can be a temperature from about 45° C . to about 81° C . , 
peptide ) in a fusion protein can provide one or more advan - with a more preferred temperature range being from about 
tages . For example , while not intending to be bound by 50 45° C . to about 65° C . This can also be described as a 
theory , it is believed that use of a rigid linker peptide can temperature range in which the RNA does not form a 
stabilize the fusion protein by decreasing the amount of significant amount of stable secondary or tertiary structure . 
movement of the two halves of the fusion protein relative to Due to the high fidelity and other advantages of group II 
one another . While very short ( i . e . , 1 or 2 amino acid ) linkers intron - derived RTs , their use may be preferred . For example , 
can be used , it is preferable to use linkers that include from 55 the stabilized reverse transcriptase fusion protein can 
3 to 5 amino acids . include a group II intron - derived reverse transcriptase with 
The linker peptide can be either cleavable or non - cleav - an amino acid sequence identity that is substantially similar 
able by a protease . Affinity proteins are often associated to to a sequence selected from the group consisting of SEQ ID 
another protein in a fusion protein using a cleavable peptide NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 3 , SEQ ID NO : 4 , or 
so that the affinity protein can be removed . However , in the 60 SEQ ID NO : 5 , a non - cleavable linker consisting of 1 to 20 
present invention the stabilizer protein ( e . g . , an affinity amino acids , and the stabilizer protein comprises a solubil 
protein ) remains bound to the reverse transcriptase , for the ity - enhancing or affinity protein . The stabilized reverse 
reasons described herein . Accordingly , it is generally pref - transcriptase fusion protein can also include a linker peptide 
erable that the linker peptide be non - cleavable . However , between the stabilizer peptide and the reverse transcriptase , 
cleavable linkers can be used in some embodiments . For 65 which can have a length from 1 - 20 amino acids , can be a 
example , cleavable linkers , including rigid cleavable linker non - cleavable linker , or can be rigid linker . Embodiments of 
peptides , that are susceptible to protease cleavage can be the method can perform reverse transcription with an error 
17 
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frequency of 2 . 0x10 - 5 or less . Particularly at a temperature protein into a suitable host cell , wherein the stabilized 
from about 45° C . to about 65° C . reverse transcriptase fusion protein comprises a thermo 
The stabilized reverse transcriptase fusion proteins can stable reverse transcriptase connected to a stabilizer protein 
also be used in other applications . For example , stabilized directly or via a linker and ( b ) culturing the host cell under 
RT fusion proteins can be used for the cloning of differen - 5 conditions which allow expression of the stabilized reverse 
tially expressed 5 ' ends of mRNAs ; a process referred to as transcriptase fusion protein . The stabilized reverse transcrip 
rapid amplification of cDNA ends ( RACE ) and variations tion fusion protein can be varied to include any of the 
thereof such as RNA ligase mediated RACE ( RLM - RACE ) . features described herein , such as the inclusion of a linker 
Stabilized RT fusion proteins can also be used for the peptide connecting the thermostable reverse transcriptase 
mapping of chemical footprints in RNA , differential display 10 and the stabilizer protein . 
RT - PCR , which allows for the analysis of gene expression Following expression of a stabilized reverse transcriptase 
among cell populations , and in - situ PCR for medical diag fusion protein in a host cell , the stabilized reverse tran 
nosis . scriptase fusion protein may be recovered to provide purified 
Preparation of Stabilized Reverse Transcriptase Fusion Pro stable reverse transcriptase fusion protein . Several protein 
teins 15 purification procedures are available and suitable for use . 
An expression vector containing a stabilized reverse tran - For instance , see Example 2 provided herein . Recombinant 
scriptase fusion protein - encoding nucleic acid molecule may protein may be purified from cell lysates and extracts by 
be used for high - level expression of stabilized reverse various combinations of , or individual application of salt 
transcriptase fusion protein in a recombinant host cell . fractionation , ion exchange chromatography , size exclusion 
Expression vectors may include , but are not limited to , 20 chromatography , hydroxylapatite adsorption chromatogra 
cloning vectors , modified cloning vectors , specifically phy and hydrophobic interaction chromatography . The use 
designed plasmids or viruses . A variety of expression vec - of affinity tags in some embodiments of the invention can 
tors may be used to express recombinant stabilized reverse facilitate purification of the protein . For example , the stabi 
transcriptase fusion sequences in appropriate cell types . For lized reverse transcriptase fusion protein can be separated 
example , bacterial vectors , mammalian vectors , fungal vec - 25 from other cellular proteins by use of an immunoaffinity 
tors , and insect vectors may be used for expression in column made with monoclonal or polyclonal antibodies 
bacteria , mammalian cells , fungal cells , and insect cells , specific for the reverse transcriptase or stabilizer protein 
respectively . portion of the fusion protein . Heating can be used to separate 
Stabilized reverse transcriptase fusion proteins can be the stabilized reverse transcriptase fusion protein from host 
prepared by obtaining a nucleotide sequence capable of 30 proteins , which are not stable at elevated temperatures and 
expressing a stabilized reverse transcriptase fusion protein will therefore precipitate . 
and then expressing that nucleotide sequence in a host cell . The nucleic acids capable of expressing a stabilized RT 
The stabilized reverse transcriptase fusion proteins fusion protein may be assembled into an expression cassette 
expressed by the host cell can then be purified using a which comprises sequences designed to provide for efficient 
variety of techniques known to those skilled in the art , 35 expression of the fusion protein in a host cell . The cassette 
depending in part on the nature of the host cell . preferably contains a stabilized reverse transcriptase fusion 
Nucleotide sequences capable of expressing stabilized protein - encoding open reading frame , with related transcrip 
reverse transcriptase fusion proteins of the invention can be tional and translations control sequences operatively linked 
prepared using a variety of methods known to those skilled to it , such as a promoter , and termination sequences . For 
in the art . For example , the nucleotide sequences can be 40 example , the open reading frame can include a nucleic acid 
prepared using recombinant plasmids in which various link that encodes a polypeptide with an amino acid sequence 
ers , reverse transcriptases , and stabilizer proteins are com identity that is substantially similar to a sequence selected 
bined , as described in Example 1 herein . from the group consisting of SEQ ID NO : 6 , SEQ ID NO : 
The present invention also relates to host cells trans - 7 , SEQ ID NO : 8 , SEQ ID NO : 9 , or SEQ ID NO : 10 , as 
formed or transfected with vectors comprising a nucleic acid 45 shown in FIGS . 1 - 5 , respectively . In a preferred embodi 
molecule capable of expressing a stabilized reverse tran - ment , the promoter is a T7 or a tac promoter for expression 
scriptase fusion protein . Recombinant host cells may be in E . coli , although those skilled in the art will recognize that 
prokaryotic or eukaryotic , including but not limited to , any of a number of other known promoters may be used . E . 
bacteria such as E . coli , fungal cells such as yeast , mam - coli also has rho independent and dependent terminators and 
malian cells including , but not limited to , cell lines of 50 can use 17 polymerase for rapid DNA replication . In eukary 
bovine , porcine , monkey and rodent origin ; and insect cells o tic cells , inclusion of a polyadenylation site will be helpful 
including but not limited to Drosophila and silkworm for the correct processing of mRNA . 
derived cell lines . Such recombinant host cells can be The open reading frame can also include polynucleotide 
cultured under suitable conditions to produce a stabilized sequences as set forth in SEQ ID NO : 13 , SEQ ID NO : 14 , 
reverse transcriptase fusion protein or a biologically equiva - 55 SEQ ID NO : 15 . SEQ ID NO : 16 , and SEQ ID NO : 17 , as 
lent form . As defined herein , the term “ host cell ” is not shown in FIGS . 6 - 10 , respectively . Alternately , the open 
intended to include a host cell in the body of a transgenic reading frame can include polynucleotide sequences that are 
human being , human fetus , or human embryo . substantially similar to those set forth in SEQ ID NO : 13 , 
As noted above , an expression vector containing DNA SEQ ID NO : 14 . SEQ ID NO : 15 , SEQ ID NO : 16 , and SEO 
encoding a stabilized reverse transcriptase fusion protein 60 ID NO : 17 . In this particular context , the term “ substantially 
may be used for expression of stabilized reverse tran - similar ” refers to variants in the nucleotide sequence in 
scriptase fusion protein in a recombinant host cell . There which codons that encode the same amino acid can be used 
fore , another aspect of this invention is a process for interchangeably such that the nucleotide sequence will still 
expressing a stabilized reverse transcriptase fusion protein in result in the translation of an amino acid sequence corre 
a recombinant host cell , comprising : ( a ) introducing a vector 65 sponding to SEQ ID NO : 6 - 10 . The stabilized reverse 
comprising a nucleic acid comprising a sequence of nucleo - transcriptase fusion protein open reading frame polynucle 
tides that encodes a stabilized reverse transcriptase fusion o tide preferably has at least about 80 % identity , at least 
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about 90 % identity , at least about 95 % identity , or at least tested whether group II intron RTs could be expressed and 
about 98 % identity to a polynucleotide sequence selected purified as MalE fusions . Initially , a MalE tag was fused to 
from the group consisting of SEQ ID NO : 13 . SEQ ID NO : the N - terminus of the RT via a TEV protease - cleavable 
14 , SEQ ID NO : 15 , SEQ ID NO : 16 , and SEQ ID NO : 17 . linker in the expression vector pMal - c2t ( FIG . 12B ) . The 
Nucleotide identity is defined in the context of a com - 5 MalE - RT fusion proteins for several of the T . elongatus 
parison between a candidate stabilized reverse transcriptase group II intron RTs expressed well in E . coli and could be 
fusion protein open reading frame and a polynucleotide purified by a procedure that involves polyethyleneimine 
sequence selected from the group consisting of SEQ ID NO : ( PEI ) - precipitation to remove nucleic acids , followed by 13 , SEQ ID NO : 14 , SEQ ID NO : 15 , SEQ ID NO : 16 , and amylose - affinity and heparin - Sepharose chromatography . SEQ ID NO : 17 , and is determined by aligning the residues 10 
of the two polynucleotides to optimize the number of Further , the uncleaved MalE - RT fusion proteins assayed soon after purification had high thermostable RT activity . identical nucleotides along the lengths of their sequences ; However , the yields of these proteins were < 0 . 2 mg / l for the gaps in either or both sequences are permitted in making the Thermosynechococcus proteins . Additionally , when the alignment in order to optimize the number of shared nucleo 
tides , although the nucleotides in each sequence must none - 15 MalE tag was removed by cleavage with TEV protease , the 
theless remain in their proper order . Preferably , two nucleo RTs immediately formed an insoluble precipitate , while if 
tide sequences are compared using the Blastn program of the the tag was left uncleaved , the MalE - RI fusion proteins 
BLAST 2 search algorithm , as described by Tatusova , et al . progressively lost RT activity and were degraded within 
( FEMS Microbiology Letters , 174 , p . 247 - 50 ( 1999 ) ) , and days , even when stored on ice or flash frozen in 50 % 
available on the world wide web at the National Center for 20 glycerol . The latter findings were surprising because pro 
Biotechnology Information website , under BLAST in the teins that fold properly in the presence of a solubility tag 
Molecular Database section . Preferably , the default values tend to remain soluble after cleavage of the tag ( Nallamsetty 
for all BLAST 2 search parameters are used , including et al . , Protein Expression and Purification 45 , 175 - 182 , 
reward for match = 1 , penalty for mismatch = - 2 , open gap 2005 ) . The group II intron RTs , which were active with but 
penalty = 5 , extension gap penalty = 2 , gapxdropoff = 50 , 25 not without the attached MalE tag , appear to be an excep 
expect = 10 , wordsize = 11 , and optionally , filter on . In the tion . The finding that the stabilizer protein must remain 
comparison of two nucleotide sequences using the BLAST attached to the thermostable reverse transcriptase suggests search algorithm , nucleotide identity is referred to as “ iden that it plays an active role in keeping the thermostable tities . " reverse transcriptase soluble and active . With regard to protein preparation from nucleotide 30 To overcome these difficulties , the inventors tested sequences , it is noted that a “ triplet ” codon of four possible 
nucleotide bases can exist in over 60 variant forms . Because whether the group II intron RTs could be stabilized in active 
these codons provide the message for only 20 different form by attaching the Male tag to the protein via a non 
amino acids ( as well as transcription initiation and termina cleavable rigid linker . Such MalE - rigid fusions typically 
tion ) , some amino acids can be coded for by more than one 35 have a linker region of 3 to 5 alanine residues combined with 
codon , a phenomenon known as codon redundancy . Accord changes at the C - terminus of the MalE tag to replace charged 
ingly , the nucleotide sequences used to prepare the particular amino acid residues with alanines ( Smyth et al . , Genes and amino acid sequences of stabilized reverse transcriptase Development 19 , 2477 - 2487 , 2003 ) . These rigid fusion fusion proteins can vary considerably , depending on the 
particular codons used . For reasons not completely under - 40 linkers reduce conformational heterogeneity , enabling crys 
stood , alternative codons are not uniformly present in the tallization of proteins with attached linkers for structure 
endogenous DNA of differing types of cells , and there exists determination ( Smyth et al . , ibid ) . For the MalE - RF - RT 
a natural hierarchy or " preference ” for certain codons in fusions tested here , the MalE / linker region of pMal - c2t 
certain types of cells . Accordingly , in some embodiments the TVDEALKDAQTNS N , LENLYFQGEF ( SEQ ID NO : 
choice of codons used to express a stabilized reverse tran - 45 19 ) was moc ilized reverse tran - 45 19 ) was modified to TVDAALAAAQTAAAAA ( SEQ ID scriptase fusion protein may be optimized through use of NO : 20 ) and called a MalE - RF ( rigid fusion ) tag ( FIG . 12B ) . particular codons to result in higher levels of expression . 
In accordance with this invention , the stabilized reverse To rapidly assess whether the MalE - RF tag affects the 
transcriptase fusion protein expression cassette is inserted activity of group H intron RTs , the inventors tested whether 
into a vector . The vector is preferably a plasmid or adeno - 50 the MalE - RF - RTs could support retrohoming in vivo . For 
viral vector , although linear DNA linked to a promoter , or initial tests , the RTs chosen were the LtrA protein encoded 
other vectors , such as adeno - associated virus or a modified by the L . lactis Ll .LtrB intron , and Te14h * RT , an activated 
vaccinia virus , retroviral or lentiviral vector may also be derivative of the RT encoded by the thermostable T . elon 
used . In particular , the use of E . coli plasmid vectors is gatus Tel4h intron . In retrohoming assays at 37° C . , the 
preferred . 55 MalE - RF - LtrA protein supported retrohoming at an effi 
A detailed description of the work conducted by the ciency of 20 % compared to 86 % for native LtrA , while in 
inventors to develop and evaluate stabilized reverse tran - retrohoming assays at 48° C . , the MalE - RF - Tel4h * protein 
scriptase fusion proteins is provided below . supported retrohoming at an efficiency of 87 % compared to 
Expression and Purification of Group H Intron RTs as MalE 100 % for the unfused Te14h * protein ; see Table 1 . Thus 
Fusion Proteins 60 remarkably both MalE - RF - RTs retain the ability to support 
The expression and solubility of poorly behaved proteins retrohoming with high albeit somewhat reduced efficiencies 
can sometimes be improved by fusion of highly soluble despite the presence of the attached maltose - binding protein 
proteins , like maltose - binding protein ( MalE ) or N utiliza rigid linker sequence . These findings imply that the proteins 
tion substance A ( NusA ) ( Nallamsetty et al . , Protein Expres - retain substantial levels of all activities required for retro 
sion and Purification 45 , 175 - 182 , 2005 ) . The MalE tag 65 homing , including RT , RNA splicing , and DNA endonu 
additionally permits facile purification of the protein via clease activity . This mobility assay provides a convenient 
amylose - affinity chromatography . The inventors therefore screen for active group II intron RTs . 
22 
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TABLE 1 temperature optima ranging from 45 - 61° C . The two most 
active and thermostable RTs , MalE - RF - Gs12 and MalE - RF 
Retrohoming efficiencies for different RTs Tel4c had temperature optima of 61° C . and retained sub 
RT Efficiency stantial activity at 70° C . ( where the assay may be limited by the stability of the primer - template base pairing ) . Of the two 
Te14h * ( 48° C . ) 100 % RTS , MalE - RF - Tel4c had the highest activity and was 
MalE - RF - Te14h * ( 48° C . ) assayed at lower protein concentrations ( 50 nM ) and for LtrA ( 37° C . ) 86 % 
MalE - RF - LtrA ( 37° C . ) 20 % shorter times ( 90 sec ) than the other RTs ( 100 nM , 5 min ) in 
order to remain within the linear range . Tests with the 
10 MalE - RF - Tel4c protein showed that inclusion of maltose 
Retrohoming assays were done in E . coli HMS174 ( DE3 ) ( 10 uM to 1 mM ) , which can affect the conformation of the 
as described previously for the Ll . LtrB intron ( LtrA protein ) MalE tag , had little if any effect on RT activity . 
( Guo et al . Science 289 , 452 - 457 , 2000 , Karberg et al . Effect of Changing the Tag and Linker on RT Activity 
Nature Biotech . 19 , 1162 - 1167 , 2001 ) and Tel4h * . The Cap To determine optimal properties of the tag and linker , the 
intron - donor plasmids use a T7lac promoter to express a 15 inventors constructed variants of the MalE - RF - Tel4c RT . 
AORF intron ( I - AORF ) with short flanking 5 ' and 3 ' exons The MalE - RT - Te14c RT ( left bar ) and variant proteins ( right 
( El and E2 , respectively ) and a 17 promoter in DIV , bars ) were purified and assayed for RT activity with poly 
followed by the RT ORF downstream of E2 . The Amp ( rA ) / oligo ( dT ) 42 as described above ( FIG . 13A ) . MalE - RT 
recipient plasmids contain a target site for the intron ( ligated Tel4c has a modified MalE tag ( MalE ( mod ) ) with 3 charged 
E1 - E2 sequences ) cloned upstream of a promoterless tet 20 amino acid residues changed to alanines and a linker of 5 
gene . Intron expression was induced with IPTG ( 0 . 1 mM for alanine residues linked to the N - terminus of the RT . Variants 
LtrA and MalE - RF - LtrA and 0 . 5 mM for Tel4h * and MalE in which the 5 alanine - residue linker was removed or 
RF - Tel4h * ) for 1 h at the indicated temperature . Retrohom shortened to 1 or 2 alanine residues had substantial but 
ing of the intron carrying the T7 promoter into the target site reduced RT activity , as did a variant in which the modified 
activates the expression of the tetk gene , enabling selection 25 MalE tag was replaced with wild - type MalE ( MalE ( WT ) ) 
for Tet * + Amp colonies . Retrohoming efficiencies were ( FIG . 13A ) . A variant of Tel4c with the MalE ( WT ) tag 
calculated as the ratio of ( Amp * + Tet ) / Amp colonies . followed by the pMal - c2t linker deleted for the TEV pro 
Encouraged by these findings , the inventors constructed tease cleavage site also had substantial but reduced RT 
plasmids in which several group II intron RTS were activity ( FIG . 13A ) . A variant in which the wild - type MalE 
expressed with a MalE tag fused to the N - terminus of the 30 tag was attached to the C - terminus of the Tel4c RT did not 
protein via a rigid linker in the vector pMal - c2t . The RTs express well in E . coli , presumably reflecting that the 
tested included several T . elongatus group II intron RTs , nascent Tel4c RT cannot fold properly without prior expres 
whose ability to support retrohoming had been tested pre - sion of the MalE tag . Finally , a variant with an N - terminal 
viously using the above plasmid assay and two G . stearo rigid fusion to NusA ( N utilization substance protein ) 
thermophilus group II intron RTs related to group II intron 35 instead of MalE had substantial thermostable RT activity 
RTs that had previously been difficult to purify with high ( FIGS . 13A and B ) . 
yield and activity ( Vellore et al . , Appl . Environ . Microbiol . Temperature Profile for cDNA Synthesis 
70 , 7140 - 7147 , 2004 ; Ng et al . , Gene 393 , 137 - 144 , 2007 ) . FIG . 14 shows assays of cDNA synthesis at different 
In some constructs , the inventors added an additional C - ter - temperatures using in vitro transcribed RNA templates with 
minal His6 - tag to enrich for full - length protein in the 40 DNA primers annealed to their 3 ' ends comparing two of the 
purification . The MalE - RF - RT fusion proteins were thermostable group II intron RTs ( MalE - RF - Tel4c and 
expressed in E . coli and purified by a procedure that involves MalE - RF - Gs12 ) with a commercially available RT , Super 
PEI - precipitation of nucleic acids followed by amylose Script III ( InvitrogenTM ) , which has been reported to be 
affinity and heparin - Sepharose chromatography . An addi active at 55° C . ( Potter et al . Focus ( Invitrogen Newsletter ) 
tional Ni column chromatography step was included for 45 25 . 1 , 19 - 24 , 2003 ) . One template was a 531 - nt in vitro 
constructs with a C - terminal His6 tag . The proteins were transcript synthesized from AflIII - digested PBS KS ( + ) with 
dialyzed against the purification buffer with 50 % glycerol , a 32P - labeled 37 - nt DNA primer annealed ( FIG . 14A - C ) and 
flash frozen , and stored at - 80° C . The final protein prepa - the other was a 1 . 2 - kb kanR RNA ( SEQ ID NO : 21 ; shown 
rations were > 95 % pure with yields of 0 . 5 - 2 . 2 mg / ml and in FIG . 15 ) with a 32P - labeled 44 - nt DNA primer ( FIG . 
their RT activity was undiminished after storage for at least 50 14D - E ) . The reaction was incubated for 30 min at the 
six months . indicated temperature , and the products were analyzed by 
RT Assays electrophoresis in a denaturing 6 % polyacrylamide gel . In 
To assess their thermostability , the inventors first assayed each panel , the top and bottom autoradiograms show por 
the RT activity of fusions MalE - RF - Te14c , Tel4h * , and Te14f tions of the gel containing the full - length product and 
from Thermosynechococcus elongatus and MalE - RF - Gs11 55 unextended or partially extended primers , respectively , and 
and Gs12 from Geobacillus stearothermophilus at tempera the bar graphs show the percentage of primer that was 
tures between 25 and 77° C . These initial assays were done extended to full - length cDNA . 
by using poly ( rA ) / oligo ( dT ) 42 as the template - primer sub - With the 531 - nt RNA template , the MalE - RF - Tel4c RT 
strate and quantifying polymerization of 32P - dTTP into high had a temperature optimum for full - length cDNA synthesis 
molecular weight material . The relatively long 42 - nt dT 60 of 61 - 81° C . The MalE - RF - Gs12 RT synthesized full - length 
primer was used so that it would remain annealed to the cDNA at temperatures between 37 and 69° C . , whereas 
poly ( rA ) template at higher temperatures ( calculated SuperScript III RT had no activity at temperatures higher 
Tm = 69° C . ) . The LtrA protein with and without an N - ter - than 57° C . ( FIG . 14A - C ) . With the 1 . 2 - kb RNA template , 
minal MalE - RF tag was assayed in parallel as a mesophilic the MalE - RF - Tel4c and MalE - RF - Gs12 RT had temperature 
RT control ( FIG . 11 ) . Whereas the LtrA protein had a 65 optima of 61 - 81° C . and 61 - 69° C . , respectively , while 
temperature optimum of ~ 35° C . with or without the MalE SuperScript III RT again had no activity at temperatures 
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Analysis of cDNA Synthesis by qRT - PCR moting retrohoming of the Ll . LtrB intron , ~ 10 - 5 at 37° C . 
In addition to gel analysis , the inventors used qRT - PCR to ( Conlan et al . , Nucl . Acids Res . 33 , 5262 - 5270 , 2005 ) . 
compare the amounts of cDNAs synthesized by the MalE 
RF - Tel4c and SuperScript III RTs using the 1 . 2 - kb RNA TABLE 2 
template . The inventors first compared the amounts of 5 
full - length cDNA produced at temperatures between 50 and Fidelity of group II intron RTs as measured by frequency of nucleotide 
75° C . ( FIG . 16 ) . The cDNAs for qPCR were synthesized in misincorporation during retrohoming 
reactions containing 5x108 copies of kanR RNA as a tem - RT Tel4h * Te14h * Tel4c Tel4c 
plate , 200 nM MalE - RT - Tel4c or 200 U of SuperScript III 
TeI4h * - AORF TeI4h * - AORF TeI3c - AORF Te14c - AORF RT for 30 min at six different temperatures . Reactions with 10 Intron Temp . 48 48 48 SuperScript III were done according to the manufacturer ' s ( °C . ) 
specifications . The reaction mix containing all components Nts 244 , 253 244 , 980 265 , 858 537 , 354 
except for dNTPs was preincubated at the desired tempera sequenced 
Mutations 4 tures for 2 min and started by adding the dNTPs . After 30 Error 1 . 6 x 10 - 5 4 . 1 x 10 - 6 1 . 1 x 10 - 5 2 . 2 x 10 - 5 min , the reactions were terminated by quickly freezing on 15 Frequency 
dry ice . A 5 - ul portion of each cDNA synthesis was used in 
qPCR reactions containing TaqMan® Gene Expression mix 
and two forward , reverse , and dual - labeled primer probe Retrohoming was done in E . coli HMS174 ( DE3 ) with 
mixes located at nt 188 - 257 and 562 - 634 of the kanamycin donor plasmids expressing the indicated intron and RT and 
RNA . With the primer set closest to the 5 ' end of the RNA 20 recipient plasmids containing the intron target site ( ligated 
( nt 188 - 257 ) , the cycle threshold ( C ) values were signifi E1 - E2 ) sequences cloned upstream of a promoterless tet 
cantly lower for the MalE - RF - Tel4c RT than for SuperScript gene . After selection of Tet colonies , introns that had 
III RT at all temperatures tested ( FIG . 16 ) , indicating that integrated into the target site in recipient plasmid were 
MalE - RF - Tel4c had synthesized larger amounts of cDNAs amplified by colony PCR using the primers Rsense ( 5 ' 
extending to near the 5 ' end of the RNA template . Notably , 25 ACAAATAGGGGTTCCGCGCAC ; SEQ ID NO : 22 ) and 
the difference in amounts of cDNAs synthesized was most Teb80rc ( 5 - GTTGGTGACCGCACCAGT ; SEQ ID NO : 
pronounced at temperatures between 55 and 65° C . , where 23 ) and Te420f ( 5 ' - AACGCGGTAAGCCCGTA ; SEQ ID 
the activity of SuperScript III falls off rapidly . NO : 24 ) and Rev2pBRR ( 5 - AATGGACGATATCCCGCA ; 
To compare the processivity of cDNA synthesis by MalE - SEQ ID NO : 25 ) for the 5 ' - and 3 ' - integration junctions , 
RF - Tel4c and SuperScript III RTs , the same cDNA samples 30 respectively . The PCR fragments were then sequenced . 
obtained at 60 and 65° C . were analyzed with two different Table 2 indicates the induction temperature for retrohoming , 
amplicon primer / probe sets : 188 - 257 , which detects cDNAs the total number of intron nucleotides sequenced , the num 
that are 920 - nt long , and 562 - 634 , which detects cDNAs that ber of mutations ( errors ) , and the error frequency . 
are 546 nt long ( FIG . 17 ) . In this case , cycle threshold results The following examples of methods for preparing and 
for cDNA samples were plotted against a standard curve 35 characterizing stabilized RT fusion proteins are included for 
obtained with Novagen® double - stranded DNA plasmid purposes of illustration and are not intended to limit the 
vector pET9a to determine copy numbers equivalents . With scope of the invention . 
the 188 - 257 amplicon primer / probe set , 972 , 815 copies were 
detected with the MalE - RF - 4c Tel4c RT versus 64 , 456 EXAMPLES 
copies with SuperScript RT at 60° C . ( ~ 15 fold difference ) , 40 
and that ratio increased to 732 , 559 versus 661 at 65° C . Example 1 : Recombinant Plasmids 
( ~ 1100 fold difference ) . Further , at both temperatures , the 
MalE - RF - Tel4c RT shows little difference in the copy pMalE - Tel4c , pMalE - Tel4f , pMalE - Tel4h * contain the 
numbers of cDNAs detected by the two primer sets , showing RT ORF of the indicated mobile group II intron with a fused 
that the MalE - RF - Tel4c RT synthesizes mostly full - length 45 N - terminal MalE tag cloned behind the tac promoter in the 
cDNAs , indicative of high processivity . By contrast . Super - expression vector pMal - c2t . The latter is a derivative of 
Script III RT showed lower numbers of longer cDNAs pMal - c2x ( New England Biolabs , Ipswich Mass . ) in which 
detected by the 188 - 257 primer set than the 562 - 634 primer the factor Xa protease - cleavage site between MalE and the 
set at both temperatures , indicating that this RT falls off or expressed protein was replaced by a TEV protease - cleavage 
is otherwise impeded before reaching the 5 ' end of the RNA , 50 site ( Kristelly et al . , Acta Crystallogr D Biol Crystallogr . 59 , 
resulting in synthesis of shorter cDNAs . 1859 - 1862 , 2003 ) . The Tel4h * RT is a derivative of the 
Fidelity of Nucleotide Incorporation by Tel4c and Tel4h * native Tel4h RT with the YAGD motif in RT - 5 changed to 
RTS YADD . Recombinant plasmids containing group II introns 
The inherent fidelity of the Tel4h * and Tel4c RTs ( i . e . , the from T . elongatus strain BP1 cloned in PET11 ( Tel4f ) , 
native group II intron RT , not a stabilized RT fusion protein ) 55 PUC19 ( Tel4c ) , or PACD2X ( Tel4h * ) were described pre 
was assessed initially by sequencing introns that had under - viously . pMalE - RT plasmids were derived from these initial 
gone retrohoming in E . coli plasmid assays ( Table 2 ) . The constructs by PCR amplifying the RT ORF with primers that 
maximum error frequencies for the TeI4h * RNA promoting append restriction sites , and then cloning the PCR products 
retrohoming of a Tel4h * - AORF intron RNA at 37 and 48° C . into the corresponding sites of pMal - c2t ( Tel4c RT , EcoRI 
were 1 . 6x10 - 5 and 4 . 1x10 - 6 , respectively . The Tel4c RT is 60 and Pstl sites ; Tel4f RT , BamHI site ; Tel4h * RT , BamHI and 
encoded by the outer intron of a “ twintron ” , a configuration Pst? sites ) . Recombinant plasmids denoted pMalE - RF - pro 
in which one group II intron ( Te13c ) has inserted into tein ( e . g . , pMalE - RF - Tel4c ) were derived from the corre 
another ( TeI4c ) , and can efficiently mobilize both introns . sponding pMalE - RT plasmids by replacing the TEV - pro 
The maximum error frequencies for the Tel4c RT promoting tease cleavable linker 
retrohoming of Tel3c or Tel4c at 48° C . were 1 . 1x10 - 5 and 65 ( TVDEALKDAQTNS N1LENLYFQG ; SEQ ID NO : 19 ) 
2 . 2x10 - 5 . These error frequencies are comparable to that with a rigid linker ( TVDAALAAAQTAAAAA ; SEQ ID 
estimated previously for the Ll . LtrB intron RT ( LtrA ) pro - NO : 20 ) by the QuikChange PCR procedure using the 
25 
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Accuprime polymerase ( Invitrogen , Makarova et al . , Bio induction medium ( LB containing 0 . 2 % lactose , 0 . 05 % 
Techniques 29 , 970 - 972 , 2000 ) . glucose , 0 . 5 % glycerol , 24 mM ( NH4 ) 2SO4 , 50 mM 
Derivatives of pMalE - RF - Tel4c with different linkers KH2PO4 , 50 mM Na2HPO4 ) ( pMalE - LtrA and pMalE - RF 
were constructed by PCR mutagenesis using the LtrA ) . In either case , induction was for ~ 24 h at 18 - 25° C . , 
QuikChange procedure . The Male tag was fused to the 5 after which cells were pelleted by centrifugation , resus 
C - terminus of the Tel4c ORF in p Mal - c2L by amplifying the pended in buffer A ( 20 mM Tris - HC1 , PH 7 . 5 , 0 . 5 M KCl or 
MalE segment of pMal - c2t with primers that introduce a 5 ' NaCl , 1 mM EDTA , 1 mM dithiothreitol ( DTT ) ) , and frozen 
EcoRI site and a 3 ' Psti site , and the Tel4c ORF of pMalE - at - 80° C . 
Tel4c with gene specific primers that introduce a 5 ' Ndel site For purification of MalE - RF - Tel4c , Tel4f , Tel4h * and 
and a 3 ' EcoRI site , respectively , and cloning the fragments 10 their derivatives , the cell suspension was thawed , treated 
into pMal - c2t digested with Ndel and Pst . . with lysozyme ( 1 mg / ml ; Sigma ) for 15 min on ice , freeze 
pNusA - RF - Tel4c - His , which expresses the Tel4c RT with thawed three times on dry ice , sonicated ( Branson 450 
an N - terminal NusA tag fused to the protein via a rigid linker Sonifier , Branson Ultrasonics , Danbury Conn . ) three or four 
and a C - terminal His6 tag , was constructed by PCR ampli - 10 sec bursts or one 30 sec burst on ice at an amplitude of 
fying the Tel4c RT ORF from PMAL - Tel4c with primers 15 60 % , with 10 sec between bursts , and centrifuged for 30 min 
that append SacII and KpnI sites and cloning the resulting at 18 , 500xg at 4° C . Nucleic acids were precipitated by 
PCR product between the corresponding sites of pET - 50b ( + ) adding polyethyleneimine ( PEI ) to a final concentration of 
( Novagen ) . PCR mutagenesis was then used to replace the 0 . 1 % and centrifuging for 15 min at 15 , 000xg at 4° C . in a 
last two charged residues ( D and E ) of NusA , the existing J16 . 25 rotor in an Avanti J - E centrifuge ( Beckman Coulter , 
linker , and one of the two N - terminal His6 tags ( NICWF - 20 Brea Calif . ) . The resulting supernatant was applied to an 
GDEATSGSGH " ; SEQ ID NO : 26 ) with a rigid linker amylose column ( 10 - ml column volume ; Amylose High 
sequence ( NICWFGAAAAA ; SEQ ID NO : 27 ) . The second Flow ( New England Biolabs ) , equilibrated in buffer A ) , 
N - terminal His6 tag was removed by PCR mutagenesis and which was washed with five column volumes each of buffer 
a His6 tag was fused to the C - terminus of Tel4c RT by A containing 0 . 5 M , 1 . 5 M , or 0 . 5 M KCl , and then eluted 
QuikChange PCR . 25 with buffer A containing 10 mM maltose . Protein fractions 
pMalE - Gs11 and pMalE - Gs12 were constructed by PCR were pooled and purified further via a heparin - Sepharose 
amplifying the RT ORFs from G . stearothermophilus strain column ( 3 tandem 1 - ml columns ; GE Healthcare Biosci 
10 genomic DNA ( obtained from Greg Davis ( Sigma ences Corp . ) which had been pre - equilibrated in 20 mM 
Aldrich ) ) by PCR with primers that amplify the introns and Tris - HC1 , PH 7 . 5 containing KC1 ( 100 mM for MalE - RF - 4c , 
appended BamHI and Xbal sites ( Gsil ) or BamHI sites 30 4f , 4h * , MalE - LtrA and MalE - RF - LtrA ; 50 mM for MalE 
( Gs12 ) and then cloning the PCR products between the RF - Gsll or Gs12 ) , 1 mM EDTA , 1 mM DTT , 10 % glycerol . 
corresponding sites of pMal - c2t . Gs11 is a subgroup IIB2 The proteins were applied to the column in the same buffer 
intron that is inserted in the G . stearothermophilus recA gene and eluted with a 40 - column volume gradient from the 
and is related to the previously described RT - encoding group loading concentration to 2 M KC1 . The proteins eluted at 
11 introns in the recA genes of Geobacillus kaustophilus 35 ~ 800 mM KC1 . The peak fractions were pooled and dialyzed 
( Chee et al . , Gene 363 , 211 - 220 , 2005 ) and Bacillus caldo - against 20 mM Tris - HCl , pH 7 . 5 , 0 . 5 M KC1 , 1 mM EDTA , 
lyticus ( Ng et al . , Gene 393 , 137 - 144 , 2007 ) . The cloned 1 mM DTT , and 50 % glycerol for storage . The frozen 
GsI1 RT ORF was verified to correspond to the genomic proteins showed no decrease in RT activity for at least six 
sequence ( CP001794 ) . Gs12 is a group IIC intron found in months . 
multiple copies in the G . stearothermophilus genome . The 40 The MalE - RF - Gsli protein , which has an N - terminal 
cloned Gs12 RT ORF corresponds to the genomic sequence MalE tag and a C - terminal His6 - tag , was purified similarly , 
of one of six full - length copies of GsI2 in the G . stearo except that nucleic acids were precipitated with 0 . 2 % PEI , 
thermophilus genome ( CP001794 ) and has three amino acid and the protein eluted from the amylose column was purified 
sequence changes from the RT ORF cloned by Vellore et al . further on a nickel column prior to the final heparin 
( Appl . Environ . Microbiol . 70 , 7140 - 7147 , 2004 ) . The cor - 45 Sepharose column . The nickel column ( 5 ml His TrapTM HP 
responding pMalE - RF - RT constructs were derived from the Nickel Sepharose ; GE Healthcare Biosciences , Piscataway 
pMalE - RT constructs by QuikChange PCR , as described N . J . ) equilibrated with binding buffer ( 500 mM KC1 , 20 mM 
above . Tris - HCl PH 7 . 5 , 40 mM imidazole , and 10 % glycerol ) was 
pMalE - LtrA was constructed by PCR amplifying the LtrA loaded with pooled protein fractions from the amylose 
ORF of pImp - 2 ( Saldanha et al . , Biochemistry 38 , 9069 - 50 column , washed with 10 column volumes of binding buffer , 
9083 , 1999 ) using primers that append BamHI and HindIII eluted with five column volumes of elution buffer ( 500 mM 
sites and then cloning the PCR product between the corre - KC1 , 20 mM Tris - HC1 PH 7 . 5 , 400 mM imidazole and 10 % 
sponding sites of pMal - c2t , and pMalE - RF - LtrA was glycerol ) , and the supernatant loaded directly onto the 
derived from pMalE - LtrA by QuikChange PCR , as heparin - Sepharose column . The peak fractions from the 
described above . 55 heparin - Sepharose column were pooled , dialyzed against 20 
mM Tris - HCl , pH 7 . 5 , 0 . 5 M KC1 , 50 % glycerol , and stored 
Example 2 : Protein Purification as described above . 
For the NusA fusions , E . coli ScarabXpress / pRARE T7lac 
For expression of pMalE - RT or pMalE - RF - RT constructs , cells were induced with 0 . 5 mM IPTG for 48 h at 18° C . and 
E . coli Rosetta 2 / PRARE ( Novagen , EMD Biosciences , 60 resuspended in nickel buffer A ( 20 mM Tris pH 7 . 5 , 500 mM 
Gibbstown N . J . ) or ScarabXpress / PRARE T7lac ( Scarabge - KCI , 30 mM imidazole , 10 % glycerol ) . After disrupting the 
nomics , Madison Wis . ) were transformed with the expres - cells as described above , nucleic acids were precipitated 
sion plasmid and grown at 37° C . in TB or LB medium to from the lysate by adding a final concentration of 0 . 2 % 
mid - log phase ( O . D . 600 = 0 . 8 ) . Expression was induced either polyethyleneimine , followed by centrifugation at 10 . 000xg 
by adding isopropyl B - D - 1 - thiogalactopyranoside ( IPTG ; 1 65 for 15 min . The supernatant was applied to a 5 - ml nickel 
mM final ) to mid - log phase cells ( pMalE - RF - Te14c , Tel4f , Sepharose column pre - equilibrated with nickel buffer A , and 
Tel4h * , Gsll , and Gs12 ) or by growing cells in auto then eluted with nickel buffer A containing 500 mM imida 
28 
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zole . The protein fractions were pooled and loaded directly EDTA ( final concentrations ) followed by phenol - CIA extrac 
onto two connected 1 - ml heparin - Sepharose columns that tion . The products were analyzed by electrophoresis in a 
had been pre - equilibrated in 20 mM Tris pH 7 . 5 , 100 mM denaturing 6 % polyacrylamide gel , which was dried and 
KCI , 1 mM DTT , 1 mM EDTA , and 20 % glycerol . The quantified with a PhosphorImager . A 5 ' - labeled 10 - bp ladder 
protein was eluted with a 20 - column volume gradient of 0 . 1 5 ( InvitrogenTM ) was used as size markers . 
to 1 . 5 M KCl , and peak fractions were pooled , dialyzed 
against 20 mM Tris - HC1 , pH 7 . 5 , 0 . 5 M KC1 , 1 mM EDTA , Example 4 : Quantitative Real - Time Polymerase 
1 mM DTT , 50 % glycerol , and stored as described above . Chain Reaction ( qPCR ) 
Example 3 : Reverse Transcriptase Assays 10 cDNAs for qPCR analysis were generated in 20 ul reac 
tions containing 1xRT buffer ( 75 mM KC1 , 10 mM MgCl2 , RT activity at different temperatures was assayed by 20 mM Tris - HCl ,pH 7 . 5 ) , 1 mM DTT , 5x108 copies of kanR quantifying incorporation of 32P - dTTP using poly ( rA ) / oligo RNA , 200 nM MalE - RF - Tel4c RT and 1 mM dNTPs for 30 ( LT ) 42 as the template - primer . The RT ( 50 nM MalE - RF 
Tel4c RT or 100 nM of all other RTS ) was pre - incubated with 15 min at temperatures specified for individual experiments . 
100 nM poly ( rA ) / oligo ( dT ) 42 in 1xRT buffer ( 75 mM KCI , Parallel reactions with SuperScript III ( Invitrogen ) were 
10 mM MgCl2 , 20 mM Tris - HCl , pH 7 . 5 , and 1 mM DTT ) done according to the manufacturers specifications . Reac 
at different temperatures ( ranging from 25 - 77° C . ) , and tions were incubated at the different temperatures for 2 min 
reactions were initiated by adding 5 uCi ?a - 32P ] - dTTP and started by adding dNTPs . After incubating for 30 min , 
( 3 , 000 Ci / mmol ; Perkin Elmer , Waltham Mass . ) . The reac - 20 the reactions were quickly frozen on dry ice to stop the 
tions were incubated for Limes within the linear range and reactions . 5 ul of cDNA reaction were used for the qPCR . 
stopped by adding EDTA to a final concentration of 250 qPCR analysis was done in 96 - well plates with optical 
mM . Reaction products were spotted onto Whatman DE81 caps with each well containing 25 ul of reaction mix 
chromatography paper ( 10x7 . 5 - cm sheets ; GE Healthcare ) , consisting of 12 . 5 ul of 2x TaqMan® Gene Expression 
washed 3 times in 0 . 3 M NaCl and 0 . 03 M sodium citrate , 25 Master Mix ( Applied Biosystems , Foster City , Calif . ) , 7 . 5 ul 
and scanned with a PhosphorImager ( Typhoon Trio Variable of forward , reverse , and dual - labeled probe mix ( oligonucle 
Mode Imager ; GE Healthcare ) to quantify bound radioac otides purchased individually from Integrated DNA Tech 
tivity . nologies , Coralville , Iowa ) , and 5 ul cDNA template . The 
Other RT assays used RNA templates with annealed DNA mixture was incubated in the 7900HT Fast Real - Time PCR 
oligonucleotide primers . The RNA template was either a 30 System ( Applied Biosystems ) , using the 9600 emulation 
531 - nt in vitro transcript synthesized from pBluescript KS mode protocol ( 50° C . for 2 min , 95° C . for 10 min , then ( + ) digested with AfilII transcribed using T7 Megscript kits cycled for a total of 45 cycles at 95° C . for 15 sec and 60° cve ( Ambion , Applied Biosystems , Austin , Tex . ) or a 1 . 2 - kb C . for 60 sec ) . Data were collected and analyzed using the kanR RNA purchased from Promega ( Promega , Madison Applied Biosystems Sequence Detection System Software , Wis . ) . In vitro transcription was done according to the 35 Versions 2 . 2 or 2 . 3 . manufacturer ' s instructions for 4 h at 37° C . After digesting 
the DNA template with Turbo DNase I ( 5 min , 37° C . ) , The Novagen® double - stranded DNA plasmid vector 
RNAs were extracted with phenol : chloroform : isoamyl alco - PET9a ( EMD Chemicals ) was used to quantitate kank 
hol ( 25 : 24 : 1 ; phenol - CIA ) and purified by two cycles of gel cDNA levels . The pET9a vector contains the kanR coding 
filtration through Sephadex G - 50 ( Sigma . St Louis , Mo . ) 40 sequence ( bases 3523 - 4335 ) and has 100 % sequence homol 
spin columns . The RNA concentration was determined by ogy at each primer / probe binding site with the Promega 
using a Nanodrop ( Thermo Scientific , Wilmington , Del . ) . 1 . 2 - kb kanR RNA . Purified and quantitated PET9a DNA 
RNAs were stored in Milli - O - grade H , O and stored at - 20° vector was initially diluted to 1x10 copies / ul stock aliquots 
and stored at - 20° C . For each run , fresh stocks were thawed 
DNA oligonucleotide primers complementary to the 3 ' 45 and then serially diluted to generate a quantitative standard 
ends of the RNAs were synthesized by IDT ( Coralville , curve used in qPCR . Cycle threshold results for cDNA 
Iowa ; AflIII primer : 5 ' - CCGCCTTIGAGTGAGCTGATAC - samples were then plotted against the standard curve to 
CGCTCGCCGCAGCCG ; SEQ ID NO : 28 : P078 Kanamy determine copy numbers equivalents . 
cin Rev 5 - GGTGGACCAGTTGGTGATITGAACTIT Primers used were : 
TIGCTTGCCACGGAAC ; SEQ ID NO : 29 ) . Primer 50 
concentrations were determined by A260 . The primers were 
5 32P - labeled with T4 polynucleotide kinase ( New England P078 Kanamycin RT - 1107R SEQ ID NO : 29 Biolabs ) according to the manufacturer ' s instructions , and 5 ' - GGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCA 
free nucleotides were removed by gel filtration through a CGGAAC - 3 ' ; 
Sephadex G - 25 column . The primers were mixed with the 55 ( Tm = 800 C . ) 
template at a molar ratio of 1 . 0 : 1 . 1 and annealed by heating primer sets nt 188 - 257 : to 82° C . for 2 min and then cooling to room temperature in Forward - P029 kan - 188F : 
a GeneAmp 9700 PCR cycler with the ramp setting of 10 % . SEQ ID NO : 30 
For gel analysis of cDNA synthesis , 100 nM of annealed 5 ' - GGGTATAAATGGGCTCGCG - 3 ' ; 
template / primer was incubated with 200 nM enzyme in 100 60 Reverse - P030 kan - 257R : 
mM KC1 , 20 mM Tris HCl pH 7 . 5 , 10 mM MgCl , and 1 mM SEQ ID NO : 31 
DTT for MalE - RF - Tel4c RT and in 10 mM NaCl , 20 mM 5 ' - CGGGCTTCCCATACAATCG - 3 ' ; 
Tris HC1 pH 7 . 5 , 10 mM MgCl , and 1 mM DTT for 
MalE - RF - Gs12 RT . Reactions were initiated by adding Taqman Probe - P031 kan - 213T : SEQ ID NO : 32 
dNTPs and MgCl , to final concentrations of 1 . 25 mM and 10 65 5 ' ( 6 - carboxyfluorescein ( 6FAM ) ) - TCGGGCAATC 
mM , respectively , incubated for 30 min at the indicated AGGTGCGACAATC - 3 ' ; 
temperature , and terminated by adding 0 . 1 % SDS / 250 mM 
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- continued chloramphenicol , 25 ug / ml ; tetracycline , 25 ug / ml . The 
( Iowa Black FQ ; a dark non - fluorescent intron - donor plasmids , derivatives of PACD2X ( San Filippo quencher ) ; et al . , Journal of Molecular Biology , 324 , 933 - 951 , 2002 ) , 
Amplicon 70 bp : carry a cap marker and use a T7lac promoter to express a 
SEQ ID NO : 33 5 AORF intron ( I - AORF ) with short flanking 5 ' and 3 ' exons 
5 ' GGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGT ( El and E2 , respectively ) and a 17 promoter in DIV , GCGACAATCTATCGATTGTATGGGAGCCCG - 3 ' ; followed by the RT ORF downstream of E2 . The recipient 
Primer Set ( nt 562 - 634 ) : plasmids , derivatives of PBRR - tet ( Guo et al . , Science 289 , 
Forward - P001 kan - 562R : 452 - 457 , 2000 ; Karberg et al . , Nature Biotech . 19 , 1162 SEQ ID NO : 34 10 i 
5 ' - CGCTCAGGCGCAATCAC - 3 ' ; 1167 , 2001 ) , carry an amp marker and contain a target site for the intron ( ligated E1 - E2 sequences ) cloned upstream of 
Reverse - PO02 kan - 634R : a promoterless tet gene . The latter is activated by insertion 
SEO ID NO : 35 of the intron carrying the T7 promoter , enabling selection for 5 ' - CCAGCCATTACGCTCGTCAT - 3 ' ; Tet + Amp colonies . For the assays , cells were co - trans 
Tagman Probe - PO03 kan - 581T : formed with the Cap donor and Amp recipient plasmids , 
SEQ ID NO : 36 inoculated into 5 ml of LB medium containing chloram 
5 ' ( 6 - FAM ) - ATGAATAACGGTTTGGTTGATGCGAGT phenicol and ampicillin , and grown with shaking ( 200 rpm ) GA - 3 ' - ( TAMRA ) ; overnight at 37° C . A small portion ( 50 ul ) of the overnight 
Amplicon 73 bp culture was inoculated into 5 ml of fresh LB medium 
SEQ ID NO : 37 20 containing the so containing the same antibiotics and grown for 1 h as above . 
5 ' CGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGA The cells were then induced with IPTG for 1 h under TGCGAGTGATTTTGATGACGAGCGTAATGGCTGG - 3 ' ; conditions specified in the legend of Table 1 for individual 
experiments . The cultures were then placed on ice , diluted 
Example 5 : Retrohoming Assays with ice - cold LB , and plated at different dilutions onto LB 25 agar containing ampicillin or ampicillin + tetracycline . After 
Retrohoming assays were done in E . coli HMS174 ( DE3 ) incubating the plates overnight at 37° C . , the mobility 
( NovagenTM ) grown on LB medium , with antibiotics added efficiency was calculated as the ratio of ( Tet + Amp ) / AmpR 
at the following concentrations : ampicillin , 100 ug / ml ; colonies . 
15 
SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 46 
V 
< 210 > SEO ID NO 1 
< 211 > LENGTH : 562 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Thermosynechococcus elongatus 
V 
V
< 400 > SEQUENCE : 1 
Met Glu Thr Arg Gin Met Thr Val Asp Gin Thr Thr Gly Ala Val Thr 
5 
Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asn Trp Thr Lys Ala Asn 
25 
Arg Glu Val Lys Arq Leu Gin Val Arq Ile Ala Lys Ala Val Lys Glu 
Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu Leu Thr His Ser 
Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr Asp Asn Ser Gly 
65 70 80 
Ser Arg Thr Pro Gly Val Asp Gly Ile Thr Trp Ser Thr Gin Glu Gin 
Lys Thr Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly Tyr Lys Pro Gin 
105 
Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Asn Gly Lys Gin Arg Pro 
Leu Gly Ile Pro Thr Met Lys Asp Arg Ala Met Gin Ala Leu Tyr Ala 
Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp Arg Asn Ser Tyr 
145 150 160 
Gly Phe Arg Arg Gly Arg Cys Thr Ala Asp Ala Ala Gly Gin Cys Phe 
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- continued 
Leu Ala Leu Ala Lys Ala Lys Ser Ala Glu His Val Leu Asp Ala Asp 
185 190 
Ile Ser Gly Cys Phe Asp Asn Ile Ser His Glu Trp Leu Leu Ala Asn 
195 200 205 
Thr Pro Leu Asp Lys Gly Ile Leu Arg Lys Trp Leu Lys Ser Gly Phe 
215 220 
Val Trp Lys Gin Gin Leu Phe Pro Thr His Ala Gly Thr Pro Gin Gly 
225 235 240 
Gly Val Ile Ser Pro Val Leu Ala Asn Ile Thr Leu Asp Gly Met Glu 
245 255 
Glu Leu Leu Ala Lys His Leu Arg Gly Gin Lys Val Asn Leu Ile Arg 
265 270 
Tyr Ala Asp Asp Phe Val Val Thr Gly Lys Asp Glu Glu Thr Leu Glu 
275 280 285 
Lys Ala Arg Asn Leu Ile Gin Glu Phe Leu Lys Glu Arg Gly Leu Thr 
295 300 
Leu Ser Pro Glu Lys Thr Lys Ile Val His Ile Glu Glu Gly Phe Asp 
305 315 320 
Phe Leu Gly Trp Asn Ile Arg Lys Tyr Asn Gly Val Leu Leu Ile Lys 
325 335 
Pro Ala Lys Lys Asn Val Lys Ala Phe Leu Lys Lys Ile Arg Asp Thr 
345 350 
Leu Arg Glu Leu Arg Thr Ala Thr Gin Glu Ile Val Ile Asp Thr Leu 
355 360 365 
Asn Pro Ile Ile Arg Gly Trp Ala Asn Tyr His Lys Gly Gin Val Ser 
375 380 
Lys Glu Thr Phe Asn Arg Val Asp Phe Ala Thr Trp His Lys Leu Trp 
385 395 400 
Arg Trp Ala Arg Arg Arg His Pro Asn Lys Pro Ala Gin Trp Val Lys 
405 415 
Asp Lys Tyr Phe Ile Lys Asn Gly Ser Arg Asp Trp Val Phe Gly Met 
425 430 
Val Met Lys Asp Lys Asn Gly Glu Leu Arg Thr Lys Arg Leu Ile Lys 
435 440 445 
Thr Ser Asp Thr Arg Ile Gin Arg His Val Lys Ile Lys Ala Asp Ala 
455 460 
Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu Lys Arg Lys Lys 
465 475 480 
Leu Lys Lys Ala Pro Ala Gin Tyr Arg Arg Ile Arg Arg Glu Leu Trp 
485 495 
Lys Lys Gin Gly Gly Ile Cys Pro Val Cys Gly Gly Glu Ile Glu Gin 
505 510 
Asp Met Leu Thr Asp Ile His His Ile Leu Pro Lys His Lys Gly Gly 
520 525 515 
Ser Asp Asp Leu Asp Asn Leu Val Leu Ile His Ala Asn cys His Lys 
535 540 
Gin Val His Ser Arg Asp Gly Gin His Ser Arg Ser Leu Leu Lys Glu 
545 550 555 560 
Gly Leu 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 562 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Thermosynechococcus elongatus 
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- continued 
< 400 > SEQUENCE : 2 
Met Glu Thr Arg Gin Met Ala Val Glu Gin Thr Thr Gly Ala Val Thr 
15 
Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asp Trp Ala Lys Ala Asn 
25 30 
Arg Glu Val Lys Arg Leu Gin Val Arg Ile Ala Lys Ala Val Lys Glu 
40 
Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu Leu Thr His Ser 
55 
Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr Asp Asn Ser Gly 
75 
Ser Lys Thr Pro Gly Val Asp Gly Ile Thr Trp Ser Thr Gin Glu Gin 
95 
Lys Ala Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly Tyr Lys Pro Gin 
105 110 
Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Asn Gly Lys Gin Arg Pro 
120 
Leu Gly Ile Pro Thr Met Lys Asp Arg Ala Met Gin Ala Leu Tyr Ala 
135 
Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp Arq Asn Ser Tyr 
155 
Gly Phe Arg Arg Gly Arg Cys Ile Ala Asp Ala Ala Thr Gin Cys His 
175 
Ile Thr Leu Ala Lys Thr Asp Arg Ala Gin Tyr Val Leu Asp Ala Asp 
185 190 
Ile Ala Gly Cys Phe Asp Asn Ile Ser His Glu Trp Leu Leu Ala Asn 
200 
Ile Pro Leu Asp Lys Arg Ile Leu Arg Lys Trp Leu Lys Ser Gly Phe 
215 
Val Trp Lys Gin Gin Leu Phe Pro Ile His Ala Gly Thr Pro Gin Gly 
235 
Gly Val Ile Ser Pro Met Leu Ala Asn Met Thr Leu Asp Gly Met Glu 
255 
Glu Leu Leu Asn Lys Phe Pro Arg Ala His Lys Val Lys Leu Ile Arg 
265 270 
Tyr Ala Asp Asp Phe Val Val Thr Gly Glu Thr Lys Glu Val Leu Tyr 
280 
Ile Ala Gly Ala Val Ile Gin Ala Phe Leu Lys Glu Arg Gly Leu Thr 
295 
Leu Ser Lys Glu Lys Thr Lys Ile Val His Ile Glu Glu Gly Phe Asp 
315 
Phe Leu Gly Trp Asn Ile Arg Lys Tyr Asp Gly Lys Leu Leu Ile Lys 
335 
Pro Ala Lys Lys Asn Val Lys Ala Phe Leu Lys Lys Ile Arg Asp Thr 
345 350 
Leu Arq Glu Leu Arq Thr Ala Pro Gln Glu Ile Val Ile Asp Thr Leu 
360 
Asn Pro Ile Ile Arg Gly Trp Thr Asn Tyr His Lys Asn Gin Ala Ser 
375 
Lys Glu Thr Phe Val Gly Val Asp His Leu Ile Trp Gin Lys Leu Trp 
395 400 
Arg Trp Ala Arg Arg Arg His Pro Ser Lys Ser Val Arg Trp Val Lys 
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405 410 415 
Ser Lys Tyr Phe Ile Gin Ile Gly Asn Arg Lys Trp Met Phe Gly Ile 
420 425 430 
Trp Thr Lys Asp Lys Asn Gly Asp Pro Trp Ala Lys His Leu Ile Lys 
435 440 445 
Ala Ser Glu Ile Arg Ile Gin Arg Arg Gly Lys Ile Lys Ala Asp Ala 
460 
Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu Gln Arg Lys Lys 
475 480 
Leu Lys Glu Ala Pro Ala Gin Tyr Arg Arg Thr Arg Arg Glu Leu Trp 
485 495 
Lys Lys Gin Gly Gly Ile Cys Pro Val Cys Gly Gly Glu Ile Glu Gin 
500 505 510 
Asp Met Leu Thr Glu Ile His His Ile Leu Pro Lys His Lys Gly Gly 
515 520 525 
Thr Asp Asp Leu Asp Asn Leu Val Leu Ile His Thr Asn Cys His Lys 
540 
Gin Val His Asn Arg Asp Gly Gln His Ser Arg Phe Leu Leu Lys Glu 
545 555 560 
Gly Leu 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 562 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Thermosynechococcus elongatus 
< 400 > SEQUENCE : 3 
Met Glu Thr Ara Gln Met Ala Val Glu Gin Thr Thr Gly Ala Val Thr 
10 
Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asp Trp Ala Lys Ala Asn 
30 
Arg Glu Val Lys Arg Leu Gin Val Arg Ile Ala Lys Ala Val Lys Glu 
40 
Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu Leu Thr His Ser 
55 
Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr Asp Asn Ser Gly 
65 75 
Ser Lys Thr Pro Gly Val Asp Gly Ile Thr Trp Ser Thr Gin Glu Gin 
90 
Lys Ala Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly Tyr Lys Pro Gin 
110 
Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Ser Gly Lys Gin Arg Pro 
120 
Leu Gly Ile Pro Thr Thr Lys Asp Arg Ala Met Gin Ala Leu Tyr Ala 
135 
Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp Arg Asn Ser Tyr 
145 150 155 
Gly Phe Arg Gin Gly Arg Cys Thr Ala Asp Ala Ala Gly Gin Cys Phe 
170 
Thr Val Leu Gly Arg Ser Asp Cys Ala Lys Tyr Ile Leu Asp Ala Asp 
190 
Ile Thr Gly Cys Phe Asp Asn Ile Ser His Glu Trp Leu Leu Asp Asn 
200 
Ile Pro Leu Asp Lys Glu Val Leu Arg Lys Trp Leu Lys Ser Gly Phe 




Val Trp Lys Gin Gin Leu Phe Pro Thr His Ala Gly Thr Pro Gin Gly 
225 230 235 
Gly Val Ile Ser Pro Met Leu Ala Asn Met Thr Leu Asp Gly Met Glu 
255 
Glu Leu Leu Lys Lys His Leu Arg Lys Gin Lys Val Asn Leu Ile Arg 
265 270 
Tyr Ala Asp Asp Phe Val Val Thr Gly Glu Ser Lys Glu Thr Leu Glu 
280 285 
Lys Val Thr Thr Val Ile Gin Glu Phe Leu Lys Glu Arg Gly Leu Thr 
Leu Ser Glu Glu Lys Thr Lys Val Val His Ile Glu Glu Gly Phe Asp 
310 315 305 
Phe Leu Gly Trp Asn Ile Arg Lys Tyr Gly Glu Lys Leu Leu Ile Lys 
335 
Pro Ala Lys Lys Asn Ile Lys Ala Phe His Lys Lys Ile Arg Asp Ala 
345 350 
Leu Lys Glu Leu Arg Thr Ala Thr Gin Glu Ala Val Ile Asp Thr Leu 
360 365 
Asn Pro Ile Ile Lys Gly Trp Ala Asn Tyr His Arg Asn Gin Val Ser 
Lys Arg Ile Phe Asn Arg Ala Asp Asp Asn Ile Trp His Lys Leu Trp 
385 390 395 
Arg Trp Ala Lys Arg Arg His Pro Asn Lys Pro Ala Arg Trp Thr Lys 
415 
Asn Lys Tyr Phe Ile Lys Ile Gly Asn Arg His Trp Val Phe Gly Thr 
425 430 
Trp Lys Lys Asp Lys Glu Gly Arg Leu Arg Ser Arg Tyr Leu Ile Lys 
440 445 
Ala Gly Asp Thr Arg Ile Gin Arg His Val Lys Ile Lys Ala Asp Ala 
Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu Glu Arg Lys Lys 
465 470 475 
Leu Lys Glu Ala Pro Ala Gin Tyr Arg Arg Ile Arg Arg Glu Leu Trp 
495 
Lys Lys Gin Gly Gly Ile Cys Pro Val Cys Gly Gly Glu Ile Glu Gin 
505 510 
Asp Met Leu Thr Glu Ile His His Ile Leu Pro Lys His Lys Gly Gly 
520 525 
Ser Asp Asp Leu Asp Asn Leu Val Leu Ile His Ala Asn cys His Lys 
Gin Val His Ser Arg Asp Gly Gin His Ser Arg Phe Leu Leu Lys Glu 
545 550 555 560 
Gly Leu 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 635 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Geobacillus stearothermophilus 
< 400 > SEQUENCE : 4 
Met Lys Val Asn Lys Leu Val Val Lys Ser Glu Gin Asp Leu Arg Asn 
10 15 
Cys Leu Asp Leu Leu Tyr Gin Glu Ala Lys Lys Gly Lys His Phe Tyr 




Gly Met Leu Glu Leu Leu Gln Asn Asp Val Val Ile Leu Glu Ala Ile 
35 Giu Leu Leu Gin Asn Asp val val Ile Leu Glu Ala lle 40 45 
Arg Asn Ile Lys Ser Asn Lys Gly Ser Lys Thr Ala Gly Ile Asp Gin 
55 
Lys Ile Val Asp Asp Tyr Leu Leu Met Pro Thr Glu Lys Val Phe Gly 
65 70 
Met Ile Lys Ala Lys Leu Asn Asp Tyr Lys Pro Ile Pro Val Arg Arg 
85 95 
Cys Asn Lys Pro Lys Gly Asn Ala Lys Ser Ser Lys Arg Lys Gly Asn 
100 110 
Ser Pro Asn Glu lu Gly Glu Thr Arg Pro Leu Gly Ile Ser Ala Val 
115 120 125 
Thr Asp Arg Ile Ile Gln Glu Met Leu Arq Ile Val Leu Glu Pro Ile 
135 
Phe Glu Ala Gln Phe Tyr Pro His Ser Tyr Gly Phe Arg Pro Tyr Arg 
145 150 
Ser Thr Glu His Ala Leu Ala Trp Met Leu Lys Ile Ile Asn Gly Ser 
165 175 
Lys Leu Tyr Trp Val Val Lys Gly Asp Ile Glu Ser Tyr Phe Asp His 
180 190 
Ile Asn His Lys Lys Leu Leu Asn Ile Met Trp Asn Met Gly Val Arg 
195 200 205 
Asp Lys Arg Val Leu Cys Ile Val Lys Lys Met Leu Lys Ala Gly Gin 
215 
Val Ile Gin Gly Lys Phe Tyr Pro Thr Ala Lys Gly Ile Pro Gin Gly 
225 230 
Gly Ile Ile Ser Pro Leu Leu Ala Asn Val Tyr Leu Asn Ser Phe Asp 
245 255 
Trp Met Val Gly Gin Glu Tyr Glu Tyr His Pro Asn Asn Ala Asn Tyr 
260 270 
Arg Glu Lys Lys Asn Ala Leu Ala Ala Leu Arg Asn Lys Gly His His 
275 280 285 
Pro Val Phe Tyr Ile Arg Tyr Ala Asp Asp Trp Val Ile Leu Thr Asp 
295 
Thr Lys Glu Tyr Ala Glu Lys Ile Arg Glu Gin Cys Lys Gin Tyr Leu 
305 310 
Ala Cys Glu Leu His Leu Thr Leu Ser Asp Glu Lys Thr Phe Ile Ala 
325 335 
Asp Ile Arg Glu Gin Arg Val Lys Phe Leu Gly Phe Cys Ile Glu Ala 
340 350 
Gly Lys Arg Arg Phe His Lys Lys Gly Phe Ala Ala Arg Met Ile Pro 
355 360 365 
Asp Met Glu Lys Val Asn Ala Lys Val Lys Glu Ile Lys Arg Asp Ile 
375 
Arg Leu Leu Arg Thr Arg Lys Ser Glu Leu Glu Lys Ala Leu Asp Ile 
385 390 
Glu Asn Ile Asn Thr Lys Ile Ile Gly Leu Ala Asn His Leu Lys Ile 
405 415 Ile Ile Giy hacen 
Gly Ile Ser Lys Tyr Ile Met Gly Lys Val Asp Arg Val Ile Glu Glu 
420 430 
Thr Ala Tyr Arg Thr Trp Val Lys Met Tyr Gly Lys Glu Lys Ala Ala 
435 440 445 
US 10 , 150 , 955 B2 
- continued 
Gin Tyr Lys Arg Pro Val Ser Glu Phe His Asn Arg Ile Asp Arg His 
Lys Gly Tyr Gin Met Lys His Phe Ser Val Val Thr Glu Asp Gly Ile 
465 470 475 480 
Arg Val Gly Ile Thr His Ala Lys Ile Thr Pro Ile Gin Tyr Ala Thr 
Val Phe Lys Gin Glu Met Thr Pro Tyr Thr Ala Asp Gly Arg Lys Met 
Tyr Glu Glu Lys His Arg Lys Ile Arg Leu Pro Asp Lys Met Ser Leu 
515 520 
Phe Asp His Asp Ser Ile Phe Ile Tyr Ile Leu Ser Glu His Asn Asp 
Gly Lys Tyr Asn Leu Glu Tyr Phe Leu Asn Arg Val Asn Val Phe His 
545 550 555 560 
Arg Asp Lys Gly Lys Cys Lys Ile Cys Ala Val Tyr Leu Ser Pro Gly 
Asn Phe His Cys His His Ile Asp Pro Ser Lys Pro Leu Ser Glu Ile 
Asn Lys Thr Val Asn Leu Ile Ser Leu Cys Asn Gin Cys His Arg Leu 
595 600 
Val His Ser Asn Gin Glu Pro Pro Phe Thr Glu Arq Lys Met Phe Asp 
Lys Leu Thr Lys Tyr Arg Asn Lys Leu Lys Ile 
625 630 635 
< 210 > SEO ID NO 5 
< 211 > LENGTH : 420 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Geobacillus stearothermophilus 
< 400 > SEQUENCE : 5 
Met Ala Leu Leu Glu Arq Ile Leu Ala Arg Asp Asn Leu Ile Thr Ala 
Leu Lys Arg Val Glu Ala Asn Gin Gly Ala Pro Gly Ile Asp Gly Val 
25 
Ser Thr Asp Gin Leu Arg Asp Tyr Ile Arg Ala His Trp Ser Thr Ile 
40 
His Ala Gin Leu Leu Ala Gly Thr Tyr Arg Pro Ala Pro Val Arg Arg 
Val Glu Ile Pro Lys Pro Gly Gly Gly Thr Arg Gin Leu Gly Ile Pro 
65 
Thr Val Val Asp Arg Leu Ile Gin Gin Ala Ile Leu Gin Glu Leu Thr 
Pro Ile Phe Asp Pro Asp Phe Ser Ser Ser Ser Phe Gly Phe Arg Pro 
105 
Gly Arg Asn Ala His Asp Ala Val Arg Gin Ala Gin Gly Tyr Ile Gin 
120 
Glu Gly Tyr Arg Tyr Val Val Asp Met Asp Leu Glu Lys Phe Phe Asp 
Arg Val Asn His Asp Ile Leu Met Ser Ara Val Ala Arq Lys Val Lys 
145 
Asp Lys Arg Val Leu Lys Leu Ile Arg Ala Tyr Leu Gin Ala Gly Val 
175 
Met Ile Glu Gly Val Lys Val Gin Thr Glu Glu Gly Thr Pro Gin Gly 




Gly Pro Leu Ser Pro Leu Leu Ala Asn Ile Leu Leu Asp Asp Leu Asp 
200 
Lys Glu Leu Glu Lys Arg Gly Leu Lys Phe Cys Arg Tyr Ala Asp Asp 
215 
Cys Asn Ile Tyr Val Lys Ser Leu Arg Ala Gly Gin Arg Val Lys Gin 
225 230 235 240 
Ser Ile Gin Arg Phe Leu Glu Lys Thr Leu Lys Leu Lys Val Asn Glu 
250 
Glu Lys Ser Ala Val Asp Arg Pro Trp Lys Arg Ala Phe Leu Gly Phe 
265 270 
Ser Phe Thr Pro Glu Arg Lys Ala Arg Ile Arg Leu Ala Pro Arg Ser 
280 
Ile Gin Arg Leu Lys Gin Arg Ile Arg Gin Leu Thr Asn Pro Asn Trp 
295 
Ser Ile Ser Met Pro Glu Arq Ile His Arq Val Asn Gin Tyr Val Met 
305 310 315 320 
Gly Trp Ile Gly Tyr Phe Arg Leu Val Glu Thr Pro Ser Val Leu Gin 
330 
Thr Ile Glu Gly Trp Ile Arg Arg Arg Leu Arg Leu Cys Gin Trp Leu 
345 350 
Gin Trp Lys Arg Val Arg Thr Arg Ile Arg Glu Leu Arg Ala Leu Gly 
360 
Leu Lys Glu Thr Ala Val Met Glu Ile Ala Asn Thr Arg Lys Gly Ala 
375 
Trp Arg Thr Thr Lys Thr Pro Gln Leu His Gln Ala Leu Gly Lys Thr 
385 390 395 400 
Tyr Trp Thr Ala Gin Gly Leu Lys Ser Leu Thr Gin Arg Tyr Phe Glu 
405 410 415 
Leu Arg Gin Gly 
420 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 934 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
NN 
< 400 > SEQUENCE : 6 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
15 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
20 25 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
His Asp Arg Phe Gly Gly Tyr Ala Gin Ser Gly Leu Leu Ala Glu Ile 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
95 
Ala Val Arq Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
100 105 
US 10 , 150 , 955 B2 
46 
- continued 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
115 120 125 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
135 
Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Tri Pro 
145 150 155 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
175 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
185 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
195 200 205 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys i Gly Glu Thr Ala 
215 
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
225 230 235 
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
255 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
265 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
275 280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
295 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
305 310 315 
Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gin 
335 
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala 
345 
Ser Gly Arg Gln Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala 
355 360 365 
Ala Ala Ala Ala Met Glu Thr Arg Gln Met Thr Val Asp Gin Thr Thr 
375 
Gly Ala Val Thr Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asn Trp 
385 390 395 
Thr Lys Ala Asn Arg Glu Val Lys Arg Leu Gin Val Arg Ile Ala Lys 
415 
Ala Val Lys Glu Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu 
425 
Leu Thr His Ser Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr 
435 440 445 
Asp Asn Ser Gly Ser Arg Thr Pro Gly Val Asp Gly Ile Thr Trp Ser 
455 
Thr Gin Glu Gin Lys Thr Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly 
465 470 475 480 
Tyr Lys Pro Gin Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Asn Gly 
485 495 
Lys Gin Arg Pro Leu Gly Ile Pro Thr Met Lys Asp Arg Ala Met Gin 
500 505 
Ala Leu Tyr Ala Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp 
520 525 
Arg Asn Ser Tyr Gly Phe Arg Arg Gly Arg Cys Thr Ala Asp Ala Ala 




Gly Gin Cys Phe Leu Ala Leu Ala Lys Ala Lys Ser Ala Glu His Val 
545 560 
Leu Asp Ala Asp Ile Ser Gly Cys Phe Asp Asn Ile Ser His Glu Trp 
575 
Leu Leu Ala Asn Thr Pro Leu Asp Lys Gly Ile Leu Arg Lys Trp Leu 
585 590 
Lys Ser Gly Phe Val Trp Lys Gln Gln Leu Phe Pro Thr His Ala Gly 
600 605 
Thr Pro Gin Gly Gly Val Ile Ser Pro Val Leu Ala Asn Ile Thr Leu 
Asp Gly Met Glu Glu Leu Leu Ala Lys His Leu Arg Gly Gin Lys Val 
625 
Asn Leu Ile Arg Tyr Ala Asp Asp Phe Val Val Thr Gly Lys Asp Glu 
655 
Glu Thr Leu Glu Lys Ala Arg Asn Leu Ile Gin Glu Phe Leu Lys Glu 
665 670 
Arg Gly Leu Thr Leu Ser Pro Glu Lys Thr Lys Ile Val His Ile Glu 
680 685 
Glu Gly Phe Asp Phe Leu Gly Trp Asn Ile Arg Lys Tyr Asn Gly Val 
Leu Leu Ile Lys Pro Ala Lys Lys Asn Val Lys Ala Phe Leu Lys Lys 
705 
Ile Arg Asp Thr Leu Arg Glu Leu Arg Thr Ala Thr Gin Glu Ile Val 
735 
Ile Asp Thr Leu Asn Pro Ile Ile Arg Gly Trp Ala Asn Tyr His Lys 
745 750 
Gly Gin Val Ser Lys Glu Thr Phe Asn Arg Val Asp Phe Ala Thr Trp 
760 765 
His Lys Leu Trp Arg Trp Ala Arg Arg Arg His Pro Asn Lys Pro Ala 
Gin Trp Val Lys Asp Lys Tyr Phe Ile Lys Asn Gly Ser Arg Asp Trp 
785 
Val Phe Gly Met Val Met Lys Asp Lys Asn Gly Glu Leu Arg Thr Lys 
815 
Arg Leu Ile Lys Thr Ser Asp Thr Arg Ile Gin Arg His Val Lys Ile 
830 825 
Lys Ala Asp Ala Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu 
840 845 
Lys Arg Lys Lys Leu Lys Lys Ala Pro Ala Gin Tyr Arg Arg Ile Arg 
Arg Glu Leu Trp Lys Lys Gin Gly Gly Ile Cys Pro Val Cys Gly Gly 
865 
Glu Ile Glu Gin Asp Met Leu Thr Asp Ile His His Ile Leu Pro Lys 
895 
His Lys Gly Gly Ser Asp Asp Leu Asp Asn Leu Val Leu Ile His Ala 
905 910 
Asn cys His Lys Gin Val His Ser Arg Asp Gly Gin His Ser Arg Ser 
920 925 
Leu Leu Lys Glu Gly Leu 
< 210 > SEQ ID NO 7 
US 10 , 150 , 955 B2 
49 50 
- continued 
< 211 > LENGTH : 934 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
? ??NM O
< 400 > SEQUENCE : 7 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
10 15 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
20 25 30 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
35 45 40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
60 
His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile 
75 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
90 95 
Ala Val Arq Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
100 105 110 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
115 120 125 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
140 
Lys Ser Ala Leu Met Phe Asn Leu Gun Glu Pro Tyr Phe Thr Tri Pro 
155 160 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
170 175 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
180 185 190 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
195 200 205 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala 
220 
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
235 240 
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
250 255 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
260 265 270 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
275 280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
300 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
310 315 320 
Thr Met Glu Asn Ala Gin Lys Gly Glu Ile Met Pro Asn Ile Pro Gin 
325 330 335 
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala 
340 345 350 
Ser Gly Arg Gin Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala 
355 360 365 
Ala Ala Ala Ala Met Glu Thr Arg Gin Met Ala Val Glu Gin Thr Thr 
US 10 , 150 , 955 B2 
- continued 
370 375 380 
Gly Ala Val Thr Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asp Trp 
385 390 395 400 
Ala Lys Ala Asn Arg Glu Val Lys Arg Leu Gin Val Arg Ile Ala Lys 
Ala Val Lys Glu Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu 
420 430 
Leu Thr His Ser Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr 
435 440 445 
Asp Asn Ser Gly Ser Lys Thr Pro Gly Val Asp Gly Ile Thr Trp Ser 
455 
Thr Gin Glu Gin Lys Ala Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly 
465 470 475 
Tyr Lys Pro Gin Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Asn Gly 
Lys Gin Arg Pro Leu Gly Ile Pro Thr Met Lys Asp Arg Ala Met Gin 
500 510 
Ala Leu Tyr Ala Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp 
515 520 525 
Arg Asn Ser Tyr Gly Phe Arg Arg Gly Arg Cys Ile Ala Asp Ala Ala 
535 
Thr Gin Cys His Ile Thr Leu Ala Lys Thr Asp Arg Ala Gin Tyr Val 
545 550 555 
Leu Asp Ala Asp Ile Ala Gly cys Phe Asp Asn Ile Ser His Glu Trp 
Leu Leu Ala Asn Ile Pro Leu Asp Lys Arg Ile Leu Arg Lys Trp Leu 
580 590 
Lys Ser Gly Phe Val Trp Lys Gln Gln Leu Phe Pro Ile His Ala Gly 
595 600 605 
Thr Pro Gin Gly Gly Val Ile Ser Pro Met Leu Ala Asn Met Thr Leu 
615 
Asp Gly Met Glu Glu Leu Leu Asn Lys Phe Pro Arg Ala His Lys Val 
625 630 635 
Lys Leu Ile Arg Tyr Ala Asp Asp Phe Val Val Thr Gly Glu Thr Lys 
Glu Val Leu Tyr Ile Ala Gly Ala Val Ile Gin Ala Phe Leu Lys Glu 
660 670 
Arg Gly Leu Thr Leu Ser Lys Glu Lys Thr Lys Ile Val His Ile Glu 
675 680 685 
Glu Gly Phe Asp Phe Leu Gly Trp Asn Ile Arg Lys Tyr Asp Gly Lys 
695 
Leu Leu Ile Lys Pro Ala Lys Lys Asn Val Lys Ala Phe Leu Lys Lys 
705 710 715 
Ile Arg Asp Thr Leu Arg Glu Leu Arg Thr Ala Pro Gin Glu Ile Val 
Ile Asp Thr Leu Asn Pro Ile Ile Arg Gly Trp Thr Asn Tyr His Lys 
740 750 
Asn Gin Ala Ser Lys Glu Thr Phe Val Gly Val Asp His Leu Ile Trp 
755 760 765 
Gin Lys Leu Trp Arg Trp Ala Arg Arg Arg His Pro Ser Lys Ser Val 
775 
Arg Trp Val Lys Ser Lys Tyr Phe Ile Gin Ile Gly Asn Arg Lys Trp 
790 795 785 
US 10 , 150 , 955 B2 
54 
- continued 
Met Phe Gly Ile Trp Thr Lys Asp Lys Asn Gly Asp Pro Trp Ala Lys 
805 815 
His Leu Ile Lys Ala Ser Glu Ile Arg Ile Gin Arg Arg Gly Lys Ile 
825 
Lys Ala Asp Ala Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu 
840 845 
Gin Arg Lys Lys Leu Lys Glu Ala Pro Ala Gin Tyr Arg Arg Thr Arg 
855 860 
Arg Glu Leu Trp Lys Lys Gin Gly Gly Ile Cys Pro Val cys Gly Gly 
865 875 880 
Glu Ile Glu Gin Asp Met Leu Thr Glu Ile His His Ile Leu Pro Lys 
885 
His Lys Gly Gly Thr Asp Asp Leu Asp Asn Leu Val Leu Ile His Thr 
905 
Asn Cys His Lys Gin Val His Asn Arg Asp Gly Gin His Ser Arg Phe 
920 925 
Leu Leu Lys Glu Gly Leu 
930 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 934 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
V 
< 400 > SEQUENCE : 8 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
5 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
25 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
60 
His Asp Arg Phe Gly Gly Tyr Ala Gin Ser Gly Leu Leu Ala Glu Ile 
70 75 80 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
Ala Val Arq Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
105 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
120 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
140 
Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Tri Pro 
150 155 160 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
185 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
200 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala 




Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
225 230 235 240 
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
255 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
260 265 270 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
300 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
305 310 315 
Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln 
335 
Met Ser Ala Phe Trp Tyr Ala Val Arq Thr Ala Val Ile Asn Ala Ala 
340 345 350 
Ser Gly Arg Gin Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala 
360 365 
Ala Ala Ala Ala Met Glu Thr Arg Gin Met Ala Val Glu Gin Thr Thr 
380 
Gly Ala Val Thr Asn Gin Thr Glu Thr Ser Trp His Ser Ile Asp Trp 
385 390 395 400 
Ala Lys Ala Asn Arg Glu Val Lys Arg Leu Gin Val Arg Ile Ala Lys 
415 
Ala Val Lys Glu Gly Arg Trp Gly Lys Val Lys Ala Leu Gin Trp Leu 
420 425 430 
Leu Thr His Ser Phe Tyr Gly Lys Ala Leu Ala Val Lys Arg Val Thr 
440 445 
Asp Asn Ser Gly Ser Lys Thr Pro Gly Val Asp Gly Ile Thr Trp Ser 
460 
Thr Gin Glu Gin Lys Ala Gin Ala Ile Lys Ser Leu Arg Arg Arg Gly 
465 470 475 480 
Tyr Lys Pro Gin Pro Leu Arg Arg Val Tyr Ile Pro Lys Ala Ser Gly 
495 
Lys Gin Arg Pro Leu Gly Ile Pro Thr Thr Lys Asp Arg Ala Met Gin 
500 505 510 
Ala Leu Tyr Ala Leu Ala Leu Glu Pro Val Ala Glu Thr Thr Ala Asp 
520 525 
Arg Asn Ser Tyr Gly Phe Arg Gin Gly Arg Cys Thr Ala Asp Ala Ala 
540 
Gly Gin Cys Phe Thr Val Leu Gly Arg Ser Asp Cys Ala Lys Tyr Ile 
545 550 555 560 
Leu Asp Ala Asp Ile Thr Gly Cys Phe Asp Asn Ile Ser His Glu Trp 
575 
Leu Leu Asp Asn Ile Pro Leu Asp Lys Glu Val Leu Arg Lys Trp Leu 
580 585 590 
Lys Ser Gly Phe Val Trp Lys Gln Gln Leu Phe Pro Thr His Ala Gly 
600 605 
Thr Pro Gin Gly Gly Val Ile Ser Pro Met Leu Ala Asn Met Thr Leu 
620 
Asp Gly Met Glu Glu Leu Leu Lys Lys His Leu Arg Lys Gin Lys Val 
625 630 635 640 
US 10 , 150 , 955 B2 
58 
- continued 
Asn Leu Ile Ara Tyr Ala Asp Asp Phe Val Val Thr Gly Glu Ser Lys 
655 
Glu Thr Leu Glu Lys Val Thr Thr Val Ile Gln Glu Phe Leu Lys Glu 
665 670 
Arg Gly Leu Thr Leu Ser Glu Glu Lys Thr Lys Val Val His Ile Glu 
680 
Glu Gly Phe Asp Phe Leu Gly Trp Asn Ile Arg Lys Tyr Gly Glu Lys 
Leu Leu Ile Lys Pro Ala Lys Lys Asn Ile Lys Ala Phe His Lys Lys 
715 720 710 
Ile Arg Asp Ala Leu Lys Glu Leu Arg Thr Ala Thr Gin Glu Ala Val 
Ile Asp Thr Leu Asn Pro Ile Ile Lys Gly Trp Ala Asn Tyr His Arg 
745 750 
Asn Gln Val Ser Lys Arg Ile Phe Asn Arg Ala Asp Asp Asn Ile Trp 
760 
His Lys Leu Trp Arg Trp Ala Lys Arg Arg His Pro Asn Lys Pro Ala 
Arg Trp Thr Lys Asn Lys Tyr Phe Ile Lys Ile Gly Asn Arg His Trp 
790 795 800 
Val Phe Gly Thr Trp Lys Lys Asp Lys Glu Gly Arg Leu Arg Ser Arg 
Tyr Leu Ile Lys Ala Gly Asp Thr Arg Ile Gin Arg His Val Lys Ile 
825 830 
Lys Ala Asp Ala Asn Pro Phe Leu Pro Glu Trp Ala Glu Tyr Phe Glu 
840 
Glu Arg Lys Lys Leu Lys Glu Ala Pro Ala Gin Tyr Arg Arg Ile Arg 
Arg Glu Leu Trp Lys Lys Gin Gly Gly Ile Cys Pro Val Cys Gly Gly 
870 875 880 
Glu Ile Glu Gin Asp Met Leu Thr Glu Ile His His Ile Leu Pro Lys 
His Lys Gly Gly Ser Asp Asp Leu Asp Asn Leu Val Leu Ile His Ala 
905 910 
Asn Cys His Lys Gin Val His Ser Arg Asp Gly Gin His Ser Arg Phe 
920 





< 210 > SEQ ID NO 9 
< 211 > LENGTH : 1007 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
NN PEP?? V 
?? 
< 400 > SEQUENCE : 9 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
25 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
35 40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
US 10 , 150 , 955 B2 
- continued 
60 
His Asp Arg Phe Gly Gly Tyr Ala Gin Ser Gly Leu Leu Ala Glu Ile 
65 75 80 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
90 95 
Ala Val Arq Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
100 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
115 120 125 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Tri Pro 
145 155 160 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
170 175 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
180 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
195 200 205 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys G ] y Glu Thr Ala 
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
225 235 240 
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
250 255 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
260 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
275 280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
305 315 320 
Thr Met Glu Asn Ala Gin Lys Gly Glu Ile Met Pro Asn Ile Pro Gin 
330 335 
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala 
340 
Ser Gly Arg Gin Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala 
355 360 365 
Ala Ala Ala Ala Met Lys Val Asn Lys Leu Val Val Lys Ser Glu Gin 
Asp Leu Arg Asn Cys Leu Asp Leu Leu Tyr Gin Glu Ala Lys Lys Gly 
395 400 385 
Lys His Phe Tyr Gly Met Leu Glu Leu Leu Gin Asn Asp Val Val Ile 
410 415 
Leu Glu Ala Ile Arg Asn Ile Lys Ser Asn Lys Gly Ser Lys Thr Ala 
420 
Gly Ile Asp Gin Lys Ile Val Asp Asp Tyr Leu Leu Met Pro Thr Glu 
435 440 445 
Lys Val Phe Gly Met Ile Lys Ala Lys Leu Asn Asp Tyr Lys Pro Ile 
Pro Val Arg Arg Cys Asn Lys Pro Lys Gly Asn Ala Lys Ser Ser Lys 
465 475 480 
US 10 , 150 , 955 B2 
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Arg Lys Gly Asn Ser Pro Asn Glu Glu Gly Glu Thr Arg Pro Leu Gly 
485 490 495 
Ile Ser Ala Val Thr Asp Arg Ile Ile Gin Glu Met Leu Ara Ile Val 
500 510 
Leu Glu Pro Ile Phe Glu Ala Gln Phe Tyr Pro His Ser Tyr Gly Phe 
515 
Arg Pro Tyr Arg Ser Thr Glu His Ala Leu Ala Trp Met Leu Lys Ile 
535 
Ile Asn Gly Ser Lys Leu Tyr Trp Val Val Lys Gly Asp Ile Glu Ser 
545 560 
Tyr Phe Asp His Ile Asn His Lys Lys Leu Leu Asn Ile Met Trp Asn 
565 570 575 
Met Gly Val Arg Asp Lys Arg Val Leu Cys Ile Val Lys Lys Met Leu 
580 590 
Lys Ala Gly Gin Val Ile Gin Gly Lys Phe Tyr Pro Thr Ala Lys Gly 
595 
Ile Pro Gin Gly Gly Ile Ile Ser Pro Leu Leu Ala Asn Val Tyr Leu 
615 
Asn Ser Phe Asp Trp Met Val Gly Gin Glu Tyr Glu Tyr His Pro Asn 
625 640 
Asn Ala Asn Tyr Arg Glu Lys Lys Asn Ala Leu Ala Ala Leu Ara Asn 
645 650 
Lys Gly His His Pro Val Phe Tyr Ile Arg Tyr Ala Asp Asp Trp Val 
660 670 
Ile Leu Thr Asp Thr Lys Glu Tyr Ala Glu Lys Ile Arg Glu Gin Cys 
675 
Lys Gin Tyr Leu Ala Cys Glu Leu His Leu Thr Leu Ser Asp Glu Lys 
695 
Thr Phe Ile Ala Asp Ile Arg Glu Gin Arg Val Lys Phe Leu Gly Phe 
705 720 
Cys Ile Glu Ala Gly Lys Arg Arg Phe His Lys Lys Gly Phe Ala Ala 
725 730 
Arg Met Ile Pro Asp Met Glu Lys Val Asn Ala Lys Val Lys Glu Ile 
740 750 
Lys Arg Asp Ile Arg Leu Leu Arg Thr Arg Lys Ser Glu Leu Glu Lys 
755 760 
Ala Leu Asp Ile Glu Asn Ile Asn Thr Lys Ile Ile Gly Leu Ala Asn 
775 
His Leu Lys Ile Gly Ile Ser Lys Tyr Ile Met Gly Lys Val Asp Arg 
785 800 
Val Ile Glu Glu Thr Ala Tyr Arg Thr Trp Val Lys Met Tyr Gly Lys 
805 810 
Glu Lys Ala Ala Gin Tyr Lys Arg Pro Val Ser Glu Phe His Asn Arg 
820 830 
Ile Asp Arg His Lys Gly Tyr Gin Met Lys His Phe Ser Val Val Thr 
835 840 
Glu Asp Gly Ile Arg Val Gly Ile Thr His Ala Lys Ile Thr Pro Ile 
855 
Gln Tyr Ala Thr Val Phe Lys Gin Glu Met Thr Pro Tyr Thr Ala Asp 
865 875 880 Thx Val Bhe Lys Gin Glu met 
Gly Arg Lys Met Tyr Glu Glu Lys His Arg Lys Ile Arg Leu Pro Asp 
885 890 
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- continued 
Lys Met Ser Leu Phe Asp His Asp Ser Ile Phe Ile Tyr Ile Leu Ser 
905 910 
Glu His Asn Asp Gly Lys Tyr Asn Leu Glu Tyr Phe Leu Asn Arg Val 
915 920 925 
Asn Val Phe His Arg Asp Lys Gly Lys Cys Lys Ile Cys Ala Val Tyr 
935 940 
Leu Ser Pro Gly Asn Phe His Cys His His Ile Asp Pro Ser Lys Pro 
945 950 955 960 
Leu Ser Glu Ile Asn Lys Thr Val Asn Leu Ile Ser Leu Cys Asn Gln 
970 975 
Cys His Arq Leu Val His Ser Asn Gin Glu Pro Pro Phe Thr Glu Arq 
980 985 990 
Lys Met Phe Asp Lys Leu Thr Lys Tyr Arg Asn Lys Leu Lys Ile 
995 1000 1005 
V 
V 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 792 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
V NN EPPV 
< 400 > SEQUENCE : 10 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
10 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
35 40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
His Asp Arg Phe Gly Gly Tyr Ala Gin Ser Gly Leu Leu Ala Glu Ile 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
90 
Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
105 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
115 120 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
Lys Ser Ala Leu Met Phe Asn Leu Gun Glu Pro Tyr Phe Thr Tri Pro 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
170 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
185 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
195 200 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala 
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
250 
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- continued 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
270 260 265 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
275 280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
305 320 
Thr Met Glu Asn Ala Gin Lys Gly Glu Ile Met Pro Asn Ile Pro Gin 
330 335 
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala 
340 345 350 
Ser Gly Arg Gin Thr Val Asp Ala Ala Leu Ala Ala Ala Gln Thr Ala 
355 360 365 
Ala Ala Ala Ala Met Ala Leu Leu Glu Arg Ile Leu Ala Arg Asp Asn 
Leu Ile Thr Ala Leu Lys Arg Val Glu Ala Asn Gin Gly Ala Pro Gly 
385 400 
Ile Asp Gly Val Ser Thr Asp Gin Leu Arg Asp Tyr Ile Arg Ala His 
410 415 
Trp Ser Thr Ile His Ala Gin Leu Leu Ala Gly Thr Tyr Arg Pro Ala 
420 425 430 
Pro Val Arg Arg Val Glu Ile Pro Lys Pro Gly Gly Gly Thr Arg Gin 
435 440 445 
Leu Gly Ile Pro Thr Val Val Asp Arg Leu Ile Gin Gin Ala Ile Leu 
Gln Glu Leu Thr Pro Ile Phe Asp Pro Asp Phe Ser Ser Ser Ser Phe 
465 480 
Gly Phe Arg Pro Gly Arg Asn Ala His Asp Ala Val Arg Gin Ala Gin 
490 495 
GLY y Tyr Ile Gln Glu Gly Tyr Arg Tyr Val Val Asp Met Asp Leu Glu 
500 505 510 
Lys Phe Phe Asp Arg Val Asn His Asp Ile Leu Met Ser Arg Val Ala 
515 520 525 
Arg Lys Val Lys Asp Lys Arg Val Leu Lys Leu Ile Arg Ala Tyr Leu 
Gin Ala Gly Val Met Ile Glu Gly Val Lys Val Gin Thr Glu Glu Gly 
545 560 
Thr Pro Gin Gly Gly Pro Leu Ser Pro Leu Leu Ala Asn Ile Leu Leu 
570 575 
Asp Asp Leu Asp Lys Glu Leu Glu Lys Arg Gly Leu Lys Phe Cys Arg 
580 585 590 
Tyr Ala Asp Asp Cys Asn Ile Tyr Val Lys Ser Leu Arg Ala Gly Gin 
595 600 605 
Arg Val Lys Gin Ser Ile Gin Arg Phe Leu Glu Lys Thr Leu Lys Leu 
Lys Val Asn Glu Glu Lys Ser Ala Val Asp Arg Pro Trp Lys Arg Ala 
625 640 
Phe Leu Gly Phe Ser Phe Thr Pro Glu Arg Lys Ala Arg Ile Arg Leu 
645 650 655 
Ala Pro Arg Ser Ile Gin Arg Leu Lys Gin Arg Ile Arg Gin Leu Thr 
660 665 670 
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Asn Pro Asn Trp Ser Ile Ser Met Pro Glu Arg Ile His Arg Val Asn 
675 685 
Gin Tyr Val Met Gly Trp Ile Gly Tyr Phe Arg Leu Val Glu Thr Pro 
695 700 
Ser Val Leu Gin Thr Ile Glu Gly Trp Ile Arg Arg Arg Leu Arg Leu 
715 720 
Cys Gin Trp Leu Gin Trp Lys Arg Val Arg Thr Arg Ile Arg Glu Leu 
730 735 
Arq Ala Leu Gly Leu Lys Glu Thr Ala Val Met Glu Ile Ala Asn Thr 
750 
Arg Lys Gly Ala Trp Arg Thr Thr Lys Thr Pro Gin Leu His Gin Ala 
755 765 
Leu Gly Lys Thr Tyr Trp Thr Ala Gin Gly Leu Lys Ser Leu Thr Gin 
775 780 
Arg Tyr Phe Glu Leu Arg Gin Gly 
785 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 367 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
< 400 > SEQUENCE : 11 
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
25 30 
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
40 
Pro Gin Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala 
55 
His Asp Arg Phe Gly Gly Tyr Ala Gin Ser Gly Leu Leu Ala Glu Ile 
65 75 
Thr Pro Asp Lys Ala Phe Gin Asp Lys Leu Tyr Pro Phe Thr Trp Asp 
Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu 
105 110 
Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys 
120 
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly 
135 
Lys Ser Ala Leu Met Phe An Leu Gln Glu Pro Tyr Phe Thr Tri Pro 
145 155 
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly 
185 190 
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp 
200 
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala 
215 
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys 
225 235 240 
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Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gin Pro Ser 
245 255 250 
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro 
265 270 
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp 
275 280 285 
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala 
295 
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala 
310 320 
Thr Met Glu Asn Ala Gin Lys Gly Glu Ile Met Pro Asn Ile Pro Gin 
325 335 330 
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala 
345 350 
Ser Gly Arg Gin Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr 
355 360 365 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 5 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 12 
Ala Ala Ala Ala Ala 
< 210 > SEO ID NO 13 
< 211 > LENGTH : 8260 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
< 400 > SEQUENCE : 13 
ccgacaccat cgaatggtgc aaaacctttc gcggtatggc atgatagcgc ccggaagaga 60 
gtcaattcag ggtggtgaat gtgaaaccag taacgttata cgatgtcgca gagtatgccg 120 
gtgtctctta tcagaccgtt tcccgcgtgg tgaaccaggc cagccacgtt tctgegaaaa 180 
cgcgggaaaa agtggaagcg gcgatggcgg agctgaatta cattcccaac cgcgtggcac 240 
aacaactggc gggcaaacag togttgctga ttggcgttgc cacctccagt ctggccctgc 300 
acgcgccgtc gcaaattgtc gcggcgatta aatctcgcgc cgatcaactg ggtgccagcg 360 
tggtggtgtc gatggtagaa cgaagcggcg tcgaagcctg taaagcggcg gtgcacaatc 420 
ttctcgcgca acgcgtcagt gggctgatca ttaactatcc gctggatgac caggatgcca 480 
ttgctgtgga agctgcctgc actaatgttc cggcgttatt tcttgatgtc tctgaccaga 540 
cacccatcaa cagtattatt ttctcccatg aagacggtac gcgactgggc gtggagcatc 600 
tggtcgcatt gggtcaccag caaatcgcgc tgttagcggg cccattaagt tctgtctcgg 660 
cgcgtctgcg tctggctggc tggcataaat atctcactcg caatcaaatt cagccgatag 720 
cggaacggga aggcgactgg agtgccatgt ccggttttca acaaaccatg caaatgctga 780 
atgagggcat cgttcccact gcgatgctgg ttgccaacga tcagatggcg ctgggcgcaa 840 
tgcgcgccat taccgagtcc gggctgcgcg ttggtgcgga tatctcggta gtgggatacg 900 
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acgataccga agacagctca tgttatatcc cgccgttaac caccatcaaa caggattttc 960 
gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc caggcggtga 1020 
agggcaatca gctgttgccc gtctcactgg tgaaaagaaa aaccaccctg gcgcccaata 1080 
cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt 1140 
cccgactgga aagcgggcag tgagcgcaac gcaattaatg taagttagct cactcattag 1200 
gcacaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gcttctggcg 1260 
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 1320 
tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 1380 
ctggcaaata ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 1440 
attgtgagcg gataacaatt tcacacagga aacagccagt ccgtttaggt gttttcacga 1500 
gcacttcacc aacaaggacc atagcatatg aaaatcgaag aaggt aaact ggtaatctgg 1560 
attaacggcg ataaaggcta taacggtctc gctgaagtcg gtaagaaatt cgagaaagat 1620 
accggaatta aagtcaccgt tgagcatccg gataaactgg aagagaaatt cccacaggtt 1680 
goggcaactg gcgatggccc tgacattatc ttctgggcac acgaccgctt tggtggctac 1740 
gctcaatctg gcctgttggc tgaaatcacc ccggacaaag cgttccagga caagctgtat 1800 
ccgtttacct gggatgccgt acgttacaac ggcaagctga ttgcttaccc gatcgctgtt 1860 
gaagcgttat cgctgattta taacaaagat ctgctgccga acccgccaaa aacctgggaa 1920 
gagatcccgg cgctggataa agaactgaaa gcgaaaggta agagcgcgct gatgttcaac 1980 
ctgcaagaac cgtacttcac ctggccgctg attgctgctg acgggggtta tgcgttcaag 2040 
tatgaaaacg gcaagtacga cattaaagac gtgggcgtgg ataacgctgg cgcgaaagcg 2100 
ggtctgacct tcctggttga cctgattaaa aacaaacaca tgaatgcaga caccgattac 2160 
tccatcgcag aagctgcctt taataaaggc gaaacagcga tgaccatcaa cggcccgtgg 2220 
gcatggtcca acatcgacac cagcaaagtg aattatggtg taacggtact gccgaccttc 2280 
aagggtcaac catccaaacc gttcgttggc gtgctgagcg caggtattaa cgccgccagt 2340 
ccgaacaaag agctggcaaa agagttcctc gaaaactatc tgctgactga tgaaggtctg 2400 
gaagcggtta ataaagacaa accgctgggt gccgtagcgc tgaagtctta cgaggaagag 2460 
ttggcgaaag atccacgtat tgccgccact atggaaaacg cccagaaagg tgaaatcatg 2520 
ccgaacatcc cgcagatgtc cgctttctgg tatgccgtgc gtactgcggt gatcaacgcc 2580 
gccagcggtc gtcagactgt cgatgccgcc ctggccgccg cgcagactgc cgccgccgcc 2640 
gccatggaga caaggcaaat gacggtggac caaaccactg gtgcggtcac caaccaaacg 2700 
gaaacaagct ggcacagcat aaactggacc aaagccaacc gtgaggtaaa gaggctgcaa 2760 
gtgcgtatcg caaaggctgt gaaggaagga cgctggggca aagtgaaagc tttgcaatgg 2820 
ctcctgaccc actcgttcta cggcaaagcc ctcgccgtga aacgggtaac tgacaactca 2880 
ggcagtagaa cacctggtgt ggacgggata acctggtcca cacaagagca gaaaacccaa 2940 
gccataaagt ccctcaggag aagaggctat aaaccccaac ccctgaggcg ggtatacatc 3000 
ccgaaagcaa acggcaaaca gcgcccgcta ggaatcccga caatgaagga cagggcaatg 3060 
caggcactat atgccctagc cctagaacca gtcgcggaaa ccacagcgga ccggaactcc 3120 
tatgggttcc gccgagggcg atgtacggca gatgoggcag gacaatgctt ccttgctctg 3180 
gcaaaagcca agtcggctga acacgtcctt gacgctgaca tatccggatg ctttgataac 3240 
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atcagccatg agtggctact agccaacact ccactggaca aagggatott acggaaatgg 3300 
cttaaatctg ggttcgtctg gaaacagcaa ctcttcccca cccatgctgg gacacctcag 3360 
ggaggggtaa tctccccagt tcttgccaat ataaccctag atgggatgga agaactgttg 3420 
gccaaacacc tcagaggtca aaaagtcaac ctcatccgat atgctgacga ttttgtcgtg 3480 
acgggaaaag atgaggaaac cctggagaaa gccagaaacc taatccagga gttcctaaaa 3540 
gaacggggct tgaccctgtc ccccgagaag acaaaaatcg tccatattga ggaaggcttc 3600 
gactttctcg gatggaacat tcgcaagtac aacggggttc ttctcatcaa acccgcgaag 3660 
aagaacgtga aagcgttcct caagaaaatc cgagacactc taagggaact taggacagca 3720 
acccaggaaa tcgtgataga cacactcaac ccaatcatta gaggttgggc caactatcac 3780 
aaaggacaag tctctaagga aaccttcaac cgagtggact tcgccacctg gcacaaattg 3840 
tggcgatggg caaggcgccg gcacccaaac aaacctgccc aatgggtgaa ggacaaatac 3900 
ttcatcaaaa acggaagcag agactgggtg ttcggtatgg tgatgaaaga caagaacggg 3960 
gaactgagga ccaaacgcct aatcaaaacc tctgacaccc gaatccaacg ccacgtcaaa 4020 
atcaaggcag acgccaatcc gtttctccca gagtgggcag aatactttga gaaacgcaag 4080 
aaactcaaaa aagcccctgc tcaatatcgg cgcatccgcc gagaactatg gaagaaacag 4140 
ggtggtatct gtccagtatg cgggggtgaa attgagcaag acatgctcac tgacatccac 4200 
cacatattgc ccaaacacaa gggtggttct gacgacctgg ataatcttgt cttaatccac 4260 
gocaactgcc acaaacaggt gcacagccga gatggtcagc acagccggtc cctcttgaaa 4320 
gaggggcttt gactgcaggc aagcttggca ctggccgtcg ttttacaacg togtgactgg 4380 
gaaaaccctg gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg 4440 
cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag cctgaatggc 4500 
gaatggcagc ttggctgttt tggcggatga gataagattt tcagcctgat acagattaaa 4560 
tcagaacgca gaagcggtct gataaaacag aatttgcctg goggcagtag cgcggtggtc 4620 
ccacctgacc ccatgccgaa ctcagaagtg aaacgccgta gcgccgatgg tagtgtgggg 4680 
tctccccatg cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcagtcgaa 4740 
agactgggcc tttcgtttta tctgttgttt gtcggtgaac gctctcctga gtaggacaaa 4800 
tccgccggga gcggatttga acgttgcgaa gcaacggccc ggagggtggc gggcaggacg 4860 
cccgccataa actgccaggc atcaaattaa gcagaaggcc atcctgacgg atggcctttt 4920 
tgcgtttcta caaactcttt ttgtttattt ttctaaatac attcaaatat gtatccgctc 4980 
atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 5040 
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct 5100 
cacccagaaa cgctggtgaa agtaaaagat gotgaagatc agttgggtgc acgagtgggt 5160 
tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt 5220 
tctccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtgttgac 5280 
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac 5340 
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 5400 
gccata acca tgagtgataa cactgeggcc aacttacttc tgacaacgat cggaggaccg 5460 5 
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 5520 
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 5580 
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa 5640 
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caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt 5700 
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 5760 
attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg 5820 
agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt 5880 
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaccccgg 5940 
ttgataatca gaaaagcccc aaaaacagga agattgtata agcaaatatt taaattgtaa 6000 
acgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc 6060 
aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga 6120 
gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag 6180 
ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcacco aaatcaagtt 6240 
ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta 6300 
gagcttgacg gggaaagccg gegaacgtgg cgagaaagga agggaagaaa gcgaaaggag 6360 
cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg 6420 
cgcttaatgc gccgctacag ggcgcgtaaa aggatctagg tgaagatcct ttttgataat 6480 
ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa 6540 
aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca 6600 
aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt 6660 
ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg 6720 
tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc 6780 
ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga 6840 
cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc 6900 
agcttggage gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc 6960 
gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca 7020 
ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg 7080 
tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg goggagccta 7140 
tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct 7200 
cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag 7260 
tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa 7320 
goggaagagc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 7380 
atatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc cagtatacac 7440 
tccgctatcg ctacgtgact gggtcatggc tgcgccccga cacccgccaa cacccgctga 7500 
cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg tgaccgtctc 7560 
cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga ggcagctgcg 7620 
gtaaagctca tcagcgtggt cgtgcagcga ttcacagatg tctgcctgtt catccgcgtc 7680 
cagctcgttg agtttctcca gaagcgttaa tgtctggctt ctgataaagc gggccatgtt 7740 
aagggcggtt ttttcctgtt tggtcactga tgcctccgtg taagggggat ttctgttcat 7800 
gggggtaatg ataccgatga aacgagagag gatgctcacg atacgggtta ctgatgatga 7860 
acatgcccgg ttactggaac gttgtgaggg taaacaactg goggtatgga tgcggcggga 7920 
ccagagaaaa atcactcagg gtcaatgcca gcgcttcgtt aatacagatg taggtgttcc 7980 
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acagggtagc cagcagcatc ctgcgatgca gatccggaac ataatggtgc agggcgctga 8040 
cttccgcgtt tccagacttt acgaaacacg gaaaccgaag accattcatg ttgttgctca 8100 
ggtcgcagac gttttgcagc agcagtcgct tcacgttcgc tcgcgtatcg gtgattcatt 8160 
ctgctaacca gtaaggcaac cccgccagcc tagccgggtc ctcaacgaca ggagcacgat 8220 
catgcgcacc cgtggccagg acccaacgct gcccgaaatt 8260 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 8260 
< 212 > TYPE : DNA 
13 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
< 400 > SEQUENCE : 14 
ccgacaccat cgaatggtgc aaaacctttc gcggtatggc atgatagcgc ccggaagaga 60 
gtcaattcag ggtggtgaat gtgaaaccag taacgttata cgatgtcgca gagtatgccg 120 
gtgtctctta tcagaccgtt tcccgcgtgg tgaaccaggc cagccacgtt tctgegaaaa 180 
cgcgggaaaa agtggaagcg gcgatggcgg agctgaatta cattcccaac cgcgtggcac 240 
aacaactggc gggcaaacag tcgttgctga ttggcgttgc cacctccagt ctggccctgc 300 
acgcgccgtc gcaaattgtc gcggcgatta aatctcgcgc cgatcaactg ggtgccagcg 360 
tggtggtgtc gatggtagaa cgaagcggcg togaagcctg taaagcggcg gtgcacaatc 420 
ttctcgcgca acgcgtcagt gggctgatca ttaactatcc gctggatgac caggatgcca 480 
ttgctgtgga agctgcctgc actaatgttc cggcgttatt tcttgatgtc tctgaccaga 540 
cacccatcaa cagtattatt ttctcccatg aagacggtac gcgactgggc gtggagcatc 600 
tggtcgcatt gggtcaccag caaatcgcgc tgttagcggg cccattaagt tctgtctcgg 660 
cgcgtctgcg tctggctggc tggcataaat atctcactcg caatcaaatt cagccgatag 720 
cggaacggga aggcgactgg agtgccatgt ccggttttca acaaaccatg caaatgctga 780 
atgagggcat cgttcccact gcgatgctgg ttgccaacga tcagatggcg ctgggcgcaa 840 
tgcgcgccat taccgagtcc gggctgcgcg ttggtgcgga tatctcggta gtgggatacg 900 
acgataccga agacagctca tgttatatcc cgccgttaac caccatcaaa caggattttc 960 
gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc caggcggtga 1020 
agggcaatca gctgttgccc gtctcactgg tgaaaagaaa aaccaccctg gcgcccaata 1080 
cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt 1140 
cccgactgga aagcgggcag tgagcgcaac gcaattaatg taagttagct cactcattag 1200 
gcacaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gottctggcg 
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 
1260 
1320 
1380 tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 
ctggcaaata ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 1440 
attgtgagcg gataacaatt tcacacagga aacagccagt ccgtttaggt gttttcacga 1500 
gcacttcacc aacaaggacc atagcatatg aaaatcgaag aaggtaaact ggtaatctgg 1560 
attaacggcg ataaaggcta taacggtctc gctgaagtcg gtaagaaatt cgagaaagat 1620 
accggaatta aagtcaccgt tgagcatccg gataaactgg aagagaaatt cccacaggtt 1680 
gcggcaactg gcgatggccc tgacattatc ttctgggcac acgaccgott tggtggctac 1740 
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gctcaatctg gcctgttggc tgaaatcacc ccggacaaag cgttccagga caagctgtat 1800 
ccgtttacct gggatgccgt acgttacaac ggcaagctga ttgcttacco gatcgctgtt 1860 
gaagcgttat cgctgattta taacaaagat ctgctgccga acccgccaaa aacctgggaa 1920 
gagatcccgg cgctggataa agaactgaaa gcgaaaggta agagcgcgct gatgttcaac 1980 
ctgcaagaac cgtacttcac ctggccgctg attgctgctg acgggggtta tgcgttcaag 2040 
tatgaaaacg gcaagtacga cattaaagac gtgggcgtgg ataacgctgg cgcgaaagcg 2100 
ggtctgacct tcctggttga cctgattaaa aacaaacaca tgaatgcaga caccgattac 2160 
tccatcgcag aagctgcctt taataaaggc gaaacagcga tgaccatcaa cggcccgtgg 2220 
gcatggtcca acatcgacac cagcaaagtg aattatggtg taacggtact gccgaccttc 2280 
aagggtcaac catccaaacc gttcgttggc gtgctgagcg caggt attaa cgccgccagt 2340 
ccgaacaaag agctggcaaa agagttcctc gaaaactatc tgctgactga tgaaggtctg 2400 
gaagcggtta ataaagacaa accgctgggt gccgtagcgc tgaagtctta cgaggaagag 2460 
ttggcgaaag atccacgtat tgccgccact atggaaaacg cccagaaagg tgaaatcatg 2520 
ccgaacatcc cgcagatgtc cgctttctgg tatgccgtgc gtactgcggt gatcaacgcc 2580 
gccagcggtc gtcagactgt cgatgccgcc ctggccgccg cgcagactgc cgccgccgcc 2640 
gccatggaga caaggcaaat ggcagtggaa caaaccactg gtgcggtcac caaccaaacg 2700 
gaaacaagct ggcacagcat agactgggcc aaagccaacc gtgaggtaaa gaggctgcaa 2760 
gtgcgtatcg caaaggctgt gaaggaagga cgctggggca aagtgaaagc tttgcaatgg 2820 
ctcctgaccc actcgttcta cggcaaagcc ctcgccgtga aacgggtaac tgacaactcg 2880 
ggcagcaaaa cacctggtgt ggacgggata acctggtcca cacaagagca gaaagcccaa 2940 
gccataaagt ccctcaggag aagaggctat aaaccccaac ccctgaggcg ggtatacato 3000 
ccgaaagcaa acggcaaaca gcgcccgcta ggaatcccga caatgaagga cagggcaatg 3060 
caggcactat atgccctagc cctagaacca gtcgcggaaa ccacagcaga ccggaactcc 3120 
tatgggttcc ggcgaggacg atgcatagcc gatgcagcga cgcagtgtca catcacgcta 3180 
gccaaaacag accgtgcaca atacgttctc gacgccgata ttgctgggtg ctttgacaac 3240 
atcagccatg agtggctact agctaacatt ccactagaca aaagaattct acggaaatgg 3300 
cttaaatctg ggtttgtctg gaagcagcaa ctcttcccca tccatgctgg aacacctcag 3360 
ggaggggtaa tctccccgat gottgccaac atgacactgg atgggatgga agaattgtta 3420 
aacaagtttc ccagggcgca caaggtcaaa ctcatccgat atgccgacga cttcgtcgta 3480 
accggtgaaa cgaaggaagt gctctatatt gccggtgcgg taatacaagc attcctcaag 3540 
gaaaggggcc ttaccctatc aaaggaaaag acgaagatcg tacacattga agaagggttt 3600 
gactttctcg gatggaacat tcgcaaatat gatgggaaac tgctcatcaa acctgcgaag 3660 
aagaacgtta aagcgttcct caagaaaatc cgagacacct taagagaact taggacagca 3720 
ccccaggaga ttgtgataga cacactcaac ccaatcatca gaggttggac taactatcac 3780 
aaaaatcagg catccaaaga aaccttcgtc ggagtggacc acctcatatg gcaaaaatta 3840 
tggcgatggg caaggcgccg acacccaagc aaatctgtcc gatgggtgaa gagtaagtac 3900 
ttcatccaaa tcgggaacag aaaatggatg ttcggaatat ggacgaaaga caaaaacgga 3960 
gacccgtggg ccaagcattt aatcaaagcc tcggaaatcc gaatccaacg tcgcggtaaa 4020 
atcaaggcag acgccaaccc gtttctccca gaatgggcag aatactttga gcagcgcaag 4080 
aaactcaaag aggcccctgc ccaataccgg cgcacccgtc gggaattgtg gaagaaacaa 4140 
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ggcggcatct gtccagtatg tgggggagaa attgagcaag acatgctcac cgaaatccac 4200 
cacatactgc ccaaacacaa gggtggtact gacgacctgg acaatcttgt cctaatccac 4260 
actaactgcc acaaacaggt gcacaaccga gatggtcagc acagccggtt cctcttgaaa 4320 
gaggggcttt gactgcaggc aagcttggca ctggccgtcg ttttacaacg tcgtgactgg 4380 
gaaaaccctg gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg 4440 
cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag cctgaatggc 4500 
gaatggcagc ttggctgttt tggcggatga gataagattt tcagcctgat acagattaaa 4560 
tcagaacgca gaagcggtct gataaaacag aatttgcctg goggcagtag cgcggtggtc 4620 
ccacctgacc ccatgccgaa ctcagaagtg aaacgccgta gcgccgatgg tagtgtgggg 4680 
tctccccatg cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcagtcgaa 4740 
agactgggcc tttcgtttta tctgttgttt gtcggtgaac gctctcctga gtaggacaaa 4800 
tccgccggga goggatttga acgttgcgaa gcaacggccc ggagggtggc gggcaggacg 4860 
cccgccataa actgccaggc atcaaattaa gcagaaggcc atcctgacgg atggcctttt 4920 
tgcgtttcta caaactcttt ttgtttattt ttctaaatac attcaaatat gtatccgctc 4980 
atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 5040 
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct 5100 
cacccagaaa cgctggtgaa agtaaaagat gotgaagatc agttgggtgc acgagtgggt 5160 
tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt 5220 
tctccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtgttgac 5280 
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac 5340 
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 5400 
gccataacca tgagtgataa cactgeggcc aacttacttc tgacaacgat cggaggaccg 5460 
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 5520 
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 5580 
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa 5640 
caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt 5700 
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 5760 
attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg 5820 
agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt 5880 
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaccccgg 5940 
ttgataatca gaaaagcccc aaaaacagga agattgtata agcaaatatt taaattgtaa 6000 
acgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc 6060 
aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga 6120 
gtgttgttcc agtttggaac aagagtocac tattaaagaa cgtggactcc aacgtcaaag 6180 
ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcacco aaatcaagtt 6240 
ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta 6300 
gagcttgacg gggaaagccg gegaacgtgg cgagaaagga agggaagaaa gcgaaaggag 6360 
cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg 6420 
cgcttaatgc gccgctacag ggcgcgtaaa aggatctagg tgaagatcct ttttgataat 6480 
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ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa 6540 
aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca 6600 
aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt 6660 
ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg 6720 
tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc 6780 
ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga 6840 
cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc 6900 
agcttggage gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc 6960 
gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca 7020 
ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg 7080 
tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg goggagccta 7140 
tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct 7200 
cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag 7260 
tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa 7320 
gcggaagagc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 7380 
atatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc cagtatacac 7440 
tccgctatcg ctacgtgact gggtcatggc tgcgccccga cacccgccaa cacccgctga 7500 
cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg tgaccgtctc 7560 
cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga ggcagctgcg 7620 
gtaaagctca tcagcgtggt cgtgcagcga ttcacagatg tctgcctgtt catccgcgtc 7680 
cagctcgttg agtttctcca gaagcgttaa tgtctggctt ctgataaagc gggccatgtt 7740 
aagggcggtt ttttcctgtt tggtcactga tgcctccgtg taagggggat ttctgttcat 7800 
gggggtaatg ataccgatga aacgagagag gatgctcacg atacgggtta ctgatgatga 7860 
acatgcccgg ttactggaac gttgtgaggg taaacaactg gcggtatgga tgcggcggga 7920 
ccagagaaaa atcactcagg gtcaatgcca gcgcttcgtt aatacagatg taggtgttcc 7980 
acagggtagc cagcagcatc ctgcgatgca gatccggaac ataatggtgc agggcgctga 8040 
cttccgcgtt tccagacttt acgaaacacg gaaaccgaag accattcatg ttgttgctca 8100 
ggtcgcagac gttttgcagc agcagtcgct tcacgttcgc tcgcgtatcg gtgattcatt 8160 
ctgctaacca gtaaggcaac cccgccagcc tagccgggtc ctcaacgaca ggagcacgat 8220 
catgcgcacc cgtggccagg acccaacgct gcccgaaatt 8260 
< 210 > SEQ ID NO 15 
< 211 > LENGTH : 8260 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
NM O
< 400 > SEQUENCE : 15 
ccgacaccat cgaatggtgc aaaacctttc gcggtatggc atgatagcgc ccggaagaga 60 
gtcaattcag ggtggtgaat gtgaaaccag taacgttata cgatgtcgca gagtatgccg 120 
gtgtctctta tcagaccgtt tcccgcgtgg tgaaccaggc cagccacgtt tctgegaaaa 180 
cgcgggaaaa agtggaagcg gcgatggcgg agctgaatta cattcccaac cgcgtggcac 240 
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aacaactggc gggcaaacag togttgctga ttggcgttgc cacctccagt ctggccctgc 300 
acgcgccgtc gcaaattgtc gcggcgatta aatctcgcgc cgatcaactg ggtgccagcg 360 
tggtggtgtcgatggtagaa cgaagcggcg tcgaagcctg taaagcggcg gtgcacaatc 420 
ttctcgcgca acgcgtcagt gggctgatca ttaactatcc gctggatgac caggatgcca 480 
ttgctgtgga agctgcctgc actaatgttc cggcgttatt tcttgatgtc tctgaccaga 540 
cacccatcaa cagtattatt ttctcccatg aagacggtac gcgactgggc gtggagcatc 600 
tggtcgcatt gggtcaccag caaatcgcgc tgttagcggg cccattaagt tctgtctcgg 660 
cgcgtctgcg tctggctggc tggcataaat atctcactcg caatcaaatt cagccgatag 720 
cggaacggga aggcgactgg agtgccatgt ccggttttca acaaaccatg caaatgctga 780 
atgagggcat cgttcccact gcgatgctgg ttgccaacga tcagatggcg ctgggcgcaa 840 
tgcgcgccat taccgagtcc gggctgcgcg ttggtgcgga tatctcggta gtgggatacg 900 
acgataccga agacagctca tgttatatcc cgccgttaac caccatcaaa caggattttc 960 
gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc caggcggtga 1020 
agggcaatca gotgttgccc gtctcactgg tgaaaagaaa aaccaccctg gcgcccaata 1080 
cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt 1140 
cccgactgga aagcgggcag tgagcgcaac gcaattaatg taagttagct cactcattag 1200 
gcacaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gottctggcg 1260 
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 1320 
tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 1380 
ctggcaaata ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 1440 
attgtgagcg gataacaatt tcacacagga aacagccagt ccgtttaggt gttttcacga 1500 
gcacttcacc aacaaggacc atagcatatg aaaatcgaag aaggtaaact ggtaatctgg 1560 
attaacggcg ataaaggcta taacggtctc gotgaagtcg gtaagaaatt cgagaaagat 1620 
accggaatta aagtcaccgt tgagcatccg gataaactgg aagagaaatt cccacaggtt 1680 
gcggcaactg gcgatggccc tgacattatc ttctgggcac acgaccgctt tggtggctac 1740 
gctcaatctg gcctgttggc tgaaatcacc ccggacaaag cgttccagga caagctgtat 1800 
ccgtttacct gggatgccgt acgttacaac ggcaagctga ttgcttacco gatcgctgtt 1860 
gaagcgttat cgctgattta taacaaagat ctgctgccga acccgccaaa aacctgggaa 1920 
gagatcccgg cgctggataa agaactgaaa gcgaaaggta agagcgcgct gatgttcaac 1980 
ctgcaagaac cgtacttcac ctggccgctg attgctgctg acgggggtta tgcgttcaag 2040 
tatgaaaacg gcaagtacga cattaaagac gtgggcgtgg ataacgctgg cgcgaaagcg 2100 
ggtctgacct tcctggttga cctgattaaa aacaaacaca tgaatgcaga caccgattac 2160 
tccatcgcag aagctgcctt taataaaggc gaaacagcga tgaccatcaa cggcccgtgg 2220 
gcatggtcca acatcgacac cagcaaagtg aattatggtg taacggtact gccgaccttc 2280 
aagggtcaac catccaaacc gttcgttggc gtgctgagcg caggtattaa cgccgccagt 2340 
ccgaacaaag agctggcaaa agagttcctc gaaaactatc tgctgactga tgaaggtctg 2400 
gaagcggtta ataaagacaa accgctgggt gccgtagcgc tgaagtctta cgaggaagag 2460 
ttggcgaaag atccacgtat tgccgccact atggaaaacg cccagaaagg tgaaatcatg 2520 
ccgaacatcc cgcagatgtc cgctttctgg tatgccgtgc gtactgcggt gatcaacgcc 2580 
gccagcggtc gtcagactgt cgatgccgcc ctggccgccg cgcagactgc cgccgccgcc 2640 
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gccatggaga caaggcaaat ggcagtggaa caaaccactg gtgcggtcac caaccaaacg 2700 
gaaacaagct ggcacagcat agactgggcc aaagccaacc gtgaggtaaa gaggctgcaa 2760 
gtgcgtatcg caaaggctgt gaaggaagga cgctggggca aagtgaaagc tttgcaatgg 2820 
ctcctgaccc actcgttcta cggcaaagcc ctcgccgtga aacgggtaac tgacaactcg 2880 
ggcagcaaaa cacctggtgt ggacgggata acctggtcca cacaagagca gaaagcccaa 2940 
gccataaagt ccctcaggag aagaggctac aaaccccaac ccctgaggcg ggtatacatc 3000 
ccgaaagcaa gcggcaagca gcgcccgcta ggaatcccga caacgaagga cagggcaatg 3060 
caggcattat atgccctagc tctagaacct gtcgcggaaa ccacagcgga tcggaactca 3120 
tacgggttcc gtcaaggacg gtgcacggca gatgctgccg ggcagtgctt cactgtgcta 3180 
ggccgatctg actgtgcaaa atatatcctt gatgctgaca tcaccggatg ctttgacaac 3240 
attagccacg aatggctact agacaacatc ccgctggaca aagaggttct gcggaagtgg 3300 
cttaaatctg ggttcgtctg gaaacagcaa ctcttcccaa cccatgctgg gacacctcag 3360 
ggaggggtaa tctccccaat gctggccaat atgaccctag atgggatgga agaattgctg 3420 
aagaaacacC tcagaaaaca aaaagtcaac ctcatacgat atgcagacga ctttgtcgta 370 3480 
actggtgaat caaaggaaac cttggaaaag gttacaactg taatccaaga attcctcaag 3540 
gaaaggggcc ttaccctatc agaagaaaag acaaaggtcg ttcatatcga agaaggattt 3600 
gactttcttg gatggaacat tcgcaaatat ggtgagaagc ttctcatcaa acctgcgaag 3660 
aagaacatca aggcgttcca caagaaaatc cgagacgcac tgaaggaact cagaacagcc 3720 
acccaggaag ctgtgataga cacactcaac ccaattatca aaggctgggc taactatcac 3780 
agaaaccagg tttccaaaag aatcttcaac agagoggatg acaatatctg gcataaatta 3840 
tggcgatggg caaaacgtcg gcacccaaacaaaccagccc gatggacaaa gaacaaatac 3900 
ttcatcaaaa tcgggaatag gcactgggtg tttggcacat ggaaaaagga caaagaggga 3960 
aggttacggt ccagatacct aattaaagcc ggagatactc gaatccaacg tcatgtcaaa 4020 
atcaaggcag acgccaatcc gtttctccca gagtgggcag aatactttga ggaacgcaag 4080 
aaactcaaag aagcccctgc tcaatatcgg cgcatccgcc gagaactatg gaagaaacag 4140 
4200 ggtggtatct gtccagtatg cgggggtgaa attgagcaag acatgctcac tgaaatccac 
cacatattgc ccaaacacaa gggtggttct gacgacctgg ataatcttgt cttaatccac 4260 
gccaactgtc acaaacaggt gcacagccga gacggtcagc acagccggtt cctcttgaaa 4320 
gaggggcttt gactgcaggc aagcttggca ctggccgtcg ttttacaacg tcgtgactgg 4380 
gaaaaccctg gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg 4440 
cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag cctgaatggc 4500 
gaatggcagc ttggctgttt tggcggatga gataagattt tcagcctgat acagattaaa 4560 
tcagaacgca gaagcggtct gataaaacag aatttgcctg goggcagtag cgcggtggtc 4620 
ccacctgacc ccatgccgaa ctcagaagtg aaacgccgta gcgccgatgg tagtgtgggg 4680 
tctccccatg cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcagtcgaa 4740 
agactgggcc tttcgtttta tctgttgttt gtcggtgaac gctctcctga gtaggacaaa 4800 
tccgccggga goggatttga acgttgcgaa gcaacggccc ggagggtggc gggcaggacg 4860 
cccgccataa actgccaggc atcaaattaa gcagaaggcc atcctgacgg atggcctttt 4920 
tqoqtttcta caaactcttt ttqtttattt ttctaaatac attcaaatat atatocacto 4980 
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atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 5040 
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct 5100 
cacccagaaa cgctggtgaa agtaaaagat gotgaagatc agttgggtgc acgagtgggt 5160 
tacatcgaac tggatctcaa cagcggtaagatccttgaga gttttcgccc cgaagaacgt 5220 
tctccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtgttgac 5280 
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac 5340 
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 5400 
gccataacca tgagtgataa cactgeggcc aacttacttc tgacaacgat cggaggaccg 5460 
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 5520 
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 5580 
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa 5640 
caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt 5700 
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 5760 
attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg 5820 
agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt 5880 
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaccccgg 5940 
ttgataatca gaaaagcccc aaaaacagga agattgtata agcaaatatt taaattgtaa 6000 
acgttaatat tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc 6060 
aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga 6120 
gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag 6180 
ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc aaatcaagtt 6240 
ttttggggtc gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta 6300 
gagcttgacg gggaaagccg gegaacgtgg cgagaaagga agggaagaaa gcgaaaggag 6360 
cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg 6420 
cgottaatgc gccgctacag ggcgcgtaaa aggatctagg tgaagatcct ttttgataat 6480 
6540 ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa 
aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca 6600 
aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt 6660 
ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg 6720 
tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc 6780 
ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga 6840 
cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc 6900 
agottggagc gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc 6960 
gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca 7020 
ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg 7080 
tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg goggagccta 7140 
tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct 7200 
cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag 7260 
tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa 7320 
goggaagagc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 7380 
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atatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc cagtatacac 7440 
tccgctatcg ctacgtgact gggtcatggc tgcgccccga cacccgccaa cacccgctga 7500 
cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg tgaccgtctc 7560 
cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga ggcagctgcg 7620 
gtaaagctca tcagcgtggt cgtgcagcga ttcacagatg tctgcctgtt catccgcgtc 7680 
cagctcgttg agtttctcca gaagcgttaa tgtctggctt ctgataaagc gggccatgtt 7740 
aagggcggtt ttttcctgtt tggtcactga tgcctccgtg taagggggat ttctgttcat 7800 
gggggtaatg ataccgatga aacgagagag gatgctcacg atacgggtta ctgatgatga 7860 
acatgcccgg ttactggaac gttgtgaggg taaacaactg gcggtatgga tgcggcggga 7920 
ccagagaaaa atcactcagg gtcaatgcca gcgcttcgtt aatacagatg taggtgttcc 7980 
acagggtagc cagcagcatc ctgcgatgca gatccggaac ataatggtgc agggcgctga 8040 
cttccgcgtt tccagacttt acgaaacacg gaaaccgaag accattcatg ttgttgctca 8100 
ggtcgcagac gttttgcagc agcagtcgct tcacgttcgc tcgcgtatcg gtgattcatt 8160 
ctgctaacca gtaaggcaac cccgccagcc tagccgggtc ctcaacgaca ggagcacgat 8220 
catgcgcacc cgtggccagg acccaacgct gcccgaaatt 8260 
< 210 > SEQ ID NO 16 
< 211 > LENGTH : 8490 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
< 400 > SEQUENCE : 16 
ccgacaccat cgaatggtgc aaaacctttc gcggtatggc atgatagcgc ccggaagaga 60 
gtcaattcag ggtggtgaat gtgaaaccag taacgttata cgatgtcgca gagtatgccg 120 
gtgtctctta tcagaccgtt tcccgcgtgg tgaaccaggc cagccacgtt tctgcgaaaa 180 
cgcgggaaaa agtggaagcg gcgatggcgg agctgaatta cattcccaac cgcgtggcac 240 
aacaactggc gggcaaacag tcgttgctga ttggcgttgc cacctccagt ctggccctgc 300 
acgcgccgtc gcaaattgtc goggcgatta aatctcgcgc cgatcaactg ggtgccagcg 360 
tggtggtgtc gatggtagaa cgaagcggcg togaagcctg taaagcggcg gtgcacaatc 420 
ttctcgcgca acgcgtcagt gggctgatca ttaactatcc gctggatgac caggatgcca 480 
ttgctgtgga agctgcctgc actaatgttc cggcgttatt tcttgatgtc tctgaccaga 540 
cacccatcaa cagtattatt ttctcccatg aagacggtac gogactgggc gtggagcatc 600 
660 tggtcgcatt gggtcaccag caaatcgcgc tgttagcggg cccattaagt tctgtctcgg 
cgcgtctgcg tctggctggc tggcataaat atctcactcg caatcaaatt cagccgatag 720 
cggaacggga aggcgactgg agtgccatgt ccggttttca acaaaccatg caaatgctga 780 
atgagggcat cgttcccact gcgatgctgg ttgccaacga tcagatggcg ctgggcgcaa 840 
tgcgcgccat taccgagtcc gggctgcgcg ttggtgcgga tatctcggta gtgggatacg 900 
acgataccga agacagctca tgttatatcc cgccgttaac caccatcaaa caggattttc 960 
gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc caggcggtga 1020 
agggcaatca gotgttgccc gtctcactgg tgaaaagaaa aaccaccctg gcgcccaata 1080 
cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt 1140 
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cccgactgga aagcgggcag tgagcgcaac gcaattaatg taagttagct cactcattag 1200 
gcacaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gcttctggcg 1260 
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 1320 
tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 1380 
ctggcaaata ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 1440 
attgtgagcg gataacaatt tcacacagga aacagccagt ccgtttaggt gttttcacga 1500 
gcacttcacc aacaaggacc atagcatatg aaaatcgaag aaggtaaact ggtaatctgg 1560 
attaacggcg ataaaggota taacggtctc gctgaagtcg gtaagaaatt cgagaaagat 1620 
accggaatta aagtcaccgt tgagcatccg gataaactgg aagagaaatt cccacaggtt 1680 
goggcaactg gcgatggccc tgacattatc ttctgggcac acgaccgctt tggtggctac 1740 
gctcaatctg gcctgttggc tgaaatcacc ccggacaaag cgttccagga caagctgtat 1800 
ccgtttacct gggatgccgt acgttacaac ggcaagctga ttgcttacco gatcgctgtt 1860 
gaagcgttat cgctgattta taacaaagat ctgctgccga acccgccaaa aacctgggaa 1920 
gagatcccgg cgctggataa agaactgaaa gcgaaaggta agagcgcgct gatgttcaac 1980 
ctgcaagaac cgtacttcac ctggccgctg attgctgctg acgggggtta tgcgttcaag 2040 
tatgaaaacg gcaagtacga cattaaagac gtgggcgtgg ataacgctgg cgcgaaagcg 2100 
ggtctgacct tcctggttga cctgattaaa aacaaacaca tgaatgcaga caccgattac 2160 
tccatcgcag aagctgcctt taataaagge gaaacagcga tgaccatcaa cggcccgtgg 2220 
2280 gcatggtcca acatcgacac cagcaaagtg aattatggtg taacggtact gccgaccttc 
aagggtcaac catccaaacc gttcgttggc gtgctgagcg caggtattaa cgccgccagt 2340 
ccgaacaaag agctggcaaa agagttcctc gaaaactatc tgctgactga tgaaggtctg 2400 
gaagcggtta ataaagacaa accgctgggt gccgtagcgc tgaagtctta cgaggaagag 2460 
ttggcgaaag atccacgtat tgccgccact atggaaaacg cocagaaagg tgaaatcatg 2520 
ccgaacatcc cgcagatgtc cgctttctgg tatgccgtgc gtactgcggt gatcaacgcc 
gocagcggtc gtcagactgt cgatgccgcc ctggccgccg cgcagactgc cgccgccgcc 
2580 
2640 
gccatgaagg taaacaaact tgtcgtaaaa agcgaacagg acttgagaaa ctgcttggat 2700 
cttctttatc aagaagctaa aaagggaaaa catttttacg gcatgcttga gttgcttcaa 2760 
aatgatgttg tcattttaga agctattcgc aatattaaaa gcaataaagg tagcaaaacg 2820 
gcggggattg atcagaaaat agtagatgat tatttgotta tgccaacgga aaaggttttc 2880 
gggatgataa aagccaaact caatgactat aagcctatac cagtgagaag gtgcaacaag 2940 
cccaaaggaa atgccaaaag ctcaaaaaga aaaggcaata gtccgaatga ggaaggggaa 3000 
acgaggccct taggaatatc cgcagtgacg gatagaatca tccaagagat gctacggata 3060 
gtgctcgagc cgattttcga agcccaattc tatccgcaca gttatgggtt cagaccgtat 3120 
cgctccaccg aacatgcctt agcctggatg ctgaaaatca tcaacggaag caaactgtat 3180 
tgggttgtaa aaggtgacat tgaaagttat tttgatcaca tcaatcataa gaagcttctg 3240 
aacatcatgt ggaatatggg cgttagggat aaacgggtac tatgcatcgt taagaaaatg 3300 
ctgaaggegg ggcaagtgat acaaggtaaa ttctatccaa ccgctaaggg gattcctcag 3360 
ggaggaatta ttagcccgtt gttggctaat gtatatctca acagctttga ctggatggtt 3420 
ggccaagaat atgagtatca ccctaataac gcaaactatc gggaaaagaa aaacgcatta 3480 
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gcggcgttaa ggaacaaggg acatcatccc gtcttttaca ttcgttatgc tgatgattgg 3540 
gttattctta cggatacgaa agaatatgcg gaaaaaataa gggagcaatg taagcagtat 3600 
ttagcctgtg agttgcactt aactctatcg gatgagaaaa cgttcattgc agatatccgc 3660 
gaacaacggg ttaagtttct aggcttttgt attgaggcag gaaagcggcg ttttcataaa 3720 
aaaggattcg ccgctagaat gattcccgat atggaaaaag tcaatgccaa ggtcaaagaa 3780 
attaagcgcg atattcgatt gttaagaacg agaaaatcgg aattagagaa agcccttgat 3840 
attgaaaaca ttaacaccaa aattatagga ttagccaatc atctaaaaat aggcatttcc 3900 
aagtacatta tgggcaaagt agatcgcgtc attgaagaga cagcctaccg cacctgggtt 3960 
aaaatgtatg ggaaagaaaa agcggcgcaa tataaaaggc ctgtgtcaga gtttcacaat 4020 
cggattgaca gacata aagg ctatcaaatg aaacattttt ctgtcgtcac agaggatggc 4080 
ataagagtag ggattaccca tgcaaaaata acgcctatac agtatgcaac agtattcaaa 4140 
caagaaatga ccccatacac tgcagacggc agaaaaatgt atgaagaaaa gcatagaaaa 4200 
atacgattgc cggataaaat gagtctgttc gatcacgatt cgatattcat ctacatttta 4260 
totgagcata atgatgggaa atataatctt gaatatttct taaatagggt gaatgtattt 4320 
cacagagata aaggaaaatg caaaatatgt gccgtatact taagtcccgg taacttccac 4380 
tgccatcata ttgacccgag taaaccttta agtgagatca ataagaccgt taatetaatt 4440 
agcttatgca accaatgcca taggcttgtc catagcaacc aagaaccgcc gtttacagaa 4500 
cgaaaaatgt ttgacaaact aacgaaatat aggaacaagc tgaaaatata aggatcctct 4560 
agctgcaggc aagcttggca ctggccgtcg ttttacaacg tcgtgactgg gaaaaccctg 4620 
gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg cgtaatagcg 4680 
aagaggcccg caccgatcgc ccttcccaac agttgcgcag cctgaatggc gaatggcago 4740 
ttggctgttt tggcggatga gataagattt tcagcctgat acagattaaa tcagaacgca 4800 
gaagcggtct gataaaacag aatttgcctg goggcagtag cgcggtggtc ccacctgacc 4860 
ccatgccgaa ctcagaagtg aaacgccgta gcgccgatgg tagtgtgggg tctccccatg 4920 
cgagagtagg gaactgccag gcatcaaata aaacgaaagg ctcagtcgaa agactgggcc 4980 
tttcgtttta tctgttgttt gtcggtgaac gctctcctga gtaggacaaa tccgccggga 5040 
goggatttga acgttgcgaa gcaacggccc ggagggtggc gggcaggacg cccgccataa 5100 
actgccaggc atcaaattaa gcagaaggcc atcctgacgg atggcctttt tgcgtttcta 5160 
caaactcttt ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagacaat 5220 
aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt caacatttcc 5280 
gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct cacccagaaa 5340 
cgctggtgaa agtaaaagat gotgaagatc agttgggtgc acgagtgggt tacatcgaac 5400 
togatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt tctccaatga 5460 
tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtgttgac gccgggcaag 5520 
agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac tcaccagtca 5580 
cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct gccataacca 5640 
tgagtgataa cactgeggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa 5700 
ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg gaaccggagc 5760 
tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca atggcaacaa 5820 
cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa caattaatag 5880 
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actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt ccggctggct 5940 
ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc attgcagcac 6000 
tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg agtcaggcaa 6060 
ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt aagcattggt 6120 
aactgtcaga ccaagtttac tcatatatac tttagattga tttaccccgg ttgataatca 6180 
gaaaagcccc aaaaacagga agattgtata agcaaatatt taaattgtaa acgttaatat 6240 
tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga 6300 
aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc 6360 
agtttggaac aagagtocac tattaaagaa cgtggactcc aacgtcaaag ggcgaaaaac 6420 
cgtctatcag ggcgatggcc cactacgtga accatcaccc aaatcaagtt ttttggggtc 6480 
gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta gagcttgacg 6540 
gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag 6600 
6660 ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatge 
gccgctacag ggcgcgtaaa aggatctagg tgaagatect ttttgataat ctcatgacca 6720 
aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaag 6780 
gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac 6840 
cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt ccgaaggtaa 6900 
ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg tagttaggcc 6960 
accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc ctgttaccag 7020 
tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga cgatagttac 7080 
cggataaggc gcagcggtcg ggctgaacgg ggggttogtg cacacagccc agcttggagc 7140 
gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc gocacgcttc 7200 
ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca ggagagcgca 7260 
cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg tttcgccacc 7320 
tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg goggagccta tggaaaaacg 7380 
ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct cacatgttct 7440 
ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata 7500 
ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 7560 
gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc atatatggtg 7620 
cactctcagt acaatctgct ctgatgccgc atagttaagc cagtatacac tccgctatcg 7680 
ctacgtgact gggtcatggc tgcgccccga cacccgccaa cacccgctga cgcgccctga 7740 
cgggcttgtc tgctcccggc atccgcttac agacaagctg tgaccgtctc cgggagctgc 7800 
atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga ggcagctgcg gtaaagctca 7860 
tcagcgtggt cgtgcagcga ttcacagatg tctgcctgtt catccgcgtc cagctcgttg 7920 
agtttctcca gaagcgttaa tgtctggctt ctgataaagc gggccatgtt aagggcggtt 7980 
ttttcctgtt tggtcactga tgcctccgtg taagggggat ttctgttcat gggggtaatg 8040 
ataccgatga aacgagagag gatgctcacg atacgggtta ctgatgatga acatgcccgg 8100 
ttactggaac gttgtgaggg taaacaactg goggtatgga tgcggcggga ccagagaaaa 8160 
atcactcagg gtcaatgcca gcgcttcgtt aatacagatg taggtgttcc acagggtagc 8220 
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cagcagcatc ctgcgatgca gatccggaac ataatggtgc agggcgctga cttccgcgtt 8280 
tccagacttt acgaaacacg gaaaccgaag accattcatg ttgttgctca ggtcgcagac 8340 
gttttgcago agcagtcgct tcacgttcgc tcgcgtatcg gtgattcatt ctgctaacca 8400 
gtaaggcaac cccgccagcc tagccgggtc ctcaacgaca ggagcacgat catgcgcacc 8460 
cgtggccagg acccaacgct gcccgaaatt 8490 
< 210 > SEQ ID NO 17 
< 211 > LENGTH : 7834 
< 212 > TYPE : DNA 
13 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
< 400 > SEQUENCE : 17 
ccgacaccat cgaatggtgc aaaacctttc gcggtatggc atgatagcgc ccggaagaga 60 
gtcaattcag ggtggtgaat gtgaaaccag taacgttata cgatgtcgca gagtatgccg 120 
gtgtctctta tcagaccgtt tcccgcgtgg tgaaccaggc cagccacgtt tctgegaaaa 180 
cgcgggaaaa agtggaagcg gcgatggcgg agctgaatta cattcccaac cgcgtggcac 240 
aacaactggc gggcaaacag tcgttgctga ttggcgttgc cacctccagt ctggccctgc 300 
acgcgccgtc gcaaattgtc gcggcgatta aatctcgcgc cgatcaactg ggtgccagcg 360 
tggtggtgtc gatggtagaa cgaagcggcg togaagcctg taaagcggcg gtgcacaatc 420 
ttctcgcgca acgcgtcagt gggctgatca ttaactatcc gctggatgac caggatgcca 480 
ttgctgtgga agctgcctgc actaatgttc cggcgttatt tcttgatgtc tctgaccaga 540 
cacccatcaa cagtattatt ttctcccatg aagacggtac gcgactgggc gtggagcatc 600 
tggtcgcatt gggtcaccag caaatcgcgc tgttagcggg cccattaagt tctgtctcgg 660 
cgcgtctgcg tctggctggc tggcataaat atctcactcg caatcaaatt cagccgatag 720 
cggaacggga aggcgactgg agtgccatgt ccggttttca acaaaccatg caaatgctga 780 
atgagggcat cgttcccact gcgatgctgg ttgccaacga tcagatggcg ctgggcgcaa 840 
tgcgcgccat taccgagtcc gggctgcgcg ttggtgcgga tatctcggta gtgggatacg 900 
acgataccga agacagctca tgttatatcc cgccgttaac caccatcaaa caggattttc 960 
gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc caggcggtga 1020 
agggcaatca gctgttgccc gtctcactgg tgaaaagaaa aaccaccctg gcgcccaata 1080 
cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt 1140 
cccgactgga aagcgggcag tgagcgcaac gcaattaatg taagttagct cactcattag 1200 
gcacaattct catgtttgac agcttatcat cgactgcacg gtgcaccaat gottctggcg 
tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 
1260 
1320 
1380 tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 
ctggcaaata ttctgaaatg agctgttgac aattaatcat cggctcgtat aatgtgtgga 1440 
attgtgagcg gataacaatt tcacacagga aacagccagt ccgtttaggt gttttcacga 1500 
gcacttcacc aacaaggacc atagcatatg aaaatcgaag aaggtaaact ggtaatctgg 1560 
attaacggcg ataaaggcta taacggtctc gctgaagtcg gtaagaaatt cgagaaagat 1620 
accggaatta aagtcaccgt tgagcatccg gataaactgg aagagaaatt cccacaggtt 1680 
gcggcaactg gcgatggccc tgacattatc ttctgggcac acgaccgott tggtggctac 1740 
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gctcaatctg gcctgttggc tgaaatcacc ccggacaaag cgttccagga caagctgtat 1800 
ccgtttacct gggatgccgt acgttacaac ggcaagctga ttgcttacco gatcgctgtt 1860 
gaagcgttat cgctgattta taacaaagat ctgctgccga acccgccaaa aacctgggaa 1920 
gagatcccgg cgctggataa agaactgaaa gcgaaaggta agagcgcgct gatgttcaac 1980 
ctgcaagaac cgtacttcac ctggccgctg attgctgctg acgggggtta tgcgttcaag 2040 
tatgaaaacg gcaagtacga cattaaagac gtgggcgtgg ataacgctgg cgcgaaagcg 2100 
ggtctgacct tcctggttga cctgattaaa aacaaacaca tgaatgcaga caccgattac 2160 
tccatcgcag aagctgcctt taataaaggc gaaacagcga tgaccatcaa cggcccgtgg 2220 
gcatggtcca acatcgacac cagcaaagtg aattatggtg taacggtact gccgaccttc 2280 
aagggtcaac catccaaacc gttcgttggc gtgctgagcg caggt attaa cgccgccagt 2340 
ccgaacaaag agctggcaaa agagttcctc gaaaactatc tgctgactga tgaaggtctg 2400 
gaagcggtta ataaagacaa accgctgggt gccgtagcgc tgaagtctta cgaggaagag 2460 
ttggcgaaag atccacgtat tgccgccact atggaaaacg cccagaaagg tgaaatcatg 2520 
ccgaacatcc cgcagatgtc cgctttctgg tatgccgtgc gtactgcggt gatcaacgcc 2580 
gccagcggtc gtcagactgt cgatgccgcc ctggccgccg cgcagactgc cgccgccgcc 2640 
gccatggctt tgttggaacg catcttagcg agagacaacc tcatcacggc gctcaaacgg 2700 
gtcgaagcca accaaggage accgggaatc gacggagtat caaccgatca actccgtgat 2760 
tacatccgcg ctcactggag cacgatccac gcccaactct tggcgggaac ctaccggccg 2820 
gcgcctgtcc gcagggtcga aatcccgaaa ccgggcggcg gcacacggca getaggcatt 2880 
cccaccgtgg tggaccggct gatccaacaa gccattcttc aagaactcac acccattttc 2940 
gatccagact tctcctcttc cagcttcgga ttccgtccgg gccgcaacgc ccacgatgcc 3000 
gtgcggcaag cgcaaggcta catccaggaa gggtatcggt acgtggtcga catggacctg 3060 
gaaaagttct ttgatcgggt caaccatgac atcttgatga gtcgggtggc ccgaaaagtc 3120 
aaggataaac gcgtgctgaa actgatccgt gcctacctgc aagccggcgt tatgatcgaa 3180 
ggggtgaagg tgcagacgga ggaagggacg ccgcaaggcg gccccctcag ccccctgctg3240 
gcgaacatcc ttctcgacga tttagacaag gaattggaga agcgaggatt gaaattctgc 3300 
cgttacgcag atgactgcaa catctatgtg aaaagtctgc gggcaggaca acgggtgaaa 3360 
caaagcatcc aacggttctt ggagaaaacg ctcaaactca aagtaaacga ggagaaaagt 3420 
gcggtggacc goccgtggaa acgggccttt ctggggttta gottcacaco ggaacgaaaa 3480 
gcgcgaatcc ggctcgcccc aaggtcgatt caacgtctga aacagcggat tcgacagctg 3540 
accaacccaa actggagcat atcgatgcca gaacgaattc atcgcgtcaa tcaatacgtc 3600 
atgggatgga tcgggtattt tcggctcgtc gaaaccccgt ctgtccttca gaccatcgaa 3660 
ggatggattc ggaggaggct tcgactctgt caatggcttc aatggaaacg ggtcagaacc 3720 
agaatccgtg agttaagagc gctggggctg aaagagacag cggtgatgga gatcgccaat 3780 
accogaaaag gagcttggcg aacaacgaaa acgccgcaac tccaccaggc cctgggcaag 3840 
acctactgga ccgctcaagg gctcaagagt ttgacgcaac gatatttoga actccgtcaa 3900 
ggttgactgc aggcaagctt ggcactggcc gtcgttttac aacgtcgtga ctgggaaaac 3960 
cctggcgtta cccaacttaa tcgccttgca gcacatcccc ctttcgccag ctggcgtaat 4020 
agcgaagagg cccgcaccga tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg 4080 
cagcttggct gttttggcgg atgagataag attttcagcc tgatacagat taaatcagaa 4140 
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cgcagaagcg gtctgataaa acagaatttg cctggcggca gtagcgcggt ggtcccacct 4200 
gaccccatgc cgaactcaga agtgaaacgc cgtagcgccg atggtagtgt ggggtctccc 4260 
catgcgagag tagggaactg ccaggcatca aataaaacga aaggctcagt cgaaagactg 4320 
ggcctttcgt tttatctgtt gtttgtcggt gaacgctctc ctgagtagga caaatccgcc 4380 
gggagcggat ttgaacgttg cgaagcaacg gcccggaggg tggcgggcag gacgcccgcc 4440 
ataaactgcc aggcatcaaa ttaagcagaa ggccatcctg acggatggcc tttttgcgtt 4500 
tctacaaact ctttttgttt atttttctaa atacattcaa atatgtatcc gctcatgaga 4560 
caataaccct gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat 4620 
ttccgtgtcg cccttattcc cttttttgcg gcattttgcc ttcctgtttt tgctcaccca 4680 
gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc 4740 
gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttctcca 4800 
atgatgagca cttttaaagt tctgctatgt ggcgcggtat tatcccgtgt tgacgccggg 4860 
caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca 4920 
gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 4980 
accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 5040 
ctaaccgctt ttttgcacaa catgggggat catgtaactc gccttgatog ttgggaaccg 5100 
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 5160 
acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta 5220 
atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttccgget 5280 
ggctggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcgcgg tatcattgca 5340 
gcactggggc cagatggtaa gccctcccgt atcgtagtta tctacacgac ggggagt cag 5400 
gcaactatgg atgaacgaaa tagacagatc gotgagatag gtgcctcact gattaagcat 5460 
tggtaactgt cagaccaagt ttactcatat atactttaga ttgatttacc ccggttgata 5520 
atcagaaaag ccccaaaaac aggaagattg tataagcaaa tatttaaatt gtaaacgtta 5580 
atattttgtt aaaattcgcg ttaaattttt gttaaatcag ctcatttttt aaccaatagg 5640 
ccgaaatcgg caaaatccct tataaatcaa aagaatagac cgagataggg ttgagtgttg 5700 
ttccagtttg gaacaagagt ccactattaa agaacgtgga ctccaacgtc aaagggcgaa 5760 
aaaccgtcta tcagggcgat ggcccactac gtgaaccatc acccaaatca agttttttgg 5820 
ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg gagcccccga tttagagctt 5880 
gacggggaaa gccggcgaac gtggcgagaa aggaagggaa gaaagcgaaa ggagcgggcg 5940 
ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac caccacaccc gccgcgctta 6000 
atgcgccgct acagggcgcg taaaaggatc taggtgaaga tcctttttga taatctcatg 6060 
accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccgt agaaaagatc 6120 
aaaggatott cttgagatoc tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa 6180 
ccaccgctac cagcggtggt ttgtttgccg gatcaagagc taccaactct ttttccgaag 6240 
gtaactggct tcagcagagc gcagatacca aatactgtcc ttctagtgta gccgtagtta 6300 
ggccaccact tcaagaactc tgtagcaccg cctacatacc tcgctctgct aatcctgtta 6360 
ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggactc aagacgatag 6420 
ttaccggata aggcgcagcg gtcgggctga acggggggtt cgtgcacaca gcccagcttg 6480 
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gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg 6540 
cttcccgaag ggagaaaggc ggacaggt at ccggtaagcg gcagggtcgg aacaggagag 6600 
6660 cgcacgaggg agcttccagg gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc 
cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag cctatggaaa 6720 
aacgccagca acgcggcctt tttacggttc ctggcctttt gotggccttt tgctcacatg 6780 
ttctttcctg cgttatcccc tgattctgtg gataaccgta ttaccgcctt tgagtgagct 6840 
gataccgctc gccgcagccg aacgaccgag cgcagcgagt cagtgagcga ggaagcggaa 6900 
gagcgcctga tgcggtattt tctccttacg catctgtgcg gtatttcaca ccgcatatat 6960 
ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagtat acactccgct 7020 
atcgctacgt gactgggtca tggctgcgcc ccgacacccg ccaacacccg ctgacgcgcc 7080 
ctgacgggct tgtctgctcc cggcatccgc ttacagacaa gotgtgaccg tctccgggag 7140 
ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgaggcagc tgcggtaaag 7200 
ctcatcagcg tggtcgtgca gcgattcaca gatgtctgcc tgttcatccg cgtccagctc 7260 
gttgagtttc tccagaagcg ttaatgtctg gottctgata aagcgggcca tgttaagggc 7320 
ggttttttcc tgtttggtca ctgatgcctc cgtgtaaggg ggatttctgt tcatgggggt 7380 
aatgataccg atgaaacgag agaggatgct cacgatacgg gttactgatg atgaacatgc 7440 
ccggttactg gaacgttgtg agggtaaaca actggcggta tggatgcggc gggaccagag 7500 
aaaaatcact cagggtcaat gccagcgctt cgttaataca gatgtaggtg ttccacaggg 7560 
tagccagcag catcctgcga tgcagatccg gaacataatg gtgcagggcg ctgacttccg 7620 
cgtttccaga ctttacgaaa cacggaaacc gaagaccatt catgttgttg ctcaggtcgc 7680 
agacgttttg cagcagcagt cgcttcacgt tcgctcgcgt atcggtgatt cattctgcta 7740 
accagtaagg caaccccgcc agcctagccg ggtcctcaac gacaggagca cgatcatgog 7800 
cacccgtggc caggacccaa cgctgcccga aatt 7834 
< 210 > SEO ID NO 18 
< 211 > LENGTH : 5 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 18 
Ala Ala Ala Glu Phe 
< 210 > SEQ ID NO 19 
< 211 > LENGTH : 35 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
NM O
< 400 > SEQUENCE : 19 
Thr Val Asp Glu Ala Leu Lys Asp Ala Gin Thr Asn Ser Ser Ser Asn 
10 15 
Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Glu Asn Leu Tyr Phe Gln 
20 25 30 
Gly Glu Phe 
35 
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< 210 > SEQ ID NO 20 
< 211 > LENGTH : 16 
< 212 > TYPE : PRT 
ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 20 
Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala Ala Ala Ala Ala 
10 15 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 1200 
TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polynucleotide 
NNAPE W OWNE
< 400 > SEQUENCE : 21 
gaatacaagc ttgggcgtgt ctcaaaatct ctgatgttac attgcacaag ataaaaatat 60 
atcatcatga acaataaaac tgtctgctta cataaacagt aatacaaggg gtgttatgag 120 
ccatattcaa cgggaaacgt cttgctcgag gccgcgatta aattccaaca tggatgctga 180 
tttatatggg tataaatggg ctcgcgataa tgtcgggcaa tcaggtgcga caatctatcg 240 
attgtatggg aagcccgatg cgccagagtt gtttctgaaa catggcaaag gtagcgttgc 300 
caatgatgtt acagatgaga tggtcagact aaactggctg acggaattta tgcctcttcc 360 
gaccatcaag cattttatcc gtactcctga tgatgcatgg ttactcacca ctgcgatccc 420 
cgggaaaaca gcattccagg tattagaaga atatcctgag tcaggtgaaa atattgttga 480 
tgcgctggca gtgttcctgc gccggttgca ttcgattcct gtttgtaatt gtccttttaa 540 
cagcgatcgc gtatttcgtc tcgctcaggc gcaatcacga atgaataacg gtttggttga 600 
tgcgagtgat tttgatgacg agcgtaatgg ctggcctgtt gaacaagtct ggaaagaaat 660 
gcataagctt ttgccattct caccggattc agtcgtcact catggtgatt tctcacttga 720 
taaccttatt tttgacgagg ggaaattaat aggttgtatt gatgttggac gagtcggaat 780 
cgcagaccga taccaggatc ttgccatcct atggaactgc ctcggtgagt tttctccttc 840 
attacagaaa cggctttttc aaaaatatgg tattgataat cctgatatga ataaattgca 900 
gtttcatttg atgctcgatg agtttttcta atcagaattg gttaattggt tgtaacactg 960 
gcagagcatt acgctgactt gacgggacgg cggctttgtt gaataaatcg aacttttgct 1020 
gagttgaagg atcagatcac gcatcttccc gacaacgcag accgttccgt ggcaaagcaa 1080 
aagttcaaaa tcaccaactg gtccacctac aacaaagctc tcatcaaccg tggcgactct 1140 
agaggatccc cgggcgagct cccaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaccgaatt 1200 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 21 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
??? 
< 400 > SEQUENCE : 22 
acaaataggg gttccgcgca c 21 
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< 210 > SEO ID NO 23 
< 211 > LENGTH : 18 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 400 > SEQUENCE : 23 
gttggtgacc gcaccagt 18 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 17 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 400 > SEQUENCE : 24 
aacgcggtaa goccgta 17 
< 210 > SEQ ID NO 25 
< 211 > LENGTH : 18 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 400 > SEQUENCE : 25 
aatggacgat atcccgca 18 
< 210 > SEQ ID NO 26 
< 211 > LENGTH : 20 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 26 
Asn Ile Cys Trp Phe Gly Asp Glu Ala Thr Ser Gly Ser Gly His His 
15 10 
His His His His 
20 
< 210 > SEQ ID NO 27 
< 211 > LENGTH : 11 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 27 
Asn Ile Cys Trp Phe Gly Ala Ala Ala Ala Ala 
1 10 
< 210 > SEQ ID NO 28 
< 211 > LENGTH : 37 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
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< 400 > SEQUENCE : 28 
ccgcctttga gtgagctgat accgctcgcc gcagccg 37 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 44 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 400 > SEQUENCE : 29 
ggtggaccag ttggtgattt tgaacttttg ctttgccacg gaac 44 
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 19 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 




< 400 > SEQUENCE : 30 
gggtataaat gggctcgcg 19 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 19 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 400 > SEQUENCE : 31 
cgggcttccc atacaatcg 19 
< 210 > SEQ ID NO 32 
< 211 > LENGTH : 23 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
probe 
< 400 > SEQUENCE : 32 
tcgggcaatc aggtgcgaca atc 23 
< 210 > SEO ID NO 33 
< 211 > LENGTH : 70 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
oligonucleotide 
< 400 > SEQUENCE : 33 
gggtataaat gggctcgcga taatgtcggg caatcaggtg cgacaatcta tcgattgtat taatgtcggg caatcaggtg cgacaatcta tcgattgtat 60 
gggaagcccg 
< 210 > SEQ ID NO 34 
< 211 > LENGTH : 17 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
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< 400 > SEQUENCE : 34 
cgctcaggcg caatcac 17 
< 210 > SEO ID NO 35 
< 211 > LENGTH : 20 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
primer 
< 2 
< 400 > SEQUENCE : 35 
ccagccatta cgctcgtcat 20 
< 210 > SEQ ID NO 36 
< 211 > LENGTH : 29 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 36 
atgaataacg gtttggttga tgcgagtga 29 
< 210 > SEQ ID NO 37 
< 211 > LENGTH : 73 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
oligonucleotide 
< 400 > SEQUENCE : 37 
cgctcaggcg caatcacgaa tgaataacgg tttggttgat gcgagtgatt ttgatgacga 
gcgtaatggc tgg 
< 210 > SEQ ID NO 38 
< 211 > LENGTH : 492 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
polypeptide 
< 400 > SEQUENCE : 38 
Met Asn Lys Glu Ile Leu Ala Val Val Glu Ala Val Ser Asn Glu Lys Met Asn Lys Glu Ile Leu Ala val val Glu Ala val Ser Asn Glu Lys 
Ala Leu Pro Arg Glu Lys Ile Phe Glu Ala Leu Glu Ser Ala Leu Ala 
20 25 30 
Thr Ala Thr Lys Lys Lys Tyr Glu Gin Glu Ile Asp Val Arg Val Gin 
35 40 
Ile Asp Arg Lys Ser Gly Asp Phe Asp Thr Phe Arg Arg Trp Leu Val 
55 50 60 
Val Asp Glu Val Thr Gin Pro Thr Lys Glu Ile Thr Leu Glu Ala Ala 
70 65 
Arg Tyr Glu Asp Glu Ser Leu Asn Leu Gly Asp Tyr Val Glu Asp Gin 
85 
Ile Glu Ser Val Thr Phe Asp Arg Ile Thr Thr Gin Thr Ala Lys Gin 
100 105 110 
Val Ile Val Gin Lys Val Arg Glu Ala Glu Ara Ala Met Val Val Asp 
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115 120 125 
Gin Phe Arg Glu His Glu Gly Glu Ile Ile Thr Gly Val Val Lys Lys 
Val Asn Arg Asp Asn Ile Ser Leu Asp Leu Gly Asn Asn Ala Glu Ala 
150 160 
Val Ile Leu Arg Glu Asp Met Leu Pro Arg Glu Asn Phe Arg Pro Gly 
170 175 
Asp Arg Val Arg Gly Val Leu Tyr Ser Val Arg Pro Glu Ala Arg Gly 
180 190 
Ala Gln Leu Phe Val Thr Arq Ser Lys Pro Glu Met Leu Ile Glu Leu 
200 
Phe Arg Ile Glu Val Pro Glu Ile Gly Glu Glu Val Ile Glu Ile Lys 
Ala Ala Ala Arg Asp Pro Gly Ser Arg Ala Lys Ile Ala Val Lys Thr 
230 240 
Asn Asp Lys Arg Ile Asp Pro Val Gly Ala Cys Val Gly Met Arg Gly 
250 255 
Ala Arg Val Gin Ala Val Ser Thr Glu Leu Gly Gly Glu Arg Ile Asp 
260 270 
Ile Val Leu Trp Asp Asp Asn Pro Ala Gin Phe Val Ile Asn Ala Met 
280 
Ala Pro Ala Asp Val Ala Ser Ile Val Val Asp Glu Asp Lys His Thr 
Met Asp Ile Ala Val Glu Ala Gly Asn Leu Ala Gin Ala Ile Gly Arg 
310 320 
Asn Gly Gin Asn Val Arg Leu Ala Ser Gin Leu Ser Gly Trp Glu Leu 
330 335 
Asn Val Met Thr Val Asp Asp Leu Gin Ala Lys His Gin Ala Glu Ala 
340 350 
His Ala Ala Ile Asp Thr Phe Thr Lys Tyr Leu Asp Ile Asp Glu Asp 
360 
Phe Ala Thr Val Leu Val Glu Glu Gly Phe Ser Thr Leu Glu Glu Leu 
Ala Tyr Val Pro Met Lys Glu Leu Leu Glu Ile Glu Gly Leu Asp Glu 
390 400 
Pro Thr Val Glu Ala Leu Arg Glu Arg Ala Lys Asn Ala Leu Ala Thr 
410 415 
Ile Ala Gin Ala Gin Glu Glu Ser Leu Gly Asp Asn Lys Pro Ala Asp 
420 430 
Asp Leu Leu Asn Leu Glu Gly Val Asp Arg Asp Leu Ala Phe Lys Leu 
440 
Ala Ala Arg Gly Val Cys Thr Leu Glu Asp Leu Ala Glu Gin Gly Ile 
Asp Asp Leu Ala Asp Ile Glu Gly Leu Thr Asp Glu Lys Ala Gly Ala 
470 480 
Leu Ile Met Ala Ala Arg Asn Ile Cys Trp Phe Gly 
485 490 
< 210 > SEQ ID NO 39 
< 211 > LENGTH : 42 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
oligonucleotide 
N AP? ?
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< 400 > SEQUENCE : 39 
tttttttttt tttttttttttttttttttttttttttttttt 42 
V 
< 210 > SEQ ID NO 40 
< 211 > LENGTH : 4 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 




< 400 > SEQUENCE : 40 
Tyr Ala Gly Asp 
< 210 > SEQ ID NO 41 
< 211 > LENGTH : 4 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
M ??
< 400 > SEQUENCE : 41 
Tyr Ala Asp Asp 
< 210 > SEQ ID NO 42 
< 211 > LENGTH : 6 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
6xHis tag 
< 400 > SEQUENCE : 42 
His His His His His His 
< 210 > SEQ ID NO 43 
< 211 > LENGTH : 4 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 43 
Tyr Met Asp Asp 
< 210 > SEO ID NO 44 
< 211 > LENGTH : 26 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 44 
Thr Val Asp Glu Ala Leu Lys Asp Ala Gin Thr Asn Ser Ser Ser Asn 
15 10 
Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu 
20 25 
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< 210 > SEO ID NO 45 
< 211 > LENGTH : 16 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 2 
< 400 > SEQUENCE : 45 
Thr Val Asp Ala Ala Leu Ala Ala Ala Gin Thr Ala Ala Ala Ala Ala 
10 15 
< 210 > SEQ ID NO 46 
< 211 > LENGTH : 15 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Description of Artificial Sequence : Synthetic 
peptide 
< 400 > SEQUENCE : 46 
Met Ala Ala Arg Asn Ile Cys Trp Phe Gly Ala Ala Ala Ala Ala 
10 15 Z 
25 
What is claimed is : 5 . The method of claim 1 , wherein the solubility - enhanc 
1 . A method of reverse transcription , comprising carrying ing stabilizer protein does not fold into long - lived misfolded ! 
out reverse transcription of an RNA template using a stabi intermediates . 6 . The method of claim 1 , wherein the linker peptide is a lized reverse transcriptase fusion protein comprising a 30 non - cleavable linker peptide . group - II intron - derived reverse transcriptase connected at its 7 . The method of claim 1 , wherein the linker peptide is a N - terminus by a linker peptide to the C - terminus of a rigid linker peptide . 
stabilizer protein comprising 50 or more amino acids , 8 . The method of claim 1 , wherein the reverse transcrip wherein the fusion protein exhibits increased solubility and tion is carried out with an error frequency of 2 . 0x10 - 5 or less 
stability in solution . 35 at a temperature from about 45° to about 65° C . 
2 . The method of claim 1 , wherein the reverse tran 9 . The method of claim 1 , wherein the solubility - enhanc 
scriptase comprises a polypeptide having at least 85 % amino ing stabilizer protein includes an independent folding 
acid sequence identity to a sequence selected from the group domain . 
consisting of SEQ ID NO : 1 , SEQ ID NO : 2 , SEQ ID NO : 10 . The method of claim 7 , wherein the rigid linker 
3 , SEQ ID NO : 4 , or SEQ ID NO : 5 . peptide consists of 3 to 5 amino acids . 40 11 . The method of claim 10 , wherein the rigid linker 
3 . The method of claim 1 , wherein the stabilized reverse peptide consists of SEQ ID NO : 12 or SEQ ID NO : 18 . 
transcriptase fusion protein comprises an amino acid 12 . A method of reverse transcription , comprising carry 
sequence with at least 85 % amino acid sequence identity to ing out reverse transcription of an RNA template using a 
a sequence selected from the group consisting of SEQ ID stabilized reverse transcriptase fusion protein comprising a 
NO : 6 , SEQ ID NO : 7 , SEQ ID NO : 8 , SEQ ID NO : 9 , or 45 group - II intron - derived reverse transcriptase connected at its 
SEQ ID NO : 10 . N - terminus to the C - terminus of a stabilizer protein com 
4 . The method of claim 1 . wherein the solubility - enhanc - prising 50 or more amino acids , wherein the fusion protein 
ing stabilizer protein comprises a maltose binding protein or exhibits increased solubility and stability in solution . 
an N - utilization substance A protein . * * * * * 
